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Abstract
Glioblastoma Multiforme (GBM) is classified as a malignant grade IV astrocytoma, and
is considered to be the most biologically aggressive brain tumour with a 5-year survival
rate of ~4%. The most frequent issue arising with GBM tumours is the high level of
resistance observed to conventional therapeutic methods i.e. surgery, chemotherapy and
radiation, thus signifying the urgency for the development of novel therapeutic methods.
This study aims to investigate and develop both a complimentary and novel method to
overcome the current treatment barriers. We have investigated the use of novel
technologies such as cold atmospheric plasma (CAP) as an alternative to radiotherapy.
Employing methods such as cytotoxicity assays, molecular inhibitors, confocal
microscopy and flow cytometry, for the first time, we report that CAP induces a ROS,
JNK and Caspase independent mechanism of cell death in the GBM cells that can be
greatly enhanced when used in combination with low doses of TMZ. We have also
further elucidated that CAP results in the activation of autophagy prior to cell death.
Current chemotherapeutics used for the treatment of GBM have offered little
progression in the reduction of years of life lost. We have investigated the efficacy of
naturally available bioactive compound Ursolic acid (UA) as a potential alternative to
current chemotherapeutics. Using migratory assays, cytotoxicity assay, confocal
microscopy and flow cytometry we have identified that UA activates autophagy prior to
JNK dependent mechanism of cell death. A significant issue with GBM is its ability to
spread and infiltrate throughout normal brain tissue. We demonstrated that UA
successfully inhibits GBM cell migration through a JNK independent mechanism, more
effectively than the current chemotherapeutics. It is evident that there are
inconsistencies in the literature regarding the mechanism of cell death which occurs in
GBM cells, through critical analysis of the literature and multiple independent treatment
i

modalities, and following the guidelines set out by the national cell death committee, we
have demonstrated that U373MG GBM cells result in activation of the autophagy
following treatment prior to the cells demise
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1.1

Glial Tumours

The term glioma was first used to describe a tumour that arises from the glial cells
within the brain by Rudolf Virchow in 1863 (Van de Kelft, 1997). Astrocytes,
oligodendrocytes and ependymal cells all fall under the classification of a glial cell.
They are differentiated based on location and structure within the central nervous
system (CNS) and therefore produce independent and distinct tumours as seen in figure
1.1 below; astrocytoma, oligodendroglioma, ependymomas, and mixed glioma, each of
which can produce independent and distinct glial tumours.

Figure 1.1 The neuroglial cell lineage (Huse & Holland, 2010a)

It is thought that self-renewing, progenitors produce committed neuronal and glial
progenitors that eventually differentiate into mature neurons, astrocytes and
18

oligodendrocytes. The precise cells of origin for glioma variants and medulloblastoma
remain largely unknown, candidates for each are indicated in figure 1.1 above by
dashed arrows. These tumours can then be further sub-divided into categories according
to the World Health Organisation (WHO) depending on the perceived level of
malignancy (grade I-IV). Glial tumours are the most commonly occurring neoplasm of
the central nervous system (CNS), accounting for 50% of CNS tumours in adults
(Bower & Waxman, 2011). The overall prognosis for patients diagnosed with high
grade glioma is very bleak, with survival correlated to the age at which the patient is
diagnosed and the histological features of the tumour. Brain tumours are usually
attributed to change in the genetic composition of the cells; this can be inherited or can
be caused by external factors in the environment. It has been postulated that only 5% of
brain tumours can be linked to a genetic predisposition, although there are rare genetic
conditions such as Li-Fraumeni syndrome, retinoblastoma, Turcots syndrome, and
neurofibromatosis that are seen to be predisposing factors in the development of certain
tumours (Schwartzbaum et al. 2006; Hardwidge & Hettige 2012). Environmental factor
such as exposure to high dose radiation and chemicals such as formaldehyde have
increase risks of developing a malignant glioma (Schwartzbaum et al, 2006).
1.1.1

Astrocytomas

Aastrocytoma’s develop from astrocytes, star-shaped glial cells, which are part of the
supportive tissue of the brain. The primary function of astrocytes is to provide support
and nourishment to surrounding neurons, regulation of energy metabolism, transport of
blood-borne material to the neuron, and reaction to injury (Kimelberg & Nedergaard,
2010). Astrocytoma represents the majority of brain tumours found in adults making up
approximately 81% of all brain and CNS tumours (National cancer Registry Ireland,
2010). According to the WHO astrocytomas can be classified into four types (as
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described in the table 1.1 below) and are graded on a scale from I to IV based on
frequency of mitosis, necrosis and degree of differentiation. (Louis et al, 2007).
Table 1.1: WHO classification of astrocytic tumours

WHO grade

WHO description

Grade I

Pilocytic Astrocytoma

Grade II

Low-Grade Astrocytoma

Grade III

Anaplastic Astrocytoma

Grade IV

Glioblastoma

.

Pilocytic astrocytomas (Grade I) are the most common brain tumour found in children.
The pilocytic tumour is benign and tends not to spread from the area in which they grow
and are most commonly treated by surgical resection (Reifenberger et al, 2010). Lowgrade astrocytomas, (also known as diffuse astrocytomas) are regarded as malignant
tumours. They generally present with vast penetration of the surrounding brain tissue
making surgical resection more difficult. These tumours, if left untreated, are likely to
develop into a grade IV astrocytomas (Pouratian & Schiff, 2010). Anaplastic
astrocytomas are faster growing tumours then the previous tumours mentioned. They
are more difficult to remove; treatment usually involves radiation therapy or
chemotherapy and sometimes both. These grade III tumours most commonly occur in
males between the ages of 30-50 years (DeVita & Rosenberg, 2008; Pouratian & Schiff,
2010). Glioblastoma multiforme (GBM) is a highly malignant grade IV astrocytoma,
and is considered the most biologically aggressive brain tumour. These tumours are
associated with poor prognosis and a low 5 year survival rate of 5% post diagnosis
(Ostrom et al, 2014, 2015). According to the 2014 Central Brain Tumor Registry of
United States (CBRTUS) report, GBM makes up approximately 45.6% of all primary
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malignant brain tumours in USA (Ostrom et al, 2014). These tumours show high level
of resistance to conventional therapies i.e. surgery, chemotherapy and radiation,
indicating urgency for the development of new therapeutic strategies.

1.2

Glioblastoma multiforme

According to the National Cancer Registry of Ireland (NCRI), glioblastomas account
for 56% of astrocytic tumours (National cancer Registry Ireland, 2010). There is a 1.6
times higher incidence rate of GBM found in males compared to females (Dolecek et al,
2012). The median age for diagnosis is approximately 64 years of age but it can occur at
any age (Preusser et al, 2011). Epidemiological studies have shown that there is a
higher incidence of GBM cases in developed countries, for example in Western society
there is approximately 4.5/100,000 persons affected/year compared with that of underdeveloped countries where there is approximately 2.4/100,000 persons affected/year.
This is thought to be due to under-detection, different diagnostic practices, and limited
access to healthcare, and moreover this variance could also be due to ethnic, lifestyle or
environmental differences in susceptibility to developing GBM’s (Butowski & Chang,
2007; Ohgaki, 2009).
1.2.1

Primary and Secondary GBM’S

The majority of GBM’s develop in the cerebral hemisphere. Histologically,
Glioblastoma multiforme, as the name implies, displays attributes of various
morphologies, and is a heterogeneous mixture of cells that demonstrate varying degrees
of cellular and nuclear polymorphism. GBM is a non-metastasising tumour and is
characterized by regions of necrosis, mitotic activity, pleomorphic nuclei, and microvascular proliferation, all of which is essential for its histopathological diagnosis
(Reifenberger et al, 2010). GBM can be divided into primary and secondary subtypes
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according to the astrocytic lineage and on the basis of clinical presentation and genetic
make-up. The first distinction between primary and secondary GBM was first defined
by the German neuropathologist Hans-Joachim Scherer in 1940. He wrote,
“From a biological and clinical point of view, the secondary glioblastomas
developing in astrocytomas must be distinguished from ‘primary’ glioblastomas. They
are probably responsible for most of the ‘glioblastomas of long clinical
duration'.”(Scherer, 1940)
Primary glioblastomas, also known as ‘de novo’ glioblastomas, develop rapidly, with no
clinical history and with no evidence of a previous clinical precursor lesion or
malignancy (Ohgaki & Kleihues, 2007; Reifenberger et al, 2010). Secondary
glioblastomas develop much slower, by progression from a pre-existing lower grade
(WHO grade II) astrocytomas (Ohgaki & Kleihues, 2007). Primary GBM is usually
diagnosed following a description of an acute clinical presentation coupled with biopsy
showing features of IV glioblastoma, whereas diagnosing a secondary glioblastoma
requires clinical or histological confirmation of progression from a previously identified
less malignant lower grade astrocytoma.
Although the distinction has been made between primary and secondary glioblastomas,
these terms have yet to be used diagnostically, mostly due to the fact that primary and
secondary glioblastomas cannot be distinguished morphologically (Kleihues & Ohgaki,
2000; Reifenberger et al, 2010). Despite this, clinical evidence shows a difference
between these two subtypes of glioblastomas in terms of prevalence. Primary
glioblastomas are much more prevalent in older patients (>60 years) whereas secondary
glioblastoma occur in younger patients (<45 years) (Kleihues & Ohgaki, 2000). There
are also certain genetic alterations that have been associated with each subtype. The
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EGFR/PTEN/Akt/mTOR pathway is a principle signalling pathway in the development
of primary glioblastoma as illustrated in figure 1.2 below. Epidermal Growth Factor
Receptor (EGFR) over expression or amplification occurs in approximately 40 and 50%
respectively of primary glioblastomas but rarely occurs secondary glioblastomas
(Ekstrand et al, 1992). On the other hand the TP53 pathway is associated with the
development of secondary glioblastomas with approximately 60% of cases
demonstrating TP53 mutations (Riemenschneider & Reifenberger, 2009). The pathways
involved in the development of GBM will be discussed in further detail under Section
1.4 Gliomagenesis.

Figure 1.2 Genetic pathways involved in primary and secondary glioblastoma development
(Endersby & Baker, 2008) .

1.3

Incidence of Central Nervous System Tumors.

The CNS is composed of the brain and the spinal cord. It is the processing centre for the
entire nervous system. In 2008 the NCRI reported that from 1994-2008 there was a
2.3% increase in the number of cases of brain & other CNS tumours being diagnosed,
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most likely attributed to the increase in the population (National cancer Registry
Ireland, 2010). In the 2013 report of Cancer in Ireland it stated that there were 344 new
cases of brain and CNS tumours diagnosed from 2008-2010, making up approximately
2% of all invasive cancers diagnosed (National Cancer Registry, 2013). According to
the International Agency for Research on Cancer (IARC) is it estimated that
approximately 238,000 malignant brain & CNS tumours were diagnosed worldwide in
2008 (Ferlay et al, 2010). The number of cases diagnosed are significantly lower
compared to those of other cancers such as, prostate, breast and colorectal which are
among the five most frequently diagnosed cancers worldwide, but these cancers have a
considerably higher five year survival rate i.e. prostate: 81%, breast: 85% and
colorectal: 55% compared with brain & CNS tumours which is a bleak 15% (Office for
National Statistics, 2011).

1.4

Gliomagenesis

Gliomagenesis describes the development of glial tumours. With advances in
technology over the past two decades our knowledge of genetic and molecular processes
in which GBM develops has increased dramatically but there is still much to be
discovered. There are numerous genetic abnormalities that have been linked to
gliomagenesis, many of which affect processes such as proliferation, cell cycle control,
signal transduction, apoptosis, and differentiation (Zhang & Fine, 2006). It is important
to develop a better understanding of the events that result in gliomagenesis in order to
allow for the development of target specific therapies. Demonstrated in figure 1.3
below, are some of the most commonly deregulated genes/major signalling pathways
found in GBM, the RTK/PI3K/Akt pathway, p14ARF/MDM2/TP53 and the RB1p16INK4a pathway.
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Figure 1.3 Aberrant signalling pathways commonly observed in GBM. (Tanaka et
al, 2012).

As seen in figure 1.3 above (a) depicts the RTK/PI3K/Akt signal transduction pathway
that promotes survival and growth in response to extracellular signals, and has been
shown to be mutated in 88% of GBM. (b) demonstrates the p14ARF/MDM2/TP53, this
pathway responds to diverse cellular stresses to regulate target genes that induce cell
cycle arrest, cell death, cell differentiation, senescence, DNA repair. Inactivation of this
pathway is cause by mutations that occur in the p53 gene, which occur in 87% of GBM.
(c) The retinoblastoma protein (RB1) is a tumour suppressor protein that is
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dysfunctional in 78% of GBM. RB1 functions to prevent excessive cell growth by
inhibiting cell cycle progression until a cell is ready to divide.
1. RTK/PI3k/Akt/ Pathway
The RTK/PI3K/Akt refers to a cellular proliferation pathway, This first involves the
binding of extracellular growth factors to the receptor tyrosine kinase (RTK) proteins on
the cell membrane which results in autophosphorylation of the RTK where PI3 kinase
binds to a phosphorylated domain on the RTK, which then signals the phosphorylation
of serine/threonine kinase known as Akt to regulate cellular proliferation, apoptosis and
glucose metabolism (Manning & Cantley, 2007; Nakada et al, 2011a).
The receptor tyrosine kinase (RTK) family are a group of transmembrane glycoprotein’s
that activate growth factor mediated signal transduction. They play an important role in
cellular proliferation and differentiation. Aberrant signalling of the RTK family has
been associated with a variety of cancers such as breast and brain cancer. Genetic
mutations of the RTKs result in gene amplification or over expression thus leading to
constitutive activity of that protein. One of the main mechanisms of deregulated RTK
function is the activation of the autocrine growth factor/receptor loops (Zhang & Fine,
2006), which result in the promotion of tumour cell proliferation. The Epidermal
Growth Factor Receptor (EGFR) and Platelet Derived Growth Factor Receptor
(PDGFR) have been repeatedly demonstrated to play a role in gliomagenesis (Holland,
2001; Nakada et al, 2011b). EGFR is the most frequent of all RTK mutations, with
approximately 45% of all primary GBM exhibiting gene amplification (Ohgaki &
Kleihues, 2009; Tanaka et al, 2012). EGFR amplification is commonly associated with
gene amplifications and activated mutations in the EGFR locus, the most documented
being the EGFR variant III (EGFRvIII) deletion which is observed in 20-30% of all
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primary GBM with a further 50-60% of those also displaying EGFR amplification
(Ohgaki & Kleihues, 2009; Huse & Holland, 2010b; Nakada et al, 2011a).
PI3K are a family of lipid kinases that are involved in an array of diverse cellular
signalling pathways including cellular proliferation, differentiation, motility, and
survival (Nakada et al, 2011a). The PI3K complex is composed of a catalytically active
protein p110α encoded by PIK3CA) and a regulatory protein p85α (encoded by PIK3RI)
(Ohgaki & Kleihues, 2009). PIK3CA mutations have been reported in a variety of
cancers including brain tumours. In a study by Gallia, G. L. et al. 2006, it was observed
that in 73 GBM samples, 15% possessed PIK3CA mutations. In addition to this, a study
by Kita, D. et al. 2007 noted that in a sample of 107 primary GBM, PIK3CA missense
mutations and amplifications were observed in 5% and 13% respectively. It can be said
that PIK3CA mutations are quite prevalent in GBM unlike the regulatory protein
PIK3R1 which has been rarely reported. The Cancer Genome Atlas Research Network
carried out a project using GBM samples (n=206) that determines 10% of their cohort
displayed PIK3R1 mutations (The Cancer Genome Atlas Research Network, 2008).
Phosphatase and tensin homolog (PTEN) gene is a tumour suppressor gene that is
mutated in a large number of cancers at high frequency. It negatively regulates
intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and also
negatively regulates Akt pathway (NCBI), by antagonizing PI3-kinase-mediated
signalling cascades. The PTEN gene has been shown to be mutated in approximately
40% of primary GBM (Ohgaki & Kleihues, 2009), resulting in constitutive activation of
the RTK/PI3K/Akt pathway. Akt is serine/threonine kinase that regulates cellular
proliferation, apoptosis and glucose metabolism. To date there have been no oncogenic
Akt mutations detected (Nakada et al, 2011a).
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2. p14ARF/MDM2/TP53 pathway
p14ARF/MDM2/TP53 pathway refers to activation of the alternate reading frame protein
p14ARF by oncogenic signalling, which binds Mouse double minute 2 homolog
(MDM2), inhibiting its E3 ubiquitin ligase function and results in the release of P53 and
therefore reinstating its transcriptional activity (Shaoman & Van Meir, 2009).
The TP53 gene encodes for a 43.7kDa tumour suppressor protein p53. This tumour
suppressor protein is located in the nucleus of cells where it binds directly to DNA.
While distinct mutations are predominant in each subtype of GBM, alterations of
tumour suppressor p53 are observed in 28 % of primary GBM and 65 % of secondary
GBM (England et al, 2013; Nakada et al, 2014), making it the most common genetic
alteration observed in GBM. The p53 protein plays a crucial part in many cellular
processes including the cell cycle, cellular DNA damage response, cell death and
differentiation (Ohgaki & Kleihues, 2009). Subsequent to DNA damage, TP53 is
activated and induces the transcription of other genes such as p21Waf1/Cip1 which acts as
a regulator of cell cycle progression (Ohgaki & Kleihues, 2009; Nakada et al, 2011a).
TP53 plays a crucial role in the development of GBM, since the majority of GBM
tumours demonstrate TP53 mutations. The majority of p53 mutations in secondary
GBM have been located at two key codons 248 and 273, whereas they have been
demonstrated to be more widely distributed in primary GBMs (Mao et al, 2012). This
therefore proposes that p53 mutations in primary GBM occur as a secondary incident
due to general genomic instability of the GBM tumour environment. The MDM2
protein is involved in promoting tumour formation by targeting tumour suppressor
proteins such as p53 for proteosomal degradation when over expressed (Nakada et al,
2011a), and this has been shown in 10% of all malignant GBM’s (Mao et al, 2012).
MDM2 binds to both mutant and wild type p53 preventing the ability of TP53 to
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activate transcription. Contrarily, transcription of the MDM2 gene is induced by wildtype TP53, acting as an auto-regulatory feedback loop regulating the expression of
MDM2 and p53 activity (Ohgaki & Kleihues, 2009; Nakada et al, 2011a). p14ARF also
known as ARF tumour suppressor, is an alternate reading frame protein, which forms
stable complexes with MDM2. It acts as a tumour suppressor initiating P53 dependant
cell cycle arrest. ARF and p16INK4A, are crucial regulators of the key growth control
pathways p53 and pRB, respectively. One of the most frequent mutations found in
GBMs is the homozygous deletion of the p16INK4a/p14ARF/p15INK4b locus (Solomon et
al, 2008). P53 plays an important role in cell cycle. The G1/S checkpoint prevents
initiation of DNA replication in cells that have damaged DNA. Expression of p53
following DNA damage, arrests cells at the G1/S transition. Similarly, entry into mitosis
is blocked by the G2 checkpoint mechanism when DNA is damaged. DNA damage
signals cause activation of p53, which induces the expression of p21WAF1/CIP1/Sdi1, an
inhibitor of the cyclin dependent kinases (CDKs)2, 3, 4 and 6 (Taylor & Stark, 2001). It
has been demonstrated that astrocytic gliomas with altered G1/S transition control genes
also have abnormalities of the p14ARF/MDM2/p53 pathway genes (Ichimura et al,
2000), and therefore indicating that tumours with G1/S transition control gene
abnormalities exhibit disruption of the p53 pathway.
3. RB1-p16INK4a pathway
The retinoblastoma tumour suppressor protein (pRB) plays a critical role in inhibiting
cell cycle progression in the G1/S phase by binding and inhibiting transcription factors
of the E2 factor (E2f) family. The 107-kDa RB1 protein encoded by RB1 (at 13q14)
controls progression through G1 into the S-phase of the cell cycle and is regulated by
the complex of cyclin-dependent kinases (CDKs)(Mao et al, 2012). The loss of pRB
expression has been detected in GBM and the loss of 13q was also associated with the
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transition from low- to intermediate-grade gliomas (Henson et al, 1994; Bahuau et al,
1998). Genetic loss of RB1 (40%), deletion of CDKN2A (40%) and/or CDK4
amplification (15%) have been demonstrated in the majority of GBM’s (Schmidt et al,
1994; Ueki et al, 1996).

1.5

History of cancer therapy

A German chemist Paul Ehrlich in the early 1900’s, who is considered the father of
modern immunology and chemotherapy, first coined the term chemotherapy. He defined
chemotherapy as the use of chemicals to treat disease (DeVita & Chu, 2008). The 1960s
was an exciting decade for advancements in the chemotherapeutics field. The Eli Lilly
Company unearthed the bio-activity of over 30 plant alkaloids from the plant, Vinca
rosea, one of which is vincristine (Johnson et al, 1963) used for the treatment of a
variety of cancers such as acute leukaemia. Another was the discovery of the activity of
ibenzmethyzin (now known as pro-carbazine) for the treatment of Hodgkin’s disease by
Brunner and Young (Brunner, 1965). Both of these drugs are also commonly used in the
treatment of GBM today. Devita and his colleagues developed the mitochondrial outer
membrane

permeabilisation

(MOMP)

programme,

the

first

combinational

chemotherapy regime, consisting of nitrogen mustard with vincristine, methotrexate,
and prednisone. This has since become known as the MOPP (Mustargen, Oncovin,
Procarbazine, and Predinsone) programme, which has substituted methotrexate with
Procarbazine. This treatment led to Hodgkin’s disease being deemed curable by the
1970s, with approximately 80% of cases resulting in complete remissions (Devita et al,
1970). Following the success of combinational chemotherapy came the era of adjuvant
and neo-adjuvant chemotherapy. Adjuvant chemotherapy is when chemotherapy is
administered to patients in addition to the primary or initial treatment to reduce the risk
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of recurrence. Neo adjuvant chemotherapy is when chemotherapy is given pre surgery
to shrink the tumour, to aid in resection. Since the 1940s, the successful advancements
of chemotherapy to treat cancer has led to the age of specific targeted therapies, the
most successful being the BCR-Abl tyrosine kinase inhibitor ‘Imatinib’ for the
treatment of chronic myelocytic leukaemia (DeVita & Chu, 2008). Although
chemotherapy cannot be deemed to cure all forms of cancers, it has provided significant
improvements to patients, prolonging life expectancy, increasing the quality of life.

Radiotherapy first began in 1895, with the discovery of x-rays, and in 1896 only six
months later the first patients were treated with radiotherapy (Thariat et al, 2013a). It
was discovered that daily doses of radiation over several weeks greatly improved the
chances of a patient’s recovery. This breakthrough was closely followed by the isolation
of radium by Curie in 1898 (Thariat et al, 2013b). It was not until the early 20th century
that it was identified that radiation exposure also induced cancer formation, and
therefore, steps were taken to optimise dosage and exposure, forming a basis for safe
and effective therapies. Therefore, when radiation therapy is used to treat cancerous
cells in the body, it is important to measure the dose correctly to avoid unnecessary
damage to normal cells as radiation is not selective to tumour cells and can target any
cells that are in the process of replication. It has been previously demonstrated that
exposure to radiation damages the genetic material of a cell, therefore altering their
ability to divide and proliferate (Baskar et al, 2012). The Gray (Gy) is the unit used to
measure the total amount of radiation the patient is exposed to. This can also be
recorded as centigray (cGy), which is 0.01 of a single gray unit. The total radiation dose
is usually divided into several fractions. For most patients that require radiation therapy,
the total dose is broken up into daily doses for a total period of weeks. The current
standard of care for GBM patients receiving radiotherapy, is as follows; concurrent use
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of TMZ with radiotherapy to 6,000 cGy over 30 days followed by adjuvant TMZ
treatment for 6 months (Stupp et al, 2010). Studies have demonstrated increases in
GBM patient survival with postoperative radiation therapy (RT) to doses of 5,000-6,000
cGy but efforts have reported attempts beyond 6,000 cGy that resulted in increased
toxicity and no additional survival benefit (Barani & Larson, 2015). Over the years
there have been major advances in radiotherapy, with the development of techniques
such as conformal radiation therapy, stereotactic radiation therapy, intraoperative
radiation therapy, and the development of radiosensitisers, all of which are used today
for the treatment of many malignancies including GBM (Baskar et al, 2012).

1.6

Treatment and prognosis of GBM.

The current prognosis for those diagnosed with glioblastoma is unfavourable. Patients
who receive maximal treatment have a survival rate of approximately 12-18 months,
where as those who do not obtain treatment have a survival rate of <1 year (Merlo,
2003). It is clear from these statistics that despite maximal treatment for patients with
glioblastoma the outlook is grave, when compared to successful treatments of others
cancers such as breast and prostate cancer with a survival rate of >80% (National
Cancer Registry, 2013). It highlights just how aggressive and fatal GBM is, and how
challenging it is to treat, even with the advancement in treatment and therapeutics over
past decades.
As illustrated below in figure 1.4, the current standard of care for those who have been
newly diagnosed with a glioblastoma is as follows, surgical resection to the extent that
is safely feasible. Following histopathology, which identifies the stage of the tumour
according to WHO classification, the patient is either treated with radiotherapy,
chemotherapy or both. For GBM tumours following surgical resection the patient is
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treated with a 6 week course of radiotherapy (typical dose is around 60 Gy) with
concomitant systemic therapy using alkylating agent TMZ (75 mg/m2 daily), followed
by the minimum of 6 months of adjuvant TMZ (150-200 mg/m2 for 5 days every 28
days) (Stupp et al, 2005a). Patients who have recurrent GBM tumours or are less likely
to respond to treatment are also given then option to take part in clinical trials.

Figure 1.4 Illustrates a typical algorithm used by neurologists to identify the best
course of treatment following identification of a glioma (Wick et al, 2014)

A key factor as to why there is such a poor prognosis for those with GBM is due to the
high tendency for tumour recurrence. It has been suggested that the majority of patients
will develop recurring tumours after a median survival time of 32-36 weeks (Hou et al,
2006). Treating recurrent GBM requires individualisation and is patient dependent.
There are numerous factors that must be taken into account before deciding on the most
suitable therapy for that patient, i.e. age, histology, O6-methylguaninE-DNA-
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methyltransferase (MGMT) status, extent of initial resection, initial therapy received
and their response, whether recurrence is local or diffuse (Weller et al, 2013).

1.7

Commonly used chemotherapeutics employed for treatment of

GBM
Treatment of GBM has remained poor. Despite the advancements in chemotherapy in
recent years, the disease still remains incurable. The current standard of care is maximal
resection of the tumour followed by administration of TMZ, an alkylating cytotoxic
agent that is administered orally on a daily basis at a dose of 75 mg/m2 throughout
external beam radiotherapy. Four weeks later, magnetic resonance imaging (MRI) is
repeated, and TMZ is then given at a dose of 150-200 mg/m2 daily for 5 days every 28
days for maintenance. MRIs are performed after every 2-3 cycles of TMZ treatment to
ensure continuous stability or response of the tumor to treatment (Hottinger et al, 2014).
The following are some of the most common chemotherapeutics used for the treatment
of GBM.
1.7.1

Alkylating agents

An alkylating agent attaches an alkyl group to the guanine base of DNA, thus resulting
in DNA damage. In 2005 the US Food and Drug Administration (FDA) approved the
use of TMZ chemotherapeutic agent for the treatment of GBM’s. It is a cytotoxic
alkylating agent that can effectively cross the blood brain barrier (BBB). The blood
brain barrier is a diffusion barrier that excludes blood borne substances entering the
brain and protects the central nervous system. Tight junctions exist between the vascular
endothelial cells AND the BBB, and therefore can restrict many chemotherapeutic
agents from crossing into the invasive GBM cells. TMZ was first synthesized by
Stevens and his colleagues in 1984 (Stevens et al, 1984), they also demonstrated that
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TMZ has anti-tumour activity (Stevens et al, 1987). TMZ is a small lipophilic molecule
with a molecular weight of 194 Daltons and therefore, is able to cross the blood-brain
barrier. When TMZ comes in contact with the slightly basic pH of the blood and tissues,
it undergoes hydrolysis, which rapidly breaks down to form the reactive
methyldiazonium ion. The methyldiazonium ion formed by the breakdown of (3methyl-(triazen-1-yl)imidazole-4-carboxamide) MTIC primarily methylate’s guanine
residues in the DNA molecule, resulting in the formation of O6- and N7-methylguanine,
damaging DNA. When DNA mismatch repair enzymes attempt to remove O6methylguanine, they generate single- and double-strand breaks in the DNA, leading to
an activation of apoptotic pathways (Agarwala & Kirkwood, 2000).
Resistance to alkylating agents such as TMZ is a large cause of treatment failure in
patients. TMZ resistance is mediated by enzyme (methylguanine methyltransferase)
MGMT. TMZ cytotoxicity is mediated through O6-methylguanine (O6-MeG), a
mutagenic, toxic lesion. O6-MeG is removed by MGMT in tumours expressing this
protein thus counteracting the toxicity induced by TMZ. After DNA alkylation, MGMT
attaches to damaged substrate DNA, the target base is then flipped out of the helix and
bound to MGMT, altering the conformation of the DNA binding domain allowing
alkylated MGMT to be detached from DNA and degraded through the
ubiquitin/proteasomal system (Zhang et al, 2012) Therefore increased MGMT
expression levels results in resistance to alkylating agents. As demonstrated by Hegi et
al, 55% of all newly diagnosed GBM cases do not benefit from the addition of TMZ to
their treatment, in contrast to this the 45% that did benefit also saw an increase of 38%
in the two year survival (Hegi et al, 2008). Another study providing similar statistics,
was a large randomized phase III trial that found TMZ treatment along with
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radiotherapy resulted in an improved median overall survival from 12.1 to 14.6 months
and an increase in the 2-year survival rate from 10% to 27% (Mirimanoff et al, 2007).

Carmustine, also known as BCNU (1, 3- bis (2-chloroethyl)-1-nitrosurea), is a
dialkylating nitrosourea based compound that has been FDA approved for the treatment
of cancers such as GBM (recurrent and newly diagnosed), Hodgkin’s and nonHodgkin’s lymphoma. It is a cell cycle independent lipophilic compound and can cross
the blood brain barrier. In 2004 a phase II study of BCNU in combination with TMZ
was carried out on patients with either progressive or recurrent GBM. Results showed
that progression free survival at 6 months (PFS-6) was 21% and survival at one year
was 26%, previous data for PFS-6 after TMZ treatment alone was 21%, and therefore it
was concluded that combined treatment was no more effective than TMZ treatment
alone (Prados et al, 2004). BCNU has also been developed into a biodegradable
polymer that has been impregnated with BCNU, after surgical resection the wafer is
implanted into the cavity enhancing effective local drug delivery and minimising side
effects. The wafer slowly dissolves releasing the drug into the surrounding tissue,
treating any remaining malignant cells. It is the only form of treatment for brain
tumours that does not cross the blood brain barrier. Westphal et al conducted a phase III
trial in patients diagnosed with recurrent GBM, two groups, one who received either
BNCU wafer or a placebo wafer at the time of surgery followed by external beam
radiation postoperatively (Westphal et al, 2003). The results indicated that patients that
received the BCNU wafer had a 28% reduction in the risk of mortality, with a median
survival time of 13.9 months.

PCV

(Pro-carbazine,

lomustine

(CCNU)

and

Vincristine)

is

combinational

chemotherapy therapy, involving treatment with Procarbazine, Lomustine, and
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Vincristine. Procarbazine gained FDA approval in 1969 for the use in treating
Hodgkin’s lymphoma. It is a pro-drug that undergoes metabolic transformation into its
active form where it targets and inhibits DNA, RNA and protein synthesis (Armand et
al, 2007). The development of safe combinational therapies resulted in a more popular
use for pro-carbazine, It was a key component of the combinational therapy MOPP in
the 1970 (Devita et al, 1970) as described earlier, for the treatment of Hodgkin’s
lymphoma. A phase II study carried out by (Yung et al, 2000) which compared TMZ
with single agent pro-carbazine in 225 GBM patients with first relapse. Patients who
received TMZ had a PFS-6 of 21% and for those who received pro-carbazine, had a
PFS-6 of 8%, and the 6-month overall survival was 60% versus 44% with TMZ and
pro-carbazine respectively, concluding the safety and efficacy in TMZ for treatment of
recurrent GBM as opposed to pro-carbazine.

Lomustine is FDA approved for treatment in patients with brain tumour who have had
surgery or radiation therapy, it is also used for the treatment of Hodgkin’s lymphoma.
Lomustine also known as CCNU is an alkylating agent that forms cross links with DNA
inhibiting DNA and RNA synthesis. There are no recent studies indicating a benefit of
increased survival for treatment with Lomustine alone compared to that of other
available therapies. In 2009, a study evaluating the long-term survival of GBM patients
after treatment with radiotherapy and TMZ in combination with lomustine, reported a
significantly high 2-year survival rate of 47.4% with 18.5% survived 4 years.
Concluding that the combination of TMZ and Lomustine display promising efficacy for
the treatment of newly diagnosed GBM (Glas et al, 2009).

Vincristine is classified as a plant alkaloid. Vincristine is an anti-microtubule agent and
therefore inhibits the microtubule structures within the cell. Microtubules are part of
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the cell's apparatus for dividing and replicating itself. Inhibition of these structures
results in cell death. Vincristine has been extensively studied as a single agent for the
treatment of GBM since the 1960’s (Lassman et al, 1965; Smart et al, 1968), but it is
more commonly used in combinational therapeutic approaches.

The PCV regimen is made up of multiple 6 week long cycles, with a full course
consisting of 6 cycles lasting up 9 months. PCV was first studied as treatment for
malignant brain tumours in 1975 (Gutin et al, 1975). To date it is more commonly used
for the treatment of oligodenrogliomas and also anaplastic astrocytomas, which are
similar to GBM but lack the vascular proliferation of GBM tumours. A study carried
out in 2001 demonstrated that after treatment with PCV 25% of patients out of a total of
63 patients, resulted stabilisation of disease, and observed responses were observed in
11%, although further randomised phase 3 trials were required to determine the efficacy
of PCV as a chemotherapeutic for the treatment of recurrent GBM (Stupp et al, 2006).

1.7.2

Monoclonal Antibodies

Monoclonal antibodies (mAb) were first used for the treatment of cancer in the 1980s,
when it was determined that a major problem with the current therapies was the lack of
specificity for the cancer cells. The first patient treated with this monoclonal antibody
therapy was a patient suffering from Hodgkin’s lymphoma. The antibody was a murine
mAb known as AB 89 (Oldham & Dillman, 2008). The major limitation with using
murine mAb was that immunogenicity of the protein and its short half-life. Over the last
two decades there have been considerable advances made in the development of
monoclonal antibodies, table 1.2 below describes 10 current FDA approved mAb used
for the treatment of various cancers.
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Table 1.2 10 current FDA approved monoclonal antibodies for the treatment of
various malignancies
Monoclonal Antibody

Target

Malignancy

Trastuzumab (Herceptin)

ERBB2

Breast cancer

Bevacizumab (Avastin)

Colon, ovarian cancer,

VEGF

GBM
Colorectal, Small cell lung
Cetuximab (Erbitux)

EGFR

cancer, head and neck
cancer

Panitumumab (Vectibix)

EGFR

Colorectal cancer

Ipilimumab (Yervoy)

CTLA4

Melanoma

Rituximab (Mabthera)

CD20

Lymphomas, Leukemias,
Chronic lymphocytic

Alemtuzumab (Campath)

CD52

leukemia, T-cell
Lymphoma

Ofatumumab (Arzerra)

Chronic lymphocytic

CD20

leukemia
Hodgkin’s Lymphoma,
Brentuximab vedotin

CD30

Anaplastic large cell

(Adcetris)
lymphoma
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Bevacizumab was approved by the FDA in 2009 as a single agent, second line treatment
for progressive GBM following prior therapy. This is currently under review by the
FDA. Two randomized, placebo-controlled, double-blind, phase 3 trials (AVAGLIO

and RTOG 08-25) were recently carried out, both of which suggest there was a minor
increase in progression free survival from 6.2 to 10.6 months (AVAGLIO), 7.3 to

10.7 months (RTOG 08-25) but no significant increase in the overall survival, when
bevacizumab was added to the standard of care (TMZ and radiation therapy) (Weller &
Yung, 2013; Gilbert et al, 2014; Taphoorn et al, 2015).
1.7.3

Receptor Tyrosine Kinase Inhibitors

Receptor tyrosine kinase inhibitors (RTKIs) are a class of chemotherapeutics that
inhibit, or block, the enzyme tyrosine kinase, allowing for targeted specific treatment
for different cancers. In 1962, Stanly Cohen successfully isolated the nerve growth
factor from mouse salivary gland and snake venom alongside Levi Montalcini, Cohen
then isolated and characterised the epidermal growth factor from mouse salivary gland
extract. It was found to stimulate the proliferation of epithelial cells (Gschwind et al,
2004). In 1983 EGFR was targeted with mouse monoclonal antibody to block
proliferation of human cancer cells in vitro. Throughout the following decade it was
discovered that many cancers such as breast and cervical cancer displayed amplified
EGFR or EGFR related gene (human epidermal growth factor receptor 2 (HER2)
(Gschwind et al, 2004). This discovery provided prospects for the development of target
specific therapies. In 1990 the Genentech group characterise the murine monoclonal
antibody 4D5 that binds to HER2/neu on the surface of cancer cells, and this led to the
development of the first targeted anti-kinase therapeutic agent based on genomic
research, known as Trastuzumab (Herceptin) (Shawver et al, 2002; Gschwind et al,
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2004). Following the success of Herceptin in the treatment of breast cancer, it
propagated the development of small molecule inhibitors for cancer therapy. In 2002 the
first EGFR tyrosine kinase inhibitor became available in Japan, as a novel therapeutic
approach for the treatment of non-resectable non-small cell lung cancer (NSCLC).
Gefitinib is a low–molecular weight molecule and a member of the anilinoquinazoline
family that reversibly inhibits the tyrosine kinase activity associated with EGFR (Rich
et al, 2004). After treatment it was noted that there were a small population of patients
who responded well to the treatment but unfortunately for approximately 70-80% of
patients it had no effect (Araki et al, 2012). Since then many different techniques have
been used to try and predict whether a patient will respond to Gefitinib treatment.
Genotyping work identified patients with EGFR mutations in the area of the gene
coding for adenosine triphosphate (ATP) binding pocket of tyrosine kinase domain were
those that respond to Gefitinib (Araki et al, 2012). Another issue with the use of
Gefitinib is that the majority of patients develop resistance to the treatment after a
couple of years.
Approximately 50% of malignant gliomas overexpress EGFR, resulting from aberrant
signalling of the RTK/PI3K/Akt pathway (and as described in the gliomagenesis in
section 1.4,) therefore making them an ideal target for EGFR tyrosine kinase therapy
(Halatsch et al, 2006). They also have the ability to penetrate the blood brain barrier
(Rich et al, 2004). In 2002 a report was published on a phase II clinical trial to
determine the tolerability of Gefitinib for the treatment of GBM at first recurrence. They
demonstrated tolerability with moderate activity of Gefitinib in patients. It was observed
that a population of the patients experienced beneficial effects of the therapy, with over
50% of the patients showing progressive disease or toxicity. They observed a 6-month
progression free survival rate of 13.2% which is worse than observed in patients with
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first relapse GBM that were treated with TMZ (21%) but better than Procarbazine (8%)
(Rich et al, 2004). While the results from this study were poorer than expected,
Gefitinib demonstrated low toxicity and moderate efficacy therefore suggesting that
future studies should investigate alternative dosages (Rich et al, 2004). Also due to the
low toxicity of the drug, there might be a future for Gefitinib in the treatment of GBM
as a combinational therapy.
1.7.4

Plant Alkaloids

Plant alkaloids are chemotherapeutics derived from certain types of plants. Plant
alkaloids can be classified into 4 specific categories shown in table 1.3 below.
Camptothecin is a natural product, derived from traditional Chinese medication. It is a
DNA topoisomerase I (topo I) and induces DNA single-strand breaks during
transcription and DNA replication (Efferth et al, 2007). Vinca alkaloids such as
vincristine bind to β-tubulin and inhibit microtubule assembly. Vindesine is a novel
vinca alkaloid derivative that exhibits enhanced clinical features for tumour therapy
(Efferth et al, 2007), as stated earlier vincristine is used as part of the PCV
combinational therapy for the treatment of GBM.
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Table 1.3 Different categories of plant alkaloids
Plant alkaloids

Plant source

Periwinkle

Example

plant

Vinca alkaloids

Vincrisitne
(catharanthus rosea )

Taxanes

Pacific Yew tree (taxus)

Paclitaxel (Taxol)

Podophyllotoxins

May apple plant

Etoposide

Asian

"Happy

Tree"

Camptothecin analogues

Topotecan
(Camptotheca acuminate)

Medicinal herbs have played an important role in the development of western medicine.
Since the advancement of the pharmaceutical industry the role of rational for
Chinese/herbal medicines have had less of an impact on the treatment of disease. In
more recent years there has been a noticeable revival of interest in the use of bioactive
natural compounds to be used a therapeutic targets for the treatment of disease (Efferth
et al, 2007) . A large proportion of natural products are currently under development as
potential anti-cancer therapies.

1.8

Nutraceuticals

According to the scientists around 400BC the Hippocrates were the first to identify the
association of food and its medicinal properties stating “Let the food be thy medicine
and medicine be thy food.” –Hippocrates (Gupta et al, 2010), although it is only in the
past 20 years, that there has been a big emphasis on the link between nutrition and
pharmaceuticals. The rapidly growing interest in the area of bioactive natural
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compounds and their health enhancing properties, led to the development of the term
‘nutraceutical’, a term coined by Stephen DeFelice, the founder and chairman of the
Foundation for Inno-vation in Medicine (FIM). The term nutraceutical can be defined as
‘A functional food that aids in the prevention and/or treatment of disease or disorder
(except anaemia) therefore allowing for the distinction between functional food, dietary
supplements and a nutraceutical (Kalra, 2003).
1.8.1

Ursolic Acid as a novel treatment for GBM.

Ursolic acid (3β-hydroxy-urs-12-en-28-oic-acid), a bioactive active pentacyclic
triterpene acid which has been successfully isolated from various types of medicinal
plants for example, holy basil (Ocinum sanctum L.) (Vetal et.al, 2010), Salvia
officinalis (sage) (Kassi et al, 2007) and fruits such as apples, pears, cranberries
(Vaccimium macrocarpon Air) or more significantly in their peel (Kondo et al, 2011;
Shanmugam et al, 2013a). Ursolic acid (UA) as seen in figure 1.5 below, is a sterol-like
chemical with 5 fused rings. It has a chemical formula of C30H48O3, has a melting point
is 283-285oC and the molecular weight of UA is 456.7g/mol. UA belongs to a family of
plant-indigenous phytosterols. These are a group of chemical compounds that are
similar to the structure and properties of cholesterol.
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Figure 1.5: Chemical structure ursolic acid

Ursolic acid has been the major component of a many herbal medicines worldwide that
are used to treat anti-inflammatory conditions (Ikeda et al, 2008). Current research
suggests that UA has anti-proliferative and anti-tumour properties when tested on
various malignant cell lines in vitro (Shanmugam et al, 2013a; Weng et al, 2014).
Mechanisms for UA activity have been identified in some in vitro cancer models, for
example, UA down-regulates Mcl-1 and activates caspase gene expression in leukaemia
cells (Gao et al, 2012). In an ovarian cancer cell line, UA was shown to induce caspase
activation while suppressing the transcription of survival genes such as c-Myc and BclxL and interrupting phosphorylation of extracellular regulated kinases (ERK) (Song et
al, 2012). In a colon cancer cell line, UA was found to induce anti-proliferating effects
by suppressing the phosphorylation of EGFR, ERK, JNK, and P-38 (Shan et al, 2009).
It was recently demonstrated by (Yeh et al, 2010) that pretreatment of cells with UA
chemosensitises ASTC-a-1, lung adenocarcinoma cells, but not normal cells, therefore
significantly reducing the required chemotherapeutic drug dose without sacrificing
treatment outcome. Yeh et al also identified that UA is dependent on the inhibition of
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NF-κB, leading to amplified activation of the intrinsic apoptotic pathway via
augmentation of BID cleavage and activation of Fas/FasL-caspase-8 extrinsic apoptotic
pathway. (Shanmugam et al, 2011) demonstrated both in vitro and in vivo, that UA
exerts anti-metastatic effects through the suppression of CXCR4 expression in prostate
cancer. Recently in 2014, a small Phase I trial evaluating the multiple-dose safety and
antitumor activity of UA liposomes in subjects with advanced solid tumors was carried
out and demonstrated that UA liposomes were tolerable, had controllable toxicity, and
could potentially improve patient remission rates. A larger study is required to confirm
the findings observed by (Qian et al, 2014). Little research at present has been
published focusing on GBM, despite clear evidence of positive efficacy and safety data
in other tumour models and the lack of therapeutic alternatives for treating GBM. Antitumour activity by UA was determined in previous studies (Wang et al, 2012b; Shen et
al, 2014) where either apoptosis or autophagy in U251MG or U87MG GBM cells
respectively was induced by UA. More recently it was also demonstrated that UA
triggers non-programmed cells death (necrosis) in the GBM TMZ resistant cell line
DBTRG-05MG (Lu et al, 2014). UA is a promising anti-proliferative compound and
has great potential as a natural chemo-preventative target.

1.9

Novel experimental treatment for GBM

The following sections describe the novel experimental therapies that are employed in
this report for the treatment of GBM cells. Current treatment for GBM involves using a
combination of treatments including surgical resection with treatment of radiotherapy
combined with chemotherapy. With survival rates remaining low over the past decade
despite the multitude of treatments available, indicts a necessity for the development of
novel therapies for the treatment of GBM. Cold Atmospheric Plasma (CAP) is a novel
non-ionizing form of radiation that has shown great promise as a combinational therapy
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for the treatment of GBM. An advantage of CAP over treatments such as radiotherapy is
the localisation of the treatment to the site of the tumour, with reduced side effects to
the surrounding healthy tissue. There is great potential for CAP to be to be utilised as a
combination therapy with both existing and novel chemotherapeutics.

1.10 Plasma
During the 19th century the term ‘plasma’ was first coined by the Czech physiologist
Jan Evangelista Purkinje. It symbolised the translucid liquid that remains after
completely removing the corpuscles from the blood (Bellan, 2006). Following this in
1927 an American chemist and physicist Irving Langmuir became the first scientist to
describe the term ‘plasma’ as ionized gas. Langmuir developed the theory of ‘plasma
sheaths’, the boundary layers that form between ionized plasmas and solid surfaces, he
also discovered Langmuir waves, nowadays known as plasma oscillations, which are
electrostatic waves that propagate in a plasma, because of variations in the plasma's
electron density. Gradually overtime plasma research expanded in different directions
depending on its application for example space plasma physics, thermonuclear fusion,
and plasma medicine.
Over the past decade plasma science has emerged as a novel tool for applications such
as food sterilization, medical devices, polymer science, biomedicine, microelectronics
(von Woedtke et al, 2013; Ziuzina et al, 2014). This continuously evolving field has led
to the recent discovery of the biological effects of plasma, now known as plasma
medicine. This emerging field combines plasma physics, life sciences and clinical
medicine in the hope of developing therapeutic applications. Despite all of the recent
advances in medical research over the past century there are still many diseases that are
deemed incurable as there is no available therapy, or the disease has evolved and is now
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resistant to such therapies. Recent advances have highlighted the potential of
technological solutions to treat a variety of medical conditions. Over the past decade
there have been many studies investigating the biological effects of CAP in mammalian
cells both in vitro and in vivo, these studies established that CAP applied at sub-lethal
doses can induce a cytotoxic effect resulting in apoptosis, cell death, cell detachment
and cycle arrest in a variety of mammalian cells tumour cells of which have been
extensively reviewed by (Ratovitski et al, 2014). In contrast to this CAP has also been
shown to promote cellular proliferation, providing painless disinfection and reducing
the healing time of venous ulcers, and other lesions as a result of skin disorders,
proving a potential application for wound healing (Isbary et al, 2012; Arndt et al, 2013;
Haertel et al, 2014). The mechanisms that affect mammalian cells and prokaryotes are
as a result of a variety of biologically active agents generated by CAP.
Plasma is often referred to as the fourth state of matter as illustrated in figure 1.6 below.
Plasmas are defined as fully or partially ionized gas consisting of ions and electrons
(Piel, 2010). It is the combination of free electrical charges, ions and electrons that
makes plasma electrically conductive and responsive to an electromagnetic field
(Fridman & Friedman, 2012). Plasmas possess a variety of unique properties such as
ability to radiate, react chemically and conduct electricity, these properties result in
plasmas having different temperatures. Plasmas are can be distinguished as either
thermal or non-thermal.
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Figure 1.6: Four state of Matter as the temperature increases. (Jenner, 2007)

Thermal plasmas are obtained at high pressure (>10^5 Pa) and require substantial power
(~50MW) to be observed(Moreau et al, 2008). They are characterized by high electron
densities and high temperatures between 5000 -50000K, and thus are known to be in
local temperature equilibrium (LTE), meaning they can be characterised by a single
temperature value (Heberlein, 1992). Thermal plasmas are naturally occurring e.g. the
sun, they are also found in plasma torches and circuit breakers (Heberlein, 1992;
Fridman & Friedman, 2012). Non thermal plasmas are non-equilibrium plasmas and are
often referred to as ‘cold’ plasmas. They are obtained at low or atmospheric pressure,
have low power requirements and also have the ability generate chemically active
species within gasses while remaining at a low temperature. The temperature of the
electrons can reach between 10,000 -100,000 K while the gas temperature can remain as
low as room temperature. An example of naturally occurring non thermal plasma is the
effect known as the aurora borealis as seen in figure 1.7 below. Throughout the 21st
century non thermal plasmas have been established by many industries for various
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applications; sterilization of foods, dentistry, bacterial decontamination, wound healing,
improvement of packaging materials, waste and air pollution management, polymer
processing, low energy light bulbs (Kalghatgi et al, 2011; von Woedtke et al, 2013).

Figure 1.7: The Aurora borealis is an example of non-thermal plasmas occurring
in nature as opposed to the sun which is an example of thermal plasma found in
nature. Aurora Borealis, Co. Donegal (Diver, 2013)

Plasmas are generated by applying energy i.e. electrical, thermal, or electromagnetic
radiations, to a gas which primarily produces energized electrons and ions (Fridman et
al. 2005; Tendero et al. 2006). The majority of the energy applied results in the
generation of energized ‘hot’ electrons while the gas stream remains at a low energetic
state i.e. low plasma temperature (von Woedtke et al, 2013). Throughout the past two
decades there have been a variety of plasma sources developed and commercialised for
the biomedical field, the majority of which are based on using atmospheric pressure
plasmas as opposed to low-pressure plasmas which involve the use of a vacuum
chamber (von Woedtke et al, 2013). The most significant advantage being that it allows
for localized treatment of a specific area.
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1.10.1 Cold Atmospheric Plasmas
Cold atmospheric plasma occurs at atmospheric pressure in air or other gases when a
high voltage is applied between two electrodes. Energy is required in order to generate
plasma; this can be achieved using electrical energy, electromagnetic waves and gravity.
Plasma can be created using noble gases, ambient air, or aqueous vapours (Ogata et al,
2000). There are a number of requirements that must be taken into account for the
design of CAP for any given application for example; temperatures, chemical
composition, air flow, frequency of applied voltage, pressure and sustainment of the
electrical field (Conrads & Schmidt, 2000; Fridman et al, 2008). Thus each design is
created specifically for its application. The method most commonly used for creating
plasma involves the electrical breakdown of a neutral gas in the presence of an electric
field (Conrads & Schmidt, 2000). The electrical energy that is discharged firstly goes to
the electrons. This results in the temperature of the electrons to rise quickly to
approximately 10,000K and the electrons become excited, but gradually over time the
heat is transferred to the ions and neutral species (Kumar et al, 2008; Kalghatgi, 2010).
This is known as the ‘electron avalanche’ until the electrons becomes balanced and
steady-state plasma is formed.
Cold atmospheric plasmas can be generated by a diversity of electrical discharges, and
the following are examples of those which have been developed for the biomedical
industry; corona discharge, micro hollow cathode discharge, atmospheric pressure
plasma jet, dielectric barrier discharge (DBD), floating-electrode dielectric barrier
discharge (FE-DBD) plasma guns and plasma needle (von Woedtke et al, 2013). These
can generally be broken down technically into barrier discharges, plasma jets and
corona discharges. Barrier discharges are characterised by the presence of at least one
insulating layer in the discharge gap (von Woedtke et al, 2013). Atmospheric pressure
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plasma jets (APP jets) consists of one or two electrodes through which gas flows, when
the gas discharge is ignited the plasma flows through the nozzle (Schutze et al, 1998).
Corona discharge was the first scheme used to generate cold atmospheric plasma. It can
be defined as non-uniform discharges that develop in the high field region near the
sharp electrode spreading out towards the planar electrode (Kumar et al, 2008).
1.10.1.1

Dielectric Barrier Discharge

The dielectric barrier discharge also known as ‘silent discharge’ is a well-established
plasma source. It was first developed in 1857 by Werner von Siemens who focused on
the generation of ozone (Kogelschatz, 2003). A DBD is an alternating current (AC)
discharge, which provides a strong thermodynamic, non-equilibrium plasma at
atmospheric pressure and at a low gas temperature (Kumar et al, 2008). DBD’s are
composed of one or more dielectric layers placed in the current path between metal
electrodes, the presence of an insulating layer between two electrodes as illustrated in
figure 1.8 below, it is the easiest approach to creating a non-equilibrium atmospheric
discharge. The dielectric barrier can be made from glass quartz ceramics and other
materials of low dielectric cost and high breakdown strength (Fridman et al, 2005).
Most DBD’s operate with an amplitude of about 10-120 kV and frequency of 10-100
kHz (Bibinov et al, 2011). The DBD structure can be operated in a variety of
configurations for example volume discharge which can be planar electrode
arrangements, or cylindrical electrode arrangements, surface discharge and coplanar
discharge.
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Figure 1.8: Common DBD configuration.
Illustrating the two electrodes, separated by a dielectric barrier. In this schematic the
sample is place between the two electrodes, where the reactive species are generated in
the plasma field.

To ensure stable plasma operations, the gap between the electrodes is limited to a few
centimetres; while this set-up is advantageous for the purpose of sterilization and has
the ability to cover large surface areas there are limitations in certain biomedical
applications, as the surface must be smooth otherwise treatment can become patchy
(Kong et al, 2009). Stable plasmas can also be generated between electrodes with a
larger gap by applying higher voltages, as demonstrated in the system used in this
report. DBD’s that are used in medical applications use only one electrode which is
covered with a dielectric layer, allowing close contact with the skin, the human body
acts as the second electrode (Bibinov et al, 2011), this is known as the floating electrode
dielectric barrier discharge (FE-DBD). Fridman et al developed the FE-DBD in order to
enhance the safety of directly applying high voltage non thermal plasma discharges to
the skin. DBD’s are operated at atmospheric pressure i.e. air is characterised by the
formation filament structure known as ‘microdischarges’. Microdischarges have a high
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electron density and thus dissociation of oxygen and nitrogen molecules during electron
impact takes place abundantly (Fridman et al, 2005; Bibinov et al, 2011).
1.10.2 Biologically active components generated by CAP
The most significant biologically active agents generated by CAP are, Reactive
Oxygen/Nitrogen Species (ROS/RNS) and electrical current, which if present at high
concentrations can result in inhibition or stimulation of cellular function (von Woedtke
et al, 2013)
Most CAP’s generate an electrical current, primarily the dielectric barrier discharge
system. The electrical energy produced from plasma generation is used to produce
energetic electrons, this is an alternative to heating the entire gas stream (Fridman et al,
2005). The International Commission on Non-Ionizing Radiation Protection has
determined the touch perception limit of current flowing through the human body to 25
mA at both 1 and 100 kHz (ICNIRP, 1998). There are many therapies that rely on
electrical current to take effect, for example the fentanyl HCl iontophoretic transdermal
system (fentanyl ITS), it uses an electrical current (170mA) to drive ionized drug
molecules across the skin and into blood circulation. This system is used throughout
Europe and the USA for post-operative pain management, allowing for selfadministration by patients (Power, 2007). Therefore, provided the electrical current of
the plasma device is kept to a minimum, it can be deemed safe.
Once the plasma source is turned on there is a series of cascading events that occur
during plasma generation. Plasma is only generated once the power supply has been
switched on, once it is switched off the plasma rapidly dissipates.

As described

previously CAP is generated under atmospheric conditions i.e. air. Samples can be in
liquid form (water or cell culture media), as dry samples (food products such as fruit) or
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in the case of adherent mammalian cell cultures there is a thin film of media that will
always remain in the wells covering the cells. The interface between CAP and liquid is
important. It can be present in the sample as described above or present as humidity in
the air. Without water, CAP will not generate long lived reactive species. CAP induces
longer lived species that accumulate in liquid (i.e. water or media) such as the
production of the ROS / RNS as described below. Water, or media, allows the longer
lived species to remain in the vicinity of the treatment, and of course facilitates the
production of long lived reactive species. Studies have shown that media that has been
treated with CAP (plasma activated media, PAM) is able to retain its cytotoxic and
genotoxic activity upon storage at +4 °C or -80 °C, as well as H2O2 concentration in
PAM remains stable during at least 7 days of storage at +4 °C and −80 °C (Judée et al,
2016). In the case of CAP and direct treatment on cellular material such as cancer cells,
there are a number of physical and chemical changes on biological surfaces that occur.
When compared to normal cells, cancer cells display elevated levels of ROS which
enhances their ability to proliferate and promote their malignant progression (Marengo
et al, 2016). This results in redox adaptation in response to the increase in oxidative
stress, leading to an upregulation of antioxidant molecules such as glutathione (GSH).
As a result, this renders the cancer cells highly dependent on these antioxidant systems,
therefore making them an ideal target to treatment modalities that abrogate these
antioxidant molecules (Trachootham et al, 2009).This provides biochemical bases for
selective attack of cancer cells by CAP, mediated by the influx of extracellular RONS,
resulting in oxidative damage overcoming the antioxidant capacity of the cell, resulting
in cell death. It has also recently been demonstrated that CAP can modify the expression
of nearly 3,000 genes encoding structural proteins and inflammatory mediators, such as
growth factors and cytokines (Gay-Mimbrera et al, 2016; Schmidt et al, 2016). The
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mechanism of how CAP exactly interacts with tissues is not completely understood, but
unlike penetrating ionisation radiation, CAP is a surface or near-surface treatment
modality. It is unknown whether the intracellular RNS following CAP treatment is
being created by the cell in response to CAP treatment or as a results of the generated
ROS penetrated through the cell membrane (Graves, 2014).

Figure 1.9 CAP and cell interaction (Graves, 2014)

As demonstrated above in figure 1.9, CAP generates RONS that can either enter a cell
surface-covering liquid layer or enter the cells directly. The effects of the solvated
RONS and their products are in the surface layer of cells that are exposed to them, the
effects on deeper layers of tissue therefore, involve some cell–cell communication. It
has been postulated that these mechanisms are similar to radiation-induced “bystander
effects,” such as the involvement of the immune system.
Reactive Oxygen/Nitrogen Species
CAP attained at low or atmospheric pressure, generate chemically active species within
gases such as reactive oxygen species (ROS) (O2•, O, O3, OH•, and H2O2) and reactive
nitrogen species (RNS). One of the major components generated as a result of CAP is
56

Ozone (O3). The US Environmental Protection Agency in 2008 revised the level of the
8-hour national ambient air quality standards to 0.075 parts per million (ppm) (von
Woedtke et al, 2013). Ozone has been used in the medical field for over 80 years, and
still remains a topic of controversy. A recent review by (Graves, 2012) describes
published articles that are both for and against the use of ozone therapy. The American
Cancer Society’s journal CA: A Cancer Journal for Clinicians published an article that
strongly against recommending the use of ozone and other hyper oxygenation therapies,
although they conclude with the following statement:
‘This recommendation, however, is not intended to preclude the use of oxygen-rich
compounds or hyperbaric oxygen therapy in situations for which efficacy has been
demonstrated. Nor is it meant to discourage responsible study of these methods by the
scientific community.’
In opposition to this is (Bocci, 2006, 2007) has published articles showing that although
the effects of ozone exposure can be toxic, the effects can be controlled when
administered correctly and can be used in the treatment on many diseases (Graves,
2012).
1.10.3 Reactive Oxygen/Nitrogen Species
The term ROS (reactive oxygen species), has been coined to define an emerging class of
endogenous, highly reactive, oxygen (and nitrogen) -bearing molecules, derived from
molecular oxygen. They mediate many biological functions within the cell such as
phagocytosis of bacteria and cellular redox signalling (Simon et al, 2000; Ahn et al,
2011). Molecular oxygen (O2) is a free radical containing two unpaired electrons with
the same spin in its outer shell. O2 is capable of accepting electrons to its anti-bonding
orbital’s and thus becomes reduced (Thannickal & Fanburg, 2000). The mitochondrion
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is the main source for ROS in mammalian cells (Murphy, 2009). The reduction of
oxygen by one electron results in the formation of superoxide anion (O2ˉ•), which is a
precursor of many ROS. Rapid dismutation of O2ˉ• by superoxide dismutase (MnSOD)
results in formation of hydrogen peroxide H2O2 which can then be further reduced to
hydroxyl radical (OH•) which is considered one of the strongest oxidants in nature
(Turrens, 2003), this process is known as the Fenton reaction:
Fe2+ + H2O2 → Fe3+ + OH• + OH–
Hydroxyl molecules can also be generated through the Haber-Weiss reaction:
O2•‾ + H2O2 → O2 + OH• +OH‾
While the dismutation of O2ˉ• accounts for the majority of H2O2 produced in the cell,
H2O2 can also be generated by two electron reductions of O2. Hydrogen peroxide is
more stable than O2ˉ• and also has the ability to diffuse across the mitochondrial
membrane unlike O2ˉ• (Thannickal & Fanburg, 2000). In table 1.4 is a list of the most
common ROS/RNS species found in normal cells.
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Table 1.4 : List of the most common ROS and RNS species found in normal cells
(del Río et al, 2006; Fransen et al, 2012).
Reactive oxygen

Reactive Oxygen

Reactive

Species

Species

Nitrogen Species

(Radicals)

Radicals)

(Non-

(RNS)

Hydroxyl

OH•

Lipid Peroxide

LOOH

Nitrous Oxide

N2O

Superoxide

O2ˉ•

Hypochloric acid

HOCl

Peroxynitrite

ONOO‾

Nitric Oxide

NO•

Hydrogen

H2O2

Nitroxyl anion

NO‾

Nitrogen dioxide

NO2•

Nitrous acid

HNO2

peroxide
Peroxyl

RO2•

Ozone

O3

Lipid Peroxyl

LOO•

Singlet Oxygen

‾ O2

1

Reactive nitrogen species are recognised as a derivate of nitric oxide (NO). NO is
biosynthesised endogenously from the oxidation of L-arginine to L-citrulline by the
family of enzymes, nitric oxide synthases (NOS) (Curtin et al, 2002). NO plays a
pivotal role in many biological processes, for example is a mediator for smooth muscle
relaxation, regulator of skeletal muscle contractility (Bredt, 1999), activates GTP
binding protein on p21Ras pathway, and regulation of Ras/NFκB pathway (Patel et al,
1999). Free radicals such as superoxide (O2ˉ) react with NO to form peroxynitrite
(ONOO‾) a short lived powerful oxidant. RNS formed in the cytosol by nNOS, eNOS,
and iNOS and also in the mitochondrion by mtNOS (Curtin et al, 2002).
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1.1.1.1 Antioxidants
It is important for the cells to maintain a steady state concentration of O2ˉ• in order to
prevent oxidative stress, which is described as the deleterious process resulting from an
imbalance between the over production of ROS/RNS and inadequate antioxidant
defences (Turrens, 2003). Cellular damage and apoptosis due to the high reactivity of
ROS/RNS is avoided by various antioxidant enzymes present in the cell such as
glutathione peroxidise, superoxide dismutase (SOD), and catalase which act as
scavengers, detoxifying ROS (King & Robins, 2006). There are three types of SOD that
have been identified (intra-mitochondrial manganese MnSOD, cytosolic Cu,Zn-SOD,
and extracellular SOD) (Raha & Robinson, 2000), all of which catalyses the
dismutation of O2ˉ• to H2O2 and O2, . Since O2ˉ• has the ability to reduce both transition
metals which results in OH• formation or spontaneously react with NO resulting in
ONOO‾ formation, it is vital that the concentration of O2ˉ• is maintained at a low steady
state. One of the primary defences against hydrogen peroxide is the catalase enzyme
which is found in peroxisomes, it catalyses the decomposition of H2O2 to form water
and molecular oxygen (Curtin et al, 2002):
2 H2O2 → 2 H2O + O2
There have been numerous studies that have demonstrated the cytotoxic effects of
endogenous and exogenous H2O2 (Datta et al, 2002a; Ahn et al, 2014), which highlight
the importance of the catalase and a cells antioxidant defence system. Glutathione
(GSH) is a tripeptide consisting of glutamate, cysteine and glycine (L-γ-glutamyl-Lcysteinyl-glycine), is low molecular weight thiol molecule which is a very important
antioxidant in a cell defence system in its protection against ROS. GSH has two main
functions; it acts as a ROS scavenger and also regulates the intracellular redox state
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(Curtin et al, 2002). GSH is synthesised by all cells and approximately 15% of cytosolic
GSH is transported to the mitochondria (Stańczyk et al, 2005). The GSH system is
composed of GSH, glutathione peroxidase and glutathione reductase. GSH is involved
in the regulation of apoptosis, reduced levels of GSH have been shown to induce
oxidative stress and therefore induce apoptosis (Franco & Cidlowski, 2009).
Glutathione peroxidase catalyses the reduction of H2O2 into water, and the conversion
of GSH into glutathione disulphide (GSSG). The regulation of the redox cycle is based
on the GSH: GSSG ratio, and not the concentration of GSH present.

1.11 History of cell death
Cell death has been recognised and understood since the 19th century, but there was no
experimental examination until the mid-20th century. The first to recognise ‘cell death’
was Carl Vogt in 1842 (Clarke & Clarke, 1996) although at that time it was not
identified as cell death. It was till much later in 1885 that Walter Flemming was the first
to describe what we now identify today as apoptotic morphologies, such as shrinkage of
cells, chromatin condensation, nuclear fragmentation and formation of apoptotic bodies;
he termed this process chromatolysis (Curtin & Cotter, 2003). Research on cell death
drifted for much of the 20th century until the 1960’s, when Glücksmann described the
characteristics of karyorrhexis and karyopyknosis, that we now know to be events
associated with apoptosis (Glücksmann, 1951; Curtin & Cotter, 2003). As a
consequence of Glücksmann’s findings, this led to a revived interest in the investigation
of cell death. In 1965, Australian pathologist John F. Kerr, noted an unusual form of cell
death in liver tissue from rats. He described the unique morphological changes as
shrinkage necrosis, which was subsequently identified through electron microscopy as
condensation of the cytoplasm and the nuclear chromatin (Curtin & Cotter, 2003). In
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wasn’t until 1972 when Kerr published one of the most highly regarded papers to date
in relation to cell death, where he first coins the term apoptosis, which replaced his
original terminology of necrosis shrinkage (Kerr et al, 1972). At a similar time, in
1964 Lockshin & Williams from their studies on the demise of intersegmental muscles
in developing silk moths, coined the term ‘programmed cell death’ (Lockshin &
Williams, 1964), where they described the death of any cell is mediated by an
intracellular programme. Today, programmed cell death (PCD) can be divided into
three main categories which ultimately decide a cells fate; PCD type 1 also known as
apoptosis, PCD type 2 known as autophagy and more recently described type 3
programmed necrosis/necroptosis (SEN, 1992).
In recent years, our knowledge on the mechanisms of cell death have developed thus
resulting in the identification of alternative cell death pathways such as caspase
independent cell death. This has led to different mechanisms of cell death that have
been defined by morphological criteria, without a clear reference to precise biochemical
mechanisms. The development underscores the importance of clearly defining what is
referred to as 'cell death' as well as the multiple processes leading to it. As a result,
members of the scientific community with expertise in the area of cell death have come
together and established a committee known as the ‘The Nomenclature Committee on
Cell Death’ (NCCD). The aim of this committee is to unified criteria for the definition
of cell death and of different cell death morphologies, while formulating several
warnings against the misuse of words and concepts that slow down progress in the area
of cell death research (Kroemer et al, 2005). They recommend the use of functional
descriptive terms for example, expressions such as percentage cell death or percentage
apoptosis, percentage cell survival must now be accompanied with more descriptive
terms such as percentage cell death with condensed chromatin, or percent of dead cells
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with a low mitochondrial transmembrane potential'. Encouraging the quantification of
cell death with more than one assay(Kroemer et al, 2005). The NCCD have published
four articles since 2005 critically evaluating how cell death is represented in the
literature and the most appropriate ways to do so in terms of how to identify different
mechanisms of cell death and the correct expressions and terms in which to do so.
1.11.1 Caspases
Caspases are a family of endoproteases that are important for maintaining homeostasis
through regulating cell death and apoptosis. In humans, there are 11 known caspases,
and have been classified based on the function, caspase 2, 3, 6, 7, 8, 9, 10 and 14 are
involved in apoptosis, 1, 4, 5, are involved in inflammation. Caspase 12 is present in the
murine genome but is not expressed in humans. Caspase 11 is a pro-inflammatory
caspase found in mice, and its human homolog is caspase 4. Caspase 13 was originally
reported to be a member of the human caspases but following studies could not identify
caspase 13 expression in any human tissue. Studies have shown caspase 13 is not of
human origin but represents a bovine gene (Humke, 1998; Koenig et al, 2001). The
apoptotic caspases can be sub classified based on their role in the apoptotic process,
they are divided into initiator (8, 9) and executioner (also known as ‘effector’) caspases
(3, 6, and 7). Caspase 2 plays a central role in the execution phase of apoptosis, it is
involved in proteolytic cleavage of other proteins. It is a highly conserved protein but
function remains poorly defined. It belongs to a family of cysteine proteases that cleave
proteins only at an amino acid following an aspartic acid residue. Caspase-2 has been
shown to be involved in the regulation of cell death that is induced by metabolic
imbalance, DNA damage, endoplasmic reticulum (ER) stress, mitotic catastrophe (Fava
et al, 2012) and more recently it has been shown to exist in the mitochondria and that it
is essential for mitochondrial oxidative stress-induced apoptosis (Lopez-Cruzan et al,
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2016). Caspase 10 is highly homologous to caspase-8, it is involved in the activation
cascade of caspases and is responsible for the execution of apoptosis. However, the full
role of caspase 10 in extrinsic apoptosis remains unclear. A recent article by McIlwain
et al reviews the conflicting reports suggesting a role for Caspase-10 in CD95-mediated
apoptosis in the absence of Caspase-8 (McIlwain et al, 2013a), while others have
demonstrated that Caspase-10 acts in an atypical CD95-induced cell death pathway
(Sprick et al, 2002; Lafont et al, 2010). It has also been suggested that Caspase 10 is
recruited to both Fas- and TNFR-1 receptors in a FADD dependent manner as well as
cleaves and activates Caspase-3, -4, -6, -7, -8, and -9 (Wang et al, 2001; McIlwain et al,
2013a). The initiator caspases exist as procaspases which when become dimerised are
activated. The activated initiator caspases then activate the executioner caspases.
Caspases and the apoptotic signalling pathway are tightly regulated, it would be logical
to consider that any form of altered expression of these proteins would result in
dysregulation and therefore aid in disease and tumorigenesis. Although mutations in
caspases are rare, other elements of the apoptotic signalling pathway such as P53 are
commonly mutated, especially in GBM (as noted in section 1.4) and therefore as a
result effect their expression downstream. There have been some reports noting
mutations in caspase 8 in a variety of cancers (McIlwain et al, 2013b). In a study of 180
cases of human colorectal carcinoma 5% were shown to express mutated caspase 8
(Kim et al, 2003).
The initiator caspases (8, 9) exist as procaspases that retain low levels of intrinsic
activity and cleave in trans when they become dimerised, resulting in their activation.
The activated initiator caspases then activate the executioner caspases (3, 6, 7), which
do not possess any intrinsic activity in the procaspase form. Caspase 8 plays a pivotal
role in the extrinsic apoptotic signalling pathway via death receptors, it has been
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demonstrated (Kruidering & Evan, 2000) that ligand binding of death receptors results
in the recruitment of the receptor-specific adapter protein Fas-associated death domain
(FADD), which in turn recruits caspase-8. Activated caspase-8 can transmit apoptotic
signals by directly cleaving and activating downstream caspases or by cleaving the BH3
containing Bcl2-interacting protein, which in turn leads to the release of cytochrome c,
resulting in the activation of caspase 9 by binding Apaf-1 and dATP (Kruidering &
Evan, 2000; Kuida, 2000). Activated Caspase 9 cleaves downstream caspases such as
Caspase 3, 6 and 7 initiating the caspase cascade (Kuida, 2000).
1.11.2 Apoptosis
Apoptosis occurs normally during development and aging but also as a homeostatic
mechanism for tissue development (Elmore, 2007), on the other hand apoptosis also
occurs as a defense mechanism in response to stress for example DNA damage.
Apoptosis is the most studied mechanism of cell death, and is now accepted as a
distinctive and important mode of “programmed” cell death, which involves the
genetically determined elimination of cells. As first described by Kerr et al, apoptosis is
characterised morphologically by the following attributes: condensation of both nucleus
and cytoplasm, nuclear fragmentation, pyknosis and separation of protrusions that form
on the cell surface (karyorrhexis) (Kerr et al, 1972; Elmore, 2007). Cells can respond
differently to the same apoptotic stimuli, for example drugs that induce DNA damage
can result in activation of apoptosis in some cells while others remain unaffected. Also
it should be noted that low doses of external stimuli such as radiation can induce and
apoptotic response whereas at higher doses induce necrosis (Elmore, 2007). Apoptosis
is a highly regulated process, and once Caspase 3 has been cleaved and activated it will
unavoidably lead to cell death as beyond this point it is an irreversible process, below
will describe in details the two mechanisms by which apoptosis is initiated.
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1.11.2.1

Mechanisms of apoptosis

Apoptosis can be initiated by one of two pathways; intrinsic or extrinsic pathway. The
intrinsic pathway also known as the mitochondrial pathway as it is under control of the
mitochondria. The pathway becomes activated by extracellular and intracellular
stressors such as cytotoxic drugs and oxidative stress. This causes a conformational
change in the pro-apoptotic B-cell lymphoma 2 (Bcl-2) members Bax and Bak and
which results in permeability of the mitochondrial membrane (by producing MOMP)
and then releasing cytochrome c along with mitochondrial proteins (apoptotic inhibitors
Smac and Diablo) into the cytosol. As demonstrated in figure 1.10 below, Cytochrome c
that is released into the cytosol binds to Apaf-1 which initiates the formation of the
apoptosome and catalyses the activation of initiator Caspase 9 which in turn activates
executioner Caspase 3 that carries out the known physiological steps of apoptosis
(membrane blebbing, pyknosis, karryohexis etc.)
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Figure 1.10 Intrinsic & extrinsic apoptotic signalling pathway (Carlo-Stella et al,
2007)

The extrinsic apoptotic pathway is also known as the death receptor mediated pathway
is the other major pathway of apoptosis. Death receptors exist on the plasma membrane
and the most studied are Fas-R, tumour necrosis factor receptor (TNF-R1) and TNFrelated apoptosis-inducing ligand receptor (TRAIL). Extracellular ligands, FasL, TNFα, and TRAIL bind to these receptors and initiate apoptotic pathway (Lawen, 2003;
McIlwain et al, 2013b). Binding of the death receptor ligand to the death receptors
results in recruitment of initiator Caspase 8 and 10 to produce the death inducing
signalling complex (DISC) (Lawen, 2003) and this then activates the executioner
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Caspase 3 which results in apoptosis. As demonstrated in figure 1.10 above, there is
cross talk between these two pathways, whether apoptosis has become activated by the
extrinsic pathway or the intrinsic pathway,

the mitochondrial membrane becomes

permeable and Cytochrome c is released which triggers Caspase 9/3 signalling cascade
and ultimately resulting in apoptosis (Li & Yuan, 2008).
1.11.2.2

Apoptosis resistance in GBM cells

The poor survival statistics of GBM is fundamentally due to their highly deregulated
tumour genome, expressing deletions of tumour suppressor genes, amplification and/or
mutations resulting in hyper activation of

tyrosine kinase receptors (Krakstad &

Chekenya, 2010). It is these genetic alternations that results in the deregulation of both
survival and apoptotic signalling pathway and therefore development of tumour
resistance to therapies. GBM’s are associated with apoptotic resistance, a recent study
carried out demonstrated heterogeneity of apoptosis associated protein expression in
GBM (Murphy et al, 2013). They identify low basal levels of Procaspase-9 both in vitro
and in vivo, which has been shown previously by others to be expressed at high levels
(Bodey et al). Whereas, on the contrary they demonstrate differential levels of
Procaspase-3 in both GBM patient samples and GBM cell lines. Moreover, they noted
differential expression of procaspase-3 in the GBM patient samples and in the in vitro
studies, but interestingly was found to correlate with TMZ sensitivity in the cell lines
and also progression free survival times in GBM patients (Murphy et al, 2013). A key
player in the intrinsic apoptotic pathway, Bcl-2 family of proteins which consists of
both a proapoptotic form such as Bax and Bak, which induce mitochondrial
permeability progression of the intrinsic apoptotic pathway, but also exist in antiapoptotic form such as Bcl-2 and Bcl-XL which bind and inhibit Bax and Bak therefore
acts as a cell survival mechanism. One study has demonstrated an upregulation of pro68

survival proteins Bcl-2 and Bcl-XL and a down regulation of pro- apoptotic protein Bax
in recurrent GBM patients (Strik et al, 1999). It has also been shown that anti-apoptotic
protein Bcl2-like protein 12 (Bcl-2L12) is over expressed in nearly all GBM’s which
also leads to dysregulation of the apoptotic signalling network (Stegh et al, 2007).
The expression levels of the Bcl-2 family are controlled by P53. Dysregulation of this
tightly controlled system signifies an important feature in GBM. As discussed earlier
some of the most common mutations found in GBM are TP53, PTEN, and EGFR. P53
and Bcl-2 have a close relationship with P53 promoting transcription of BCL-2 family
member Bax (Krakstad & Chekenya, 2010). Therefore, with altered expression of both
of these proteins commonly occurring in GBM, it therefore increases the resistance to
the apoptotic mechanism of cell death, enhancing cell survival. This presents a possible
rational as to why autophagy has been a well-documented mechanism of cell death in
GBM, for example treatment of TMZ and radiotherapy are known to induce autophagy
and not apoptosis (Ito et al, 2005a).

1.11.3 Caspase Independent Cell Death (CICD)
In recent years, there has been accumulating evidence in the literature that supports the
existence of caspase independent cell death pathways. Similar to classical apoptosis the
mitochondrion is the main organelle orchestrating the series of events which are
required for the induction of CICD, in addition, the pro-apoptotic proteins Bax and Bid
also remain to be key participants. CICD can be induced by the addition of chemical
caspase inhibitors such as zVAD-fmk, but studies have also demonstrated CICD in cells
expressing genetically encoded caspase inhibitors such as XIAP, or p35 (Okuno et al,
1998; Wilkinson et al, 2004; Tait & Green, 2008a). Two ways in which cell can die
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independent of caspase which has been extensively reviewed by (Tait & Green, 2008a)
can be induced through death receptors, which has been described as death receptor
activated necrosis, and Mitochondrial outer membrane permeabilisation (MOMP).
Following induction of MOMP in response to a stimulus, various mitochondrial
proteins are released triggering loss of mitochondrial function and/or proactively
contributing to cell death. The reasons for this have not fully been elucidated, but as
demonstrated in figure 1.11 below, studies have suggested that loss in ATP generation
following disruption of the mitochondria, AIF and Endonuclease G (EndoG),
Omi/HtrA2 (mammalian serine protease) are implicated in MOMP-CICD (Lorenzo &
Susin, 2004; Tait & Green, 2008a).
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Figure 1.11 Caspase independent cell death signalling pathway (Kroemer & Martin,
2005a)

1.11.4 Autophagy
Autophagy has been the subject of much attention with regards to cell death in recent
years, with some scientists suggesting that autophagy can act in both pro-survival
mechanism or as a mechanism of cell death depending on the stimulus and surrounding
environment (Codogno & Meijer, 2005). Autophagy is a critical process for all cells
whereby damaged or long-lived proteins and organelles are removed. Autophagy
involves engulfment of portions of cytoplasm and proteins by autophagosomes, bound
for lysosome fusion and degradation. The degraded autophagic contents serve as
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building blocks for protein synthesis and energy production. Until recently, autophagy
was considered to be a non-selective process for degradation of cytoplasmic
components during nutrient deprivation, it has since been discovered that this is not the
case, the process of selective autophagy relies on cargo-specific autophagy receptors
that facilitate sequestration of cytoplasmic material into autophagosomes (Glick et al,
2010a; Boya et al, 2013). There are three types of autophagy that have been described
in the literature; (A) macro-autophagy (most commonly referred to as autophagy) which
delivers cytoplasmic material to the lysosome through a double membrane-bound
vesicle, referred to as an autophagosome, that fuses with the lysosome to form an
autolysosome (Kroemer et al, 2009). (B) micro-autophagy which is when cytosolic
material is directly taken up by the lysosome through invagination of the lysosomal
membrane. Both macro-and micro-autophagy are able to engulf large structures through
both selective and non-selective mechanisms (Glick et al, 2010a; Boya et al, 2013). (C)
chaperone-mediated autophagy (CMA), targeted proteins are translocated across the
lysosomal membrane in a complex with chaperone proteins (i.e. Hsc-70) these are
recognized by the lysosomal membrane receptor and triggers their unfolding and
degradation (Glick et al, 2010a). For the purpose of this thesis we will refer to macroautophagy as autophagy unless stated otherwise.
Autophagy can be distinguished morphologically from apoptosis by the extensive
double membrane vacuolisation of the cytoplasm, which will be described in more
detail below. Autophagy is classified as class ІІ PCD, an alternative mechanism to the
conventional type І programmed cell death ‘apoptosis’. It is a highly regulated process
that all eukaryotic cells can carry out. It is a self-degradative process that’s acts by
sequestering and degrading the bulk of cytoplasmic contents, abnormal protein
aggregates, and excess of damaged or defective organelles within a double membrane
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bound vesicle called an autophagosome, which then fuses with a lysosome to form an
autolysosome and in turn degrades or recycles the aggregated material and organelles
(Kondo et al, 2005; Levine & Kroemer, 2008). As noted previously, some studies have
shown autophagy to exhibit a dual function in the regulation of both cell survival and
cell death. When under stressful conditions such as nutrient deprivation a cell will
promote autophagy by removing degraded organelles and proteins before they have a
negative impact on the cell and therefore sustaining cellular integrity, and maintaining
cellular homeostasis (Levine & Kroemer, 2008; Mizushima et al, 2008). Depending on
the stimulus and surrounding environment, autophagy can also promote cell death and it
is now appreciated that defective autophagy contributes to cellular pathology in certain
cases as described below by the NCCD. In 2012 the NCCD published an article stating
that the term ‘autophagic cell death' has widely been used to indicate instances of cell
death that are accompanied by a massive cytoplasmic vacuolization, which often (but
not always) indicates increased autophagic flux with the implication that the autophagic
process is actually executing the cells demise. They did note that this can occur in some
cases, more specially some cancer cells that lack essential apoptotic modulators such as
BAX and BAK or caspases, that respond to certain chemotherapeutic agents. (Shimizu
et al, 2004; Fazi et al, 2008; Galluzzi et al, 2012). However, the autophagic process
most commonly acts in a cytoprotective manner and that the term autophagic cell death
must be used with caution. As our knowledge on the autophagic processes develop, the
NCCD in the their most recent article published in 2015 have further expanded on their
recommendations for identifying autophagic cell death. Stating that this term is only for
‘regulated cell death instances that can be influenced by the pharmacologic or genetic
interventions targeting at least two distinct components of the molecular machinery for
autophagy’ (Galluzzi et al, 2015). Interestingly they also make note of increasing
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evidence that inhibition of the processes that are essential for cell death often does not
result in inhibition of the cells demise but more often result in altering the biochemical
pathway results in cell death via a different mechanism. Therefore, indicating that if a
cell is destined for death employing inhibitors as a therapeutic intervention, this might
prevent cell death from occurring via that pathway but ultimately the cell will succumb
to cell death via an alternative pathway. This has been demonstrated in a number of
studies (Prabhakaran et al, 2004; Dunai et al, 2012; Steinhart et al, 2013).
1.11.5 Cross talk between autophagy and apoptosis.
Both apoptosis and autophagy are highly conserved processes where their main function
is in the maintenance of the homeostasis. Apoptosis is a tightly regulated process that is
implicated in the removal of damaged cells, whereas autophagy is involved in
lysosomal degradation and recycling of damaged proteins and organelles, and is
considered an important survival/protective mechanism for the maintenance of
homeostasis within an organism but also in cancer cells as their molecular mechanisms
can be counteracted in by protective mechanisms of cancer cells. Although the
mechanisms of autophagy and apoptosis are different, some proteins modulate both
autophagy and the apoptosis pathway. Recent evidence suggests that interactions among
the crucial proteins of autophagy and apoptosis are involved in the crosstalk between
the two processes (Mariño et al, 2014). The B-cell lymphoma 2 (Bcl-2) proteins plays a
significant role in both autophagy and apoptosis (Mariño et al, 2014; Li et al, 2016a).
These proteins direct the mitochondria outer membrane permeabilisation (MOMP) thus
releasing Cytochrome c into the cytosol. As described previously these proteins exist as
either pro or anti apoptotic form and play an important role in the apoptotic process.
Beclin-1 is a component of the class III PI3K/Vps34 complex and as described
previously in section 1.14 and is necessary for the formation of the autophagosome. In
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autophagy, Bcl-2 binds to Beclin-1 and prevents the binding of Beclin-1 to class III
PI3K, leading to an inhibition autophagosome formation, preventing autophagy. In
contrast, mutations of the BH3 domain of either Beclin-1 or the Bcl-2 will alter the Bcl2-Beclin-1 complex, resulting in the activation of autophagy (Mariño et al, 2014; Li et
al, 2016a). The interplay between Bcl-2 and Beclin-1 is an essential component of the
regulation involved in the crosstalk between autophagy and apoptosis. Under stressful
conditions such as nutrient deprivation, autophagy is activated to promote cell survival.
C-Jun N-terminal protein kinase 1 (JNK1) is activated which results in the destruction
of the Bcl-2-Beclin-1 complex, therefore inducing autophagy. During this process
phosphorylated Bcl-2 combines with Bax inhibiting apoptosis, allowing the autophagic
process to occur and act in a pro survival mechanism (El-Khattouti et al, 2013; Mariño
et al, 2014; Li et al, 2016a). On the other hand, if the autophagic process cannot
alleviate the stress induced by nutrient starvation, JNK promotes the Bcl-2 hyper
phosphorylation, resulting in the in the separation of Bcl-2 from Bax (El-Khattouti et al,
2013; Mariño et al, 2014; Li et al, 2016a), thus inducing apoptosis via caspase-3dependent pathway and initiating cell death.
Autophagosome formation
There are five key stages in autolysosome formation as depicted in figure 1.12 below, 1.
Phagophore formation: The autophagic process begins with the isolation membrane
known as the phagophore. It is thought that this is derived from the lipid bilayer
contributed by the endoplasmic reticulum (ER), but this process is not fully understood.
2. Atg5–Atg12 conjugation: The phagophore elongates to form a autophagosome which
is controlled by Atg genes through Atg12-Atg5 and LC3 complexes (Xie & Klionsky,
2007; Glick et al, 2010b). Atg12-Atg5 also interacts with Atg16 to form larger
complexes (Xie & Klionsky, 2007). Modification of Atg5 by Atg12 is essential for the
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elongation of the initial membrane. 3. Capture of targets for degradation: The
phagophore expands and begins to sequester and engulf protein aggregates, degraded
organelles, and ribosomes. 4. LC3 processing and extension of phagophore membrane:
LC3 is cleaved by ATG4 protease to generate cytosolic LC3. Cleavage of LC3 is
necessary for the terminal fusion of the phagophore in order

to become a

autophagosome (Liou et al, 1997). 5. Fusion of the autophagosome with the lysosome:
The loaded autophagosome becomes a mature autolysosome through fusion with a
lysosome, which functions in providing lyososomal acid proteases and aids in the
degradation of the internal constituents.

Figure 1.12 Autophagosome formation and lysosomal degradation (Ciechanover &
Kwon, 2015).

1.11.5.1

Regulation of autophagy

All cells undergo a basal level of autophagy, therefore cells need a well-organized
mechanism to effectively up-regulate and down-regulate during times of stress and to
maintain the order of homeostasis. One of the key players in the autophagy signalling
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network is the mechanistic target of rapamycin (mTOR) complex. This protein kinase is
a critical regulator of autophagy induction with activated mTOR (Akt and MAPK
signalling) suppressing autophagy, and negative regulation of mTOR (AMPK and p53
signalling) promoting it. mTOR is a serine/threonine kinase that is involved in the
regulation of many cellular signalling networks such cell growth, proliferation,
transcription, cell survival and also autophagy. When mTOR is activated by Akt and
MAPK signalling, autophagy is suppressed, but mTOR is also negatively regulated by
AMPK and p53 signalling therefore promoting autophagy. mTOR binds several
proteins to form two distinct protein complexes mTORC1 (mTOR complex 1)
(rapamycin sensitive) and mTORC2 (mTOR complex 2) which contains rapamycin
insensitive companion of mTOR (rictor) (Jung et al, 2010).

Figure 1.13 mTOR signalling pathway (Fleming et al, 2010)
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Autophagy is induced through reduced growth factor signalling as well as nutrient
starvation. The growth factor signalling as observed above in figure 1.13 that regulates
mTORC1 mainly involves the insulin/insulin-like growth factor (IGF-1)-PI3K
(phosphoinositide 3-kinase class I)-Akt pathway, which negatively regulates autophagy
induction. The insulin/IGF-1 pathway involves PDK1 and Rheb, the positive regulators
of mTORC1 signalling, and PTEN and tuberous sclerosis complex 2 (TSC2), the
negative regulators of mTORC1 signalling (Jung et al, 2010). It has been previously
demonstrated that there is a close link between the mitochondria and mTORC-1 (Desai
et al, 2002), it has been postulated that cellular stressors such as reactive oxygen species
and their obstructive effects on mitochondrial function could therefore trigger
mitochondrial autophagy (Jung et al, 2010). This also provides evidence that CAP, as a
result of the significant production of ROS could induce mitochondrial autophagy.
mTORc-1 is also inhibited by rapamycin or nutrient starvation which results in dephosphorylation of Unc-51 Like Autophagy Activating Kinase 1 (ULK1) and initiation
of autophagy.
Another regulator of autophagy is the PI3K which is upstream of mTOR, the survival
PI3K/AKT pathway modulates mTOR activity. The PI3K signalling network plays
critical roles in the regulation of cell growth, proliferation, differentiation, motility, and
cell survival and when deregulated, it is a major driver of oncogenesis. There are three
major classes of PI3K, class I, class II, and class III. PI3K class1 responsible for the
production of phosphatidylinositol 3-phosphate (PI3P), phosphatidylinositol (3,4)bisphosphate (PIP2), and phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (Li et al,
2016b). PI3K class II and III are differentiated from class I by their structure. Class II
catalyses the production of PIP3 through phosphorylation of PI and PIP2 from PIP
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whereas class III only produces PIP3 from PI. Phosphorylation to PIP3 results in
downstream activation of AKT which has also been shown to function as a nutrientregulated lipid kinase mediating signalling through mTOR indicating a potential role in
regulating cell growth (Liu et al, 2009; Li et al, 2016b). As previously described,
members of the PI3K/Akt signalling cascade are among the most frequently altered in
GBM, resulting in hyperactivation. The PI3K/Akt/mTOR survival signalling cascade
has been identified as a promising therapeutic target, particularly as PTEN, its negative
regulator, is among the most frequent mutated proteins in GBM. The PI3k/AKT/mTOR
pathway when activated negatively regulates autophagy. The various dysregulations of
the PI3K pathway can lead to increased downstream activation of mTOR and inhibition
of autophagy-mediated cytoprotection. It is the over expression of the PI3K signalling
pathway that results in resistance to chemotherapeutics such as TMZ (Stupp et al,
2005a), therefore regulating PI3K expression through targeted therapy could sensitise
GBM cells to TMZ therapy. Studies have shown that targeting PI3K signalling pathway
with small molecule inhibitors may prove to be an effective therapeutic target. Initial
studies employing pan-PI3K inhibitors such as wortmannin and LY294002
demonstrated excellent anti-cancer effect both in vivo and in vitro (Vlahos et al, 1994;
Guerreiro et al, 2008). Unfortunately, both drugs were halted at preclinical studies due
to the toxicity, and poor pharmacodynamics. More recently a new group of PI3K
inhibitors are being investigated in a number of tumour models. BKM120 has
demonstrated lower toxicity with better drug properties and has passed phase I clinical
trials and is currently undergoing phase II trials among patients with recurrent
glioblastoma and activated PI3K pathway (Bendell et al, 2012). In addition, BKM120 is
also undergoing several clinical trials as a potential combinational therapy with
radiation and Bevacizumab (Huang et al, 2009). While in theory targeting mTOR has
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many advantages, it is important to note that the main function of autophagy is to act as
a prosurvival mechanism for the cell, some studies have demonstrated the downstream
effects of activating autophagy resulting in a prosurvival mechanisms for tumour cells
by recycling damaged cellular contents (Vignot et al, 2005a; Xie et al, 2013). A
suggested alternative to overcome this problem is to combined mTOR inhibitor with its
antitumor properties concurrently with an autophagy inhibitor to inhibit the recycling
process of the degradation tumour cells (Xie et al, 2013).
1.11.6 Necrosis
Necrosis is deemed to be a non-physiological process because it occurs in response to
external stimuli such as injury or infection. For many years’ necrosis has been noted as
an accidental uncontrolled form of cell death, but with accumulating evidence in recent
literature the international cell death committee has revised this statement and is noted
that necrosis can result in a controlled and regulated manner (Galluzzi et al, 2012),
regulated necrosis has also been described as necroptosis. Regulated necrosis has been
characterized as non-apoptotic accidental cell death resulting from environmental
distresses with release of inflammatory cellular contents, in contrast to apoptosis and
autophagy which are regulated and controlled processes. Necrosis does not follow a
signaling cascade as observed in apoptosis but results in loss of membrane integrity,
releasing cellular contents into the cytosol (Proskuryakov et al, 2003), which in turn
initiates an immune response and results in damaged cell being phagocytosed. The
causative elements that result in necrosis remain to be fully elucidated, and therefore
necrotic cell death is still largely identified in negative terms by the absence of apoptotic
or autophagic markers (Kroemer et al, 2009; Galluzzi et al, 2012). It has been widely
accepted that the loss of structural integrity of the plasma membrane is a hallmark of
necrosis and represents the common final endpoint which leads to an inflammatory
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responses by immune cells (Ouyang et al, 2012), and most frequently exhibits changes
in the nuclear morphology but not the organized chromatin condensation as observed in
apoptotic cell death. Biochemically the release of cytosolic enzymes such as lactate
dehydrogenase and uptake of membrane-impermeant dyes such as trypan blue or
propidium iodide are also indicators of necrosis but cannot be considered confirmatory
assays as loss of membrane integrity is also associated with apoptosis (Fink & Cookson,
2005).
Necrosis can be initiated by the same cell death signals that initiate apoptosis and
depending on the context of the cell can undergo necrosis rather than apoptosis, i.e. if
caspases were blocked, or ATP was low. In the case of inactivated or blocked caspases,
death receptor ligation to TNFR1 results in assembly of a complex involving caspase-8,
FADD, receptor-interacting serine-threonine kinase 1 (RIP1) and RIP3. Leading to
increased ROS formation, mitochondrial membrane permeabilisation (MMP) and
subsequent programmed necrosis (Ouyang et al, 2012) as demonstrated below in figure
1.14.
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Figure 1.14 Regulated necrosis signalling pathway (Galluzzi et al, 2012)

In GBM necrosis is not only studied as a mechanism of cell death in response to
treatment but also a classical feature of GBM is that the tumour maintenance of a
central hypoxic necrotic core (Martínez-González et al, 2012) and this form of necrosis
within GBM has been demonstrated to be a powerful predictor of poor patient prognosis
(Noch & Khalili, 2009). Here we are going to discuss necrosis as a mechanism of cell
death in response to treatment. Over the years, there have been many advances in our
understanding of the molecular mechanisms underlying glioblastoma formation, but it is
widely accepted that GBM is defective in the apoptotic process, on the other hand both
pathological and radiological observations almost always reveal obvious necrosis foci
within GBM (Jensen, 2009). Necrosis seems to be related with GBM proliferation,
angiogenesis and invasion, and therefore necrosis as a mechanism of cell death offers
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great potential therapeutic value for the treatment of GBM. It has been demonstrated
that Mouse embryo fibroblasts die by necrosis in response to DNA alkylating agents
such as staurosporine and nitrogen mustard. Also novel anticancer therapy
photodynamic treatment (PDT) results in necrotic tumour cell death as a result of loss of
plasma membrane integrity by ROS generation in GBM cells (Fabris et al, 2001; Miki
et al, 2013). Shikonin is a quinone-containing natural product commonly used in
Chinese herbal medicine, has been shown to induce regulated necrosis mediated by
RIP-1 in C6 and U87 GBM cells and ROS (Huang et al, 2013) therefore providing
efficacy for necrosis as an alternative signalling target to apoptosis to initiate cell death.
1.11.7 Cysteine proteases
There are three distinct subtypes of cysteine proteases: caspases, calpains and cathepsins
While the importance of caspases in apoptosis, and necrosis have been clearly
established, studies have indicated that several other types of non-caspase proteases may
also play a role in the execution of cell death, for example calpains. Calpains are a
family of Ca2+-activated neutral cysteine, nonlysosomal endoproteases found in all
mammalian cells that can be divided into tissue specific calpains (calpain 3 and 9) or
universally expressed (µ-calpain (I) and m-calpain (II))(Harwood et al, 2005). They are
distinguished based on the different Ca2+ requirements. There is a lot of cross talk
between apoptotic caspases and calpains, as calpains have been demonstrated to be able
to cleave pro-caspase 3,7,8 and 9 into inactive fragments, and equally, calpain is known
to be an activator of caspase 3 and 12 (Nakagawa et al, 2000; Blomgren et al, 2001).
Calpains have been noted to play a role in a number of diseases such Alzheimer’s,
cataracts, strokes, Parkinson’s disease (Momeni, 2011), and have also been implicated
in apoptotic glial cell death (Ray et al, 2002). More recently it has been demonstrated
that radiation induced necrosis though a caspase 3 independent pathway mediated by
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apoptosis-inducing factor (AIF), calpains, and cathepsins B and D in GBM (Das et al,
2016).
Cathepsins are a group of protease enzymes predominantly found within lysosomes, as
for optimal activity they require a more acidic environment, such as that found in
lysosomes. There are 15 human cathepsins, of which 11 are cysteine based, B, C, F, H,
K, L, O, S, V, X and W. Their function was originally understood to be intra-lysosomal
protein degradation but it has since established they have a role in necrosis, autophagy
and to a lesser degree apoptosis. As described early, under certain conditions and
stimuli autophagy can be detrimental to a cell and result in autophagic mediated cell
death. During the autophagic process, lysosomes fuse with the autophagosome into an
autolysosome, of which cathepsins D, B and L all play a role in this process as their
primary function is to degrade proteins and are therefore important regulators of
autophagy (Turk & Turk, 2009). Dysregulation of autophagy leads to increases in
oxidative stress, it has been demonstrated that inhibition of cathepsin D increases the
formation of reactive species (Yamasaki et al, 2007). It has also been recently
demonstrated that inhibition of cathespin S induces both autophagy and apoptosis in
GBM cells through ROS mediated PI3K/AKT/mTOR/p70S6K and JNK signalling
pathways (Zhang et al, 2014) and moreover that silencing the EGFR led to an improved
autophagic response to irradiation and suppressed migration in the T98G (Palumbo et
al, 2014a). A similar study carried out by Plaumbo et al identified that response to TMZ
and radiation both alone or combined induced an autophagic response with both cell
lines U87MG (radiosensitive) and U373MG (radioresistant) both inducing autophagy
but not apoptosis. Interestingly when U373MG cell were pre-treated with mTOR
inhibitor rapamycin and autophagy inducer, it sensitised the U373MG radioresistant
cells to radiation (Palumbo et al, 2012b). These studies provide evidence that the
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autophagic cell death pathway is more dominant then the apoptotic pathway in
irradiated GBM cells, and indicates a possible adjuvant therapeutic strategy to enhance
the conventional GBM treatment, as well as rational for the identification of novel
targeted autophagy-interfering agents either with radiation and TMZ alone or in
combination as a new potential strategy for the treatment of GBM.

Aims & Objectives
The aim of this project is to develop and investigate the application of novel
technological and medicinal therapies for the treatment of brain cancer. GBM is
considered to be the most biologically aggressive brain tumour which accounts for
approximately 16% of all brain tumours (Dolecek et al, 2012). The prognosis for
patients diagnosed with GBM is bleak, with low 5 year survival rate of <10% (Ostrom
et al, 2014), thus highlighting the need for novel and more effective methods for
treating these tumours. Even with the many chemotherapeutic agents available for the
treatment, GBM’s survival rates have remained stagnant over the past three decades.
This is due to the high number of tumours being resistant to the currently available
therapies and also the inability of most chemotherapeutics to cross the blood brain
barrier. The molecular signalling pathway of GBM is complex and remains poorly
understood.
In this PhD thesis, the first study (Chapter 2) of this PhD thesis investigates the antitumour properties including cytotoxicity and molecular mechanisms of commonly
employed medicinal and chemotherapeutic drugs in our GBM model. The novel
nutraceutical UA is also investigated. This is a compound commonly found in fruits and
plants. Employing validated procedures for extraction of UA from cranberries and High
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performance liquid chromatography (HPLC) to purify and quantify the crude extract.
The cytotoxicity of the extracted compound was analysed by cell viability and
compared to that of a known ursolic acid standard. Migration studies were also
performed using UA, and several chemotherapeutic compounds. A distinct feature of
GBM tumours is how rapidly the tumour cells infiltrate normal surrounding tissue. UA
demonstrated promising anti-proliferative capabilities with potential as a natural chemopreventative target over existing chemotherapies. It was demonstrated that UA activates
autophagy prior to cell death in GBM cells, which to date has not been shown in this
cell line. Part of this chapter is being prepared for submission to a relevant scientific
journal for peer review.
The second study outlined in Chapter 3 of which in part was published in peer reviewed
journal the ‘British Journal of Cancer’, investigates and characterises the anti-tumour
effects of a potential new therapy for treatment known as CAP using a novel DBD
system in vitro on U373MG glioblastoma and HeLa cervical cancer cell lines. Using
ROS detection/inhibition assays an understanding into the underlying molecular
mechanism that induces cell death within these cell lines began to unfold.
Chapter 4 of this PhD thesis identifies an autophagic mechanism of cell death in
U373MG cells in response to cold atmospheric plasma treatment. We have successfully
proven a mechanism of cell death that is independent of caspase and JNK through both
biochemical and imaging techniques in our GBM model. Following the appropriate
guidelines for the detection of autophagy we have identified the formation of
autophagosomes through electron microscopy, AVO’s through fluorescence microscopy
in U373MG cells. We are the first to identify autophagic mediated cell death following
treatment cold atmospheric plasma.
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This study has therefore greatly enhanced the knowledge of the molecular signaling
process of GBM, and the induction of autophagy following both UA and CAP
treatment.
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2

Optimisation of GBM cell models and characterisation

of cell death in novel nutraceutical Ursolic acid for the
treatment of brain cancer.

Part of this chapter has been submitted for publication and is currently under review.
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2.1

Introduction

Glioblastoma multiform (GBM) remains one of the most difficult tumours to treat; this
is due to a variety of factors. Localisation of the tumour within the brain tissue of the
CNS can make it difficult for surgical resection. GBM tumours are highly invasive,
infiltrating surrounding brain parenchyma and are very heterogeneous. The majority of
patients have numerous genetic mutations which increase a patient’s resistance to
therapies i.e. p53, EGF, MGMT. Patients expressing high levels of MGMT are more
resistant to TMZ (Köritzer et al, 2013). The tumour suppressor gene p53 is mutated in
30–50% of GBM. Mutation in the TP53 gene leads to tumorigenesis, because of the loss
of the transcription function of wild-type TP53 (Wang et al, 2014). Mutations or loss of
function of PTEN has also been implicated in the malignant progression of astrocytic
gliomas

and

linked

with

resistance

to

GBM

chemotherapeutic

erlotinib.

Chemotherapeutic drugs that are transported across the membrane in ATP-independent
manners transported across concentration gradients. The ATP-dependent group consists
of a protein which includes P-glycoprotein (P-gp) which is often overexpressed in GBM
and is associated with resistance to GBM chemotherapy erlotinib, vincristine and
doxorubicin (Haar et al, 2012). Poor prognosis of patients with GBM is also contributed
to the lack of successful drug delivery across the blood brain barrier (BBB). The BBB
prevents efficient passage of cancer therapeutics, including small molecules and
antibodies. Therefore, many drugs can still be blocked from reaching the GBM tumour
cells. The onset of symptoms, usually only occur when tumour has reached stage 3 and
4, this is especially evident in primary GBM’s, therefore reducing the chances of
successful treatment. In addition, GBM tumours contain self-renewing, tumorigenic
cancer stem cells (CSCs) that contribute to tumour initiation and therapeutic resistance.
This diverse grade IV malignant astrocytoma along with many other cancers have
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developed over time and become genetically unstable resulting in developed resistance
to chemotherapeutic treatments, therefore as a consequence survival statistics have
remained low. GBM accounts for 50% of the tumours of the CNS (Bower & Waxman,
2011).
The BBB is a diffusion barrier that excludes blood borne substances entering the brain
and protects the central nervous system. There are tight junctions between the vascular
endothelial cells which restricts many chemotherapeutics agents from crossing thorough
into the invasive GBM cells. This is an important feature to take into account when
investigating the use of novel therapies for the potential treatment of GBM. The
chemotherapeutic TMZ which dose cross the BBB, is converted to an alkylating
methyldiazonium cation which then methylate’s the guanine residues in the DNA
molecule, resulting in the formation of O6- and N7-methylguanine, which the inhibits
DNA repair mechanisms therefore results in DNA damage such as DNA double strand
breaks (Agarwala, 2000). Although TMZ is the current standard of care
chemotherapeutic, over 55% of newly diagnosed GBM tumours are resistant to TMZ
and therefore supplements no value when added to the patients treatment regime (Hegi
et al, 2008). This has been attributed to the overexpression of (O6-methylguanine-DNA
methyltransferase) MGMT in GBM cells (Köritzer et al, 2013). Other commonly used
chemotherapeutics that have been approved by the FDA for use in the treatment of
GBM include BCNU (carmustine), an alkylating nitrosourea that forms inter-strand
crosslinks in DNA and interferes with DNA replication. Due to the high rate of RTK
mutations in GBM, TKI inhibitors have emerged as an attractive therapeutic approach,
and while demonstrating success in other cancers, unfortunately results from clinical
trials have been poor in GBM (Joshi et al, 2012). Gefitinib, a receptor tyrosine kinase
that inhibits, or blocks, the EGF receptor, allowing for targeted specific treatment has
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been explored as a possible treatment for GBM and has been approved by the FDA for
treatment (Rich et al, 2004), with somewhat favorable results due to the low toxicity of
the compound, overall survival rates remain unchanged. Other compounds include plant
alkaloids which are employed in the combinational treatment regime, PCA
(procarbazine, CCNU, vincristine), and monoclonal antibodies which are utilized as a
second line treatment for progressive GBM following prior therapy, for example
Bevacizumab. In recent years, investigations into novel approaches for the treatment of
brain cancer have been at the forefront of the research industry, with some therapeutic
targets demonstrating promising results. As TMZ is considered the standard of care for
the treatment of GBM, a lot of the current research is investigating ways to overcome
TMZ resistance. One current strategy is direct enzyme inhibition using O6benzylguanine, which has been studied in combination with TMZ. Phase two clinical
trials have demonstrated promising results in restoring TMZ sensitivity in anaplastic
glioma but unfortunately results in GBM have remained poor (Quinn et al, 2009). As
we learn more about the biology of GBM and its aberrant signalling pathways, it has
paved the way for novel therapeutics, targeting and inhibiting aspects of these
pathways. The majority of these agents are small-molecule inhibitors or monoclonal
antibodies. Antibodies to EGFR such as cetuximab are currently under evaluation in
early-phase clinical trials (Combs et al, 2006). Temsirolimus is an inhibitor of the
mammalian target of rapamycin, the best-studied of the targets in the phosphoinositide3 kinase pathway. During clinical trials it was noted to be well tolerated by patients,
demonstrating radiographic improvement in 36% of patients, however in a recent trial it
was observed that when combined with radiotherapy there was no increase in overall
survival compared to current that of radiotherapy plus TMZ (Wick et al, 2016), in
addition there was no increase in survival when combined with bevacizumab (Lassen et
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al, 2013). Even with the multitude of therapeutic approaches available, survival rates
have remained stagnant for the past decade and therefore indicate a need for the
development of novel technologies and new strategies towards the treatment of GBM in
order to overcome the high reoccurrence rate and ever increasing resistance of these
tumours to the current therapeutic approaches.
Bioactive compounds isolated from plants and other living sources offer a source of
new compounds with therapeutic potential that may afford fewer side effects. There
have been numerous studies investigating the efficacy of phytochemicals in the
treatment of cancer (Neto, 2007; Sasidharan et al, 2011; Wang et al, 2012a; Øverby et
al, 2014; Koldaş et al, 2015). In fact, it has been postulated that drug discovery from
plant sources has been the single most successful avenue for the development of anticancer therapies (Harvey, 2000). This is not a new concept, for example, as previously
shown in table 3 (section 1.7.4) Camptothecin, isolated and extracted from the bark of
the Camptotheca acuminata tree. Two camptothecin analogues; topotecan and
irinotecan have been approved and are used in cancer chemotherapy today (Haustedt &
Siems, 2015). Vincristine which is a vinca alkaloids, extracted from the Periwinkle
plant (catharanthus rosea) and is also used in the treatment of GBM. It has been
hypothesised, through an international case controlled study that phytochemicals found
in yellow / orange and leafy green vegetables have an inverse effect on the incidence of
glioma (Terry et al, 2009). A similar observation was also observed by Das et al who
demonstrated that flavonoids apigenin, (-) epigallocatechin, EGCG, and genistein,
which are commonly found in fruit and vegetables, induce apoptosis via caspase
activation in GBM cells (Das et al, 2010). These studies underscore the long observed
association between nutrition and the incidence of cancer, highlighting the potential
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therapeutic targets of bioactive phytochemicals for the prevention or treatment of brain
cancer.
Ursolic acid (UA) is an ursane-type pentacyclic triterpenoid acid and primary
component of the thin waxy coating in popular western foods including cranberries,
apples and olives. Current research has shown that UA demonstrates potent antiproliferative properties when tested on various malignant cell lines in vitro for example
DU145 prostate cancer cells, MCF-7 breast cancer cells and A549 lung cancer cells
(Shanmugam et al, 2013a) Ursolic acid has demonstrated anti-cancer properties in a
number of glioma models (Wang et al, 2012b; Lu et al, 2014). The effects of in vivo
administration are currently under investigation in a number of pre-clinical trials
(Shanmugam et al, 2013b). Mechanisms for UA activity have been intensively studied
in in vitro cancer models, and have been extensively reviewed by (Woźniak et al, 2015).
In colon cancer cells, UA was found to induce anti-proliferating effects by suppressing
the phosphorylation of EGFR, ERK, JNK, and P38 (Shan et al, 2009). More recently it
has been demonstrated that UA not only exhibits anti-cancer properties by suppressing
Vaccinia-related kinase 1 (VRK1) mediated DNA damage repair but also that a synergy
exists between UA and other DNA damaging drugs in lung cancer cells (Kim et al,
2015). There have been few studies published focusing on GBM, despite clear evidence
of its positive efficacy, safety data in other tumour models and the lack of therapeutic
alternatives for treating GBM. It has been shown that UA demonstrated anti- tumour
activity and induced either apoptosis or autophagy in U251MG or U87MG GBM cells
respectively (Khan et al, 2012; Shen et al, 2014). In contrast it has recently been
reported that ursolic acid triggers a typical non-programmed cell death (necrosis) in the
GBM TMZ resistant cell line DBTRG-05MG through mitochondrial permeability
transition (MPT) pores (Lu et al, 2014). These studies provide evidence of the efficacy
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of UA as a potential anti-cancer drug but further studies are required to elucidate the
molecular mechanism involved in GBM cell models. Recently, there has been data
published on the effects of UA on cell migration and invasion, an important feature
when being considered as a potential target for the treatment for cancer, for example,
UA suppresses migration and invasion in gastric cancer cells, breast and lung cancer
cells (Yeh et al, 2010; Huang et al, 2011; Kim & Moon, 2015). However, another
compound known as oleanolic acid, also a pentacyclic triterpenoid, which is structurally
similar to UA differing only by the position of one methyl group on the ring E (Ovesná
et al, 2006) has demonstrated anti migratory and invasion in two GBM cell lines,
U251MG and U87MG, by inactivating the MAPK/ERK signalling pathway (Guo et al,
2013). It is postulated that due to the similarity in their structures, UA might also
display anti-migratory properties. Therefore, in conjunction with published data, stating
that UA is a promising anti-cancer compound that has high bioavailability enhances its
efficacy as a potential natural chemo-preventative target.
The aim of this study was to establish a working GBM culture model and establish
working protocols for cell death assay, and inhibitor studies. We have investigated the
mechanism of cell

death in a panel of medicinal compounds including

chemotherapeutics used for the treatment of GBM and further novel nutraceutical
ursolic acid. We also investigate the effect of both current chemotherapeutics and UA
on the rate of cell migration.
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2.2

Materials & Methods

Routine cell culture, maintenance and sub culture
The human glioblastoma cell line (U373MG-CD14) was kindly gifted from Dr Michael
Carty (Trinity College Dublin) and was the main cell line used in this study, also
employed for parts of this study were the human cervical cancer (HeLa, ATCC® CCL2™) cells were purchased from American Type Culture Collection (LGC Standards,
Middlesex, UK)
U373MG cells, were cultured in DMEM (Dulbecco’s Modified Eagles Medium high
glucose) (Sigma) supplemented with 10% FBS (Sigma) (known as full media for
remainder of the study). HeLa cells, were cultured in RPMI-1640 (Roswell Park
Memorial Institute) (Sigma) supplemented with 10% FBS. HeLa cells were used only in
chapter two of this thesis. Both are adherent cell lines. No antibiotics were used in the
regular culturing of these cells. Cell lines were maintained in a humidified incubator
containing 5% CO2 at 37°C. Media was changed every 2-3 days until 70-80%
confluency was reached to ensure logarithmic phase of growth.
Cell were routinely sub-cultured as follows: Cells were removed from the bottom of the
stock flask by using a using a 1:1 ratio EDTA: Trypsin, (EDTA: 0.1 g of EDTA in 500
ml PBS: Trypsin 2.5% 10X). Cells were spun down at 1200 revolution per minute
(RPM) using a bench top centrifuge at 4°C for 5 minutes. The supernatant was then
removed as waste and the afforded pellet was re-suspended in full media. Cells were
then counted using a haemocytometer (Abcam).
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Optimisation of cell lines
Cell growth curves were established for both cell lines in order to identify the
appropriate seeding density for further cytotoxicity analysis and various time-point
assays.
Cells were counted using a haemocytometer and then seeded at different cell densities
(1 x 10-1 to 5 x 104) in a 96-well plate (Corning Costar) at 100l per well. The plates
were then incubated at 37°C until ready for analyses. Cell viability was at four different
time points (24, 48, 72, 96 hours).
2.2.1

Panel of medicinal and nutraceutical compounds

Dose response curves for commonly employed chemotherapeutic drugs used for the
treatment of GBM: TMZ (Sigma-Aldrich, Arklow, Ireland), Carmustine (BCNU)
(Sigma-Aldrich, Arklow, Ireland) and Gefitinib (Insight Biotechnology ltd, Wembley,
UK) Cisplatin (Sigma-Aldrich, Arklow, Ireland) and Ursolic acid (Sigma-Aldrich,
Arklow, Ireland) were established. To make stock solutions UA standard, TMZ, and
Gefitinib were all dissolved in Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Arklow,
Ireland), BCNU was dissolved in sterile H2O and stored in -20°C and cisplatin was
dissolved in PBS and stored at 4°C for a maximum of 2 weeks. It should be noted that
cisplatin should not be dissolved in DMSO, as previously carried out by the majority of
published articles. It has been recently demonstrated that DMSO reacts with the
cisplatin complexes, resulting in the replacement of ligands on the platinum complexes,
which inhibited its cytotoxicity and its ability to initiate cell death (Hall et al, 2014),
This was noted for all platinum based compounds i.e. oxaliplatin. Therefore, we have
followed the guidelines suggested by (Hall et al, 2014), where they suggest a saline or
PBS based solution, making to a 2mM stock solution that is stable at 4 °C for a
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maximum of two weeks. Stocks were subsequently used to make the working standard
solutions in media. The highest concentration of DMSO was 0.5%. U373MG cells were
seeded at a density of 1x104 (24 and 48hr exposure time points) in 96 well plates
(Sigma-Aldrich, Arklow, Ireland) with 100µl media per well. In order to establish
accurate IC50 values for the chemotherapeutic compounds, a lower seeding density of
2.5x103 and a 6-day exposure period was required. Plates were left overnight in the
incubator at 37°C with 5% CO2 to allow the cells to adhere. Existing media was
removed from each well and cells were treated with either a medicinal compound,
ursolic acid, or solvent control (0.5% DMSO) and incubated for the appropriate time
point.
2.2.2

Cytotoxicity assays

Alamar Blue
Alamar blue (Invitrogen) assay was used to investigate cell viability when performing
the cytotoxicity and proliferation studies in both cell lines. After the appropriate
incubation time was been reached, all media was removed from the wells. Each well
was washed once with sterile phosphate buffered saline (PBS) (Sigma Aldrich). PBS
was pipetted out of each well and 100µL of fresh Alamar blue solution (10%) in
DMEM (minus FBS) was added to each well. Blank control wells contained medium
and Alamar blue dye only without cells. Alamar blue reagent is sensitive to light, thus
plates were wrapped in tin foil and incubated at 37oC for 2.5 hours. Absorbance was
read immediately after incubation period on a Victor 3V 1420 (Perkin Elmer) multiplate reader. Fluorescence was quantified using excitation and emission wavelengths of
540 nm and 595 nm, respectively. The data (in fluorescence units from the microplate
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reader) for the test wells were normalised to the assay control (DMEM or RPMI
medium only) and cell growth was calculated as a change of viability over time.
2.2.3

Inhibitor studies

zVAD-fmk
Commonly employed general caspase inhibitor zVAD-fmk (BD Bioscience, Oxford,
England), was used in order to determine whether caspases play a role in cell death in
U373MG GBM cells. zVAD-fmk was reconstituted in 100% DMSO and frozen at 20°C at a stock concertation of 10mM. GBM cells were pre-treated for 1 hour with
zVAD-fmk (BD Bioscience, Oxford, England). zVAD-fmk was then removed from
each well and replaced with full media. Cells were then analysed after 48 hours with
Alamar blue cell viability assay. Multiple concentrations were tested to determine the
most appropriate. Cells were also treated with a 0.5% DMSO vehicle control.
N-acetyl-cysteine
N-acetyl-cysteine (NAC) (Sigma Aldrich, Arklow, Ireland) a ROS inhibitor was used to
identify whether ROS was involved in cell death following treatment with various
medicinal/nutraceutical drugs in U373MG cells. NAC powder was reconstituted in full
cell culture media and made up fresh each time. Cells were pre-treated for 1 hour with
N-Acetyl Cysteine (NAC) (Sigma Aldrich, Arklow, Ireland). NAC was then removed
from each well and replaced with medicinal/nutraceutical compound made up in full
media. Cell viability was assessed 48 hours later using Alamar blue cell viability assay.
Dose response curves were established using a range of concentrations to determine the
most effective concentrations of NAC.
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SP600125
SP600125 is an inhibitor of JNK which is commonly associated with apoptosis.
SP600125 was reconstituted in DMSO at a stock concentration of 25mM and stored at 20°C. U373MG cells were pre-treated for 1 hour with SP600125 (Sigma Aldrich,
Arklow, Ireland), SP600125 was then removed by pipetting and fresh drug was added to
each well at a concentration around the IC50. Cell viability was assessed 48 hours later
using Alamar blue cell viability assay. Dose response curves were established for
SP600125 to determine the most effective concentration in U373MG cells. Cells were
also treated with a vehicle control of 0.5% DMSO.
3-methyladenine (3-MA)
3-Methyladenine (3- MA) (Sigma Aldrich, Arklow, Ireland) is an inhibitor of
phosphatidylinositol 3-kinases (PI3K). PI3K plays an important role in many biological
processes, including controlling the activation of mTOR, a key regulator of autophagy.
3-MA was prepared as a 100mM stock solution in sterile PBS, and gently heated in
37°C to aid solubility. Stock solution was aliquoted out and stored in the -20°C freezer
for future use. Working stock solution were made up from the 100mM stock in full
media fresh for each experiment.
2.2.4

Cell Migration Assay

U373MG cells seeded at 0.9 x 106 cells in individual 35mm dishes and incubated for 24
hours. A scratch was performed in each dish prior to treatment using a 200 µl sterile
pipette tip. Utilising the data observed from the dose response curve a sub-toxic
concentration of TMZ (100µM), BCNU (50µM), gefitinib (25µM) and UA (12.5µM)
was chosen. Cells were treated with media alone, DMSO (0.1%), or drug. Each scratch
was examined under a light microscope and images were taken using the (Nikon Eclipse
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700). Cells were also treated in the presence of UA (12.5µM) and JNK inhibitor
SP600125 (12.5µM) and analysed over a period of 7 hours. Multiple images were taken
for each time point and the average size of scratch for that time point was obtained.
Image analysis was performed using image processing and analysis software, Image J
(Rasband).
2.2.5

Flow cytometry

JC-1 mitochondrial membrane potential assay
Stock solutions of JC-1 dye (Biosciences, Dublin, Ireland) were prepared at 1 mg/mL in
dimethylsulfoxide (DMSO), aliquoted out and stored in freezer (–20°C) until required
for use. Cells were then harvested by trypsinisation and pelleted at 1200rpm for 5
minutes. A working solution of 10µg/ml JC-1 was made up in full media and kept away
from light. The cell pellet was resuspended and stained with 10µg/ml JC-1 dye and kept
at room temperature for 10 minutes. Cells were then washed twice with sterile PBS and
analysed by flow cytometry (BD Accuri C6). Fluorescence was measured using the FL1
(530 nm) and FL2 (585 nm) channels with emission.
Acridine orange
Stock solutions of acridine orange (Sigma Aldrich, Arklow Ireland) were prepared at 1
mg/mL in sterile PBS and stored in the fridge (4°C) away from light until required for
use. Cells were harvested by trypsinisation and pelleted at 1200rpm for 5 minutes. A
working solution of 1mg/ml AO was made up in full media and kept away from light.
Cell pellet was resuspended and stained with 1µg/ml acridine orange and incubated at
37°C for 20 minutes. The cells were then washed twice with sterile PBS and analysed
by flow cytometry (BD Accuri C6) with an excitation of 475nm and emission 590nm.
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2.2.6

Data analysis

Spectrophotometer data
Data retrieved from the Perkin Elmer microplate reader measures the fluorescence in
each well of the microplate and generates readings as arbitrary fluorescent unit values.
These fluorescent unit values were extrapolated for viability calculations using
statistical analyses software Prism 5, GraphPad software, Inc. (USA). All experiments
were performed at least three independent times with a minimum of five replicates per
experiment. Cell viability was calculated, by first subtracting any background
fluorescence from the Alamar blue blank reading. The mean (average) fluorescence
value from each test per plate was calculated, n=5 per individual experiment of which
was repeated independently three times.
Image J Software
The total cell fluorescence was calculated using ImageJ (v1.49, NIH) software. An
outline was drawn around each individual cell, as previously described by (McCloy et
al, 2014). The total corrected fluorescence was then calculated as follows; Total
corrected cell fluorescence (TCCF) = Integrated density – (area of selected cell x mean
fluorescence of background readings) in excel. Calculated data was then transferred to
prism where is was normalised to untreated control and statistical analysis carried out
using regression analysis and statistical significance.
2.2.7

Statistical analysis

Statistical analysis was performed on raw fluorescent values (after first removing the
background fluorescence) retrieved from the spectrophotometer or mean fluorescence
values retrieved from cytometry BD Accuri C6 software as indicated in each result

101

section. Using the Prism GraphPad statistical software the mean values were
normalised to the untreated assay controls, by subtracting the mean values from the
untreated internal assay controls to give a final result. Percentage viability was
calculated relative to the assay control, which was set to 100%. Percentage viability of
each bioassay is graphically displayed as bar charts or regression plots with. Presented
as mean ± SEM (n= total number of replicates) unless stated otherwise. Statistical
analysis was carried out using one sample tests, student t tests, One-way ANOVA,
Two-way ANOVA with Bonferroni post-test. Curve fitting on dose response curves
were carried out using both linear and nonlinear regression analysis allowing for the
calculation and comparison of IC50 values. Unless otherwise indicated differences were
considered significant with a p value <0.05.
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2.3

Results

2.3.1

Optimisation of mammalian cancer cells.

The results for the initial optimisation of both cells lines are graphically displayed
below in figures 2.1 (A-B). Growth curves allowed for the determination of the
appropriate seeding densities for both short and long term experiments i.e.48 hours up
to 6 days. It is evident from figure 2.1 that both cell lines exhibit significantly different
growth characteristics and therefore require different seeding densities when carrying
out experiments.
A.

B.

Figure 2.1 Growth curves.
Cell viability of (A) U373MG and (B) HeLa cells over time. Both cell lines were seeded
at different cell densities ranging from 100 to 50K cells/per well. Cell viability was then
analysed using Alamar blue assay at different time points. Experiments were completed
a minimum of three time and data was transformed to log form and plotted as
fluorescence units.
--------------------------------------------------------------
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2.3.2

Cytotoxicity curves for a panel of conventional therapeutic drugs in GBM
cells.

Cytotoxicity curves were established for each compound utilised in this thesis. Cells
were treated with a vehicle control the highest concentration present in drug, either
0.2% DMSO or 0.6% H2O (Appendix II). No significant reduction in cell viability was
observed in the vehicle controls, calculated using student t-test. As demonstrated in
figure 2.2 (A-D) below, after 48 hours there was little reduction in cell viability. With a
reduction of only 35%%, 28%%, 29%% in BCNU, TMZ and Gefitinib respectively,
accurate IC50 could not be calculated. A longer exposure time was carried out, after a 6day time point, IC50 values were sufficiently calculated as observed in table 2.1 below.
For Cisplatin, a 48-hour time-point sufficed in order to observe a significant cytotoxic
response compared to that of the other the chemotherapeutic compounds. Cisplatin with
an IC50 (9.17µM) (table 2.2) demonstrates the greatest level of toxicity compared to that
of other therapeutics such as clozapine (appendix VI) with IC50 values of 48.32µM at 48
hours. While cisplatin demonstrates a greater level of cytotoxicity, it also has a high
molecular weight of 300.01g/mol, is a charged compound, is hydrophilic and therefore
would be unable to cross the blood brain barrier.
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Figure 2.2 Dose response curves for therapeutic compounds.
U373MG cells were treated with increasing concentrations (0 ≤ 500 µM) of either (A)
BCNU, (B) TMZ, (C) Gefitinib, (D) cisplatin. Cells were also treated with a vehicle
control of 0.2% DMSO or 0.6% H2O. After 48 hours or 6 days’ cells were analysed
using Alamar blue cell viability assay (see appendix II). All experiments were repeated
minimum in triplicate. Data shown was normalised to the untreated control and are
shown as the % mean ± S.E.M. Non-linear regression statistical analysis was carried
out using Prism5 statistical software.
---------------------------------------------------------
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Table 2.1 Statistical analysis of GBM specific chemotherapeutic compounds over a 48hour and 6 day period
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Table 2.2 Statistical analyses of other medicinal compounds over a 48hour period.
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2.3.3

Extraction and purification of Ursolic Acid from Cranberries by HPLC

Figure 2.3 (A) demonstrates the potential of UA as anti tumour compound and possible
chemoprevention agent using both commercially available chemically synthesised UA
and UA enriched fraction isolated from cranberries. Indigenous UA was sufficiently
extracted from fresh whole lyophilized cranberry fruits using a solvent extraction
method with soxhlet apparatus and ethyl acetate (EtAOc) solvent. In order to quantify
the amount of UA present in an extracted sample of lyophilized cranberry fruits,
Reverse-Phase High Performance Liquid Chromatography (RP-HPLC) was performed
on both UA standard and cranberry extract, the method was based on a similar method
as described by (Zacchigna et al, 2009). The IC50 value for the enhanced UA extract
was determined to be 144µM. The enhanced UA extract, results in cell death at
concentrations greater than 100µM. Interestingly, the synthetic ursolic acid has a lower
IC50 value 21.72 µM. It is thought that this is due either to the impurities that might be
still present in the enhanced UA extract or due to functional modifications of UA
derived from Cranberries. In order to minimise variability between samples, the
synthetic UA standard was used for the remainder of this thesis to investigate the
biological effects in GBM cells. As demonstrated in figure 2.3a, there was no
significant difference in the IC50 value for UA when treated for 12hr, 24hr or 6 days (P
<0.05).

The enhanced extracted was identified as UA by means of Liquid

chromatography-mass Spectrometry (LC-MS) (figure 2.3 (D)). Similar peaks were
observed from both the UA standard and enhanced extract by LC-MS as seen in figure
2.3d, the ions observed on the mass spectra at m/z 455.3 for both the UA standard and
the enhanced extract represents the deprotonated mass of the intact molecule [M-H]-.
The ion at m/z 419 can be attributed to the loss of two water molecules from the intact
molecule. The chromatograms also suggest the presence of cis and trans isomers.
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Therefore, we have identified the enhanced extract as UA. Note that the UA extraction
from cranberries was carried out by a post-doc Jafar Alqudah in DIT, who is an expert
in bioactive extraction.
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Figure 2.3 Purified Enriched UA from cranberries induces dose dependent
cytotoxicity of GBM.
U373MG cells were treated with increasing concentrations (0-200µM) of (A)
chemically synthesised UA over a period from 24 hours, 48 hours and 6 days and (B)
Enriched UA fraction over 48 hours and analysed by Alamar blue analyses. Cells were
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incubated for 48 hours with enriched UA fraction and analysed by Alamar blue cell
viability assay. All experiments were repeated minimum in triplicate. Data shown was
normalised to the untreated control and are shown as the % mean ± S.E.M. Statistical
analysis was performed using non-linear regression analysis. (C) Demonstrates the
difference in the cytotoxicity between chemically synthesised UA and enriched UA
fraction over a 48 hours’ period. Non-linear regression statistical analysis was carried
out using Prism5 statistical software. (D) Shows the LC-MS analysis of purified UA
fraction from cranberries (bottom panel) compared to UA standard (top panel)
-------------------------------------------------------------
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Table 2.3 Statistical analyses for UA over a 24, 48hour and 6 day period and UA enriched fraction isolated from cranberries.

112

2.3.4

Ursolic Acids demonstrates greater cytotoxicity over conventional
chemotherapeutics

We have confirmed that chemically synthesized UA can sufficiently inhibit cell viability
in U373MG GBM cells as demonstrated above in (Figure 2.3a). Following this we
evaluated the efficacy of UA compared to the current standard chemotherapeutic drugs
used for the treatment of GBM. There was little reduction in cell viability following
treatment with the chemotherapeutics compound at 48 hours, thus IC50 could not
accurately be calculated (Figure 2.4a). In contrast, UA demonstrated a significant
reduction in cell viability following treatment after 48 hours, with an IC 50 value of 22
µM. IC50 values for the standard chemotherapeutics were calculated after a 6 days
exposed time period (TMZ 28 µM, BCNU 79 µM, and Gefitinib 16 µM) (Figure 2.4 b).
Cells were also treated with a vehicle control the highest concentration present in each
drug, either 0.2% DMSO or 0.6% H2O. No significant reduction in cell viability was
observed in the vehicle controls, calculated using student t-test.

Figure 2.4 Ursolic acid exhibits increased cytotoxicity over conventional
chemotherapeutics.
(A, B) U373MG cells were treated with increasing concentrations of UA (0-200µM),
TMZ, BCNU, or Gefitinib (0-500µM) for 48 hours (A) or 6 days (B), and analysed using
113

Alamar blue cell viability assay. Cells were also treated with a vehicle control of 0.2%
DMSO or 0.6% H2O. No deleterious effects were observed. Experiments were repeated
in triplicate. All experiments were normalised to untreated control. Statistical analysis
was carried out using non - linear regression analysis and Two-way ANOVA with
Bonferroni post-tests. (*P<0.001).
------------------------------------------------------------2.3.5

Optimisation of a panel of apoptotic, JNK inhibitors and autophagy
inhibitors

U373MG cells were exposed to a number of commonly employed inhibitors; caspase
inhibitor zVAD-fmk, JNK inhibitor SP600125 and ROS inhibitor NAC, and PI3K
inhibitor 3-methyladenine (3-MA) in order to determine the molecular mechanism
involved surrounding GBM cells death in response to various compounds. Dose
response curves were carried out for each inhibitor to determine an appropriate nontoxic
concentration to be used in future experiments. As demonstrated in figure 2.5 (A) no
significant cytotoxicity was observed even at higher concentrations of NAC. Based on
this data, for all future experiments 4mM was employed. It was evident in figure 2.5 (B)
that concentrations of SP600125 above 25µM were significantly toxic (P<0.05)
reducing cell viability by 33% at 25µM and 50% at 50µM. For all future experiments, a
concentration of 12.5µM was used. As observed in figure 2.5 (C), there was no
significant cytotoxicity induced from general caspase inhibitor zVAD-fmk, with less a
10% reduction on cell viability. Based on our data and that of the literature using
zVAD-fmk with U373MG cells (Kanzawa et al, 2003), for all future experiments 50µM
zVAD-fmk was employed. Both the JNK and caspase inhibitor were dissolved in
DMSO (sigma Aldrich) and therefore to ensure any cytotoxic effects observed as a
result of the inhibitor and not the vehicle control. Therefore, the cells were treated with
the high concentration of DMSO present (0.5% DMSO). There were no deleterious
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effects observed from the control in either JNK or ZVAD-fmk. In figure 2.5 (D) below
cells were exposed to increasing concentrations of 3-MA, a well-known autophagy
inhibitor. 3-MA inhibits autophagy by blocking autophagosome formation via the
inhibition of class I and class III PI3K. As per the manufactures instructions, the most
commonly used concentration used is 5mM, as demonstrated below we observe no
evidence of cytotoxicity following treatment with 5mM 3-MA. There appears to be a
slight increase in cell viability at 7.5mM but this was not deemed significant and is
variability within the pooled data. For all future experiments employing 3-MA, 5mM
was be used.

Figure 2.5 Optimisation of ROS, caspase, JNK and PI3K class III Inhibitors.
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(A -D) Each inhibitor was made up in full media. U373MG cells were treated with
increasing concentrations of either NAC (ROS), SP600125 (JNK), zVAD-fmk (caspase)
or 3-MA (autophagy). Following incubation of 48 hours’ cell viability was analysed by
Alamar blue analyses. Experiments were repeated in triplicate. Cells were also treated
with a vehicle control of 0.2% DMSO or 0.6% H2O. No deleterious effects were
observed. All experiments were normalised to untreated control and expressed as a %
of the SEM. Statistical analysis was carried out using One-Way ANOVA with
Bonferroni post-test (p<0.05).
------------------------------------------------------------Positive controls
Using the statistical data generated for the compounds used in this study, concentrations
around the observed IC50 values for each compound were chosen to be exposed to each
inhibitor. Cells were pre-treated with each inhibitor for 1hour, after which were co
treated with drug and inhibitor for 48 hours. As demonstrated below figure 2.6 (A)
H2O2 was used as positive control for NAC-sensitive cell death, (B) TMZ was used as a
positive control for zVAD-fmk-sensitive cell death and (C) Ursolic acid was used as a
positive control for SP600125-sensitive cell death. There was no significant loss in cell
viability following treatment with vehicle control (0.5%) DMSO. Cold atmospheric
plasma (CAP) was used as a positive control for autophagy inhibitor 3-MA. It is evident
form figure 2.6 (D) the 3-MA significantly protects against cytotoxicity induced by
CAP (P<0.001). It is evident from figure 2.6 (A-D) that each inhibitor has significantly
reduced the level of cytotoxicity induced by each compound (P<0.05), similarly the
compounds are shown to be nontoxic when added to U373MG cells alone.
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Figure 2.6 Optimisation of biochemical inhibitors employed to investigate
mechanisms of cell death.
U373MG cells were pre-treated with each inhibitor (A-D) for 1 hour prior to addition
of the positive control. Following incubation of 48 hours’ cell viability was analysed by
Alamar blue analyses. Experiments were repeated in triplicate. All experiments were
normalised to untreated control and expressed as a % of the SEM. Statistical analysis
was carried out using One-Way ANOVA with Bonferroni post-test (p<0.05).
-------------------------------------------------------------
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2.3.6

Characterisation of cell death induced by a panel of compounds.

A selection of compounds from the panel were chosen for further characterisation of the
molecular pathways that are involved in cell death. Recent studies have demonstrated
efficacy for the use of a modified form of cisplatin called platin-M (Pt(iv)), a prodrug,
which has been shown to successfully cross the BBB by a lipophilic polymeric
nanoparticle in a canine glioma model (Feldhaeusser et al, 2015). In additional current
therapeutic strategies such as the Gliadel wafer as described previously, this could
potentially be loaded with cisplatin and placed in the cavity of the brain post-surgery
therefore overcoming the need to cross the BBB. Therefore, we choose to investigate
non-conventional GBM therapeutics and assess their efficacy in a GBM model. Using
the results obtained from figure 2.5 for each inhibitor and the IC50 data established in
Tables 2.1 and 2.2 TMZ, cisplatin, was exposed to each inhibitor for either 48 hours
(cisplatin) or 6 days (TMZ). As demonstrated in figure 2.7 (A) Both zVAD and SP
successfully attenuated the effects of TMZ induced cytotoxicity by 17% and 26%
respectively (P<0.05). Our data suggests that TMZ follows a caspase dependent, JNK
dependent mechanism of cell death, interestingly with cisplatin (B) neither of the two
inhibitors were able to attenuate any cytotoxicity induced. There was no significant
reduction in cell viability in the inhibitors alone, as observed in the control data in
figure (2.5). A significant reduction in cell viability was observed following treatment
with cisplatin (48%) alone, therefore the compounds were effective killing the cells. The
vehicle control did not produce any deleterious effects. Our data suggests that cisplatin
induces cell death by a caspase and JNK independent mechanism.
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Figure 2.7 TMZ induces cell death through a caspase and JNK dependent
mechanisms.
(A-B) Cells were pre-treated with either zVAD-fmk (50µM) or SP600125 (12.5µM) for
1 hours prior to addition of the either TMZ (26.5µM) for 6 days or cisplatin (10µM) for
48 hours. Cell viability was analysed by Alamar blue analyses. Experiments were
repeated in triplicate. DMSO and negative control were carried out as described in
2.3.5. All experiments were normalised to untreated control and expressed as a % of the
SEM. Statistical analysis was carried out using One-Way ANOVA with Bonferroni posttest (p<0.05).
-------------------------------------------------------------
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2.3.7

Ursolic acids stimulates a reduction in the mitochondrial membrane
potential in GBM cells

To investigate whether UA induces apoptosis in U373MG GBM, cells were stained with
JC-1 dye and analysed using flow cytometry. Mitochondrial membrane potential (ΔΨm)
is an important factor of mitochondrial function and can be an indicator of early
intrinsic apoptosis. Collapse of the ΔΨm results in the release of cytochrome C into the
cytosol and thus leading to cell death (Salido et al, 2007). Figure 2.8 demonstrates the
loss in Mitochondrial Membrane Potential (ΔΨm) following treatment with UA. The
voltage sensitive fluorescent probe JC-1 that is sensitive to changes in ΔΨm was used to
determine whether UA could induce mitochondrial membrane depolarisation in GBM
cells. U373MG cells show a significant (P < 0.05) loss in mitochondrial function in a
dose dependent manner indicating a reduction in cell viability after UA treatment when
compared to untreated control. This result correlates with the Alamar blue results and
indicate that depolarisation of mitochondria is a feature of cell death induced by UA.
The rapid execution of the cellular death programme observed by UA possibly indicates
an alternative mechanism of activation of cell death compared with the other
chemotherapeutic agents tested
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Figure 2.8 UA induces mitochondrial membrane depolarisation in GBM.
U373MG cells were exposed to increasing concentrations of UA (standard). After a 48hr
incubation period cells were loaded with 10µg/ml JC-1 dye and analysed by flow cytometry.
Data shown depicts apoptosis measured by quantitative shifts in the ΔΨm (red to green)
fluorescence intensity ratio with increasing concentrations of UA. Cells were also treated

with a vehicle control of 0.2% DMSO. No deleterious effects were observed. All
experiments were repeated minimum in triplicate. Data shown was normalised to the untreated
control and are shown as the % mean ± S.E.M. Statistical analysis was carried out using nonlinear regression.

-------------------------------------------------------------
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2.3.8

Ursolic acid induces JNK dependent cell death

As previously described, UA was successfully isolated from cranberries, and was
demonstrated to selectivity induce a cytotoxic response in GBM cells. In order to
minimise variability between samples, the chemically synthesised UA standard was
used for the remainder of the study to investigate the biological effects in GBM cells.
The hill slope for UA is high and small changes in concentration around the IC50 value
can lead to large changes in viability. Therefore, three concentrations around the
established IC50 value were used. There was no evidence of any inhibitory effects by the
broad spectrum caspase inhibitor zVAD-fmk as seen in figure 2.9 (A), indicating that
caspase enzymatic activity may not be playing a role. It was speculated that stress
kinase signalling through JNK may be involved. Figure 2.8 (B) demonstrates that the
JNK inhibitor SP600125 alleviates the cytotoxic effects induced by UA in U373MG
cells. A dose response curve was established for SP600125 and it was determined that
concentrations above 12.5μM were cytotoxic, as previously described above. As seen in
(B), co-treatment with the JNK-specific inhibitor SP600125 significantly inhibited
(P<0.001) cytotoxicity induced by 20μM UA, and the IC50 value was also significantly
increased (p<0.05). Our results suggest that UA induces caspase independent, JNK
dependent cytotoxicity. It is important to note that while we identify JNK dependent
cytotoxicity following the use of JNK inhibitor SP600125, there are limitations to the
conclusion that can be drawn from this experimental approach due to lack of specificity
of this kinase inhibitor (Bubici & Papa, 2014a). In addition, cytotoxicity of the JNK
inhibitor must be taken into account also, as previously demonstrated in figure 2.5b, for
concentrations greater than 12.5µM, a significant loss in cell viability was observed
using the JNK inhibitor alone. In order to fully elucidate and confirm JNK dependent
cytotoxicity further analysis would be required in order to identify JNK activation. The
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next step would to carry out Western blot which can used to detect expression of
specific proteins for example phosphorylated JNK, and total JNK levels, which would
confirm its involvement in UA induced cell death.

Figure 2.9 Ursolic acid induces JNK dependent cytotoxicity in GBM cells.
U373MG cells were pre treated with 50µM zVAD-fmk (A) for 1 hr. prior to UA
treatment. Cells were then incubated for 48 hrs and analysed by Alamar blue. (B) Cells
were pre loaded 12.5 µM SP600125 JNK inhibitior for 1 hour, increasing
concentrations of UA were added in the presence of 12.5 µM SP600125 and incubated
for 48 hrs. Cells were also treated with a vehicle control of 0.2% DMSO. No deleterious
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effects were observed. Cells were then analylsed using Alamar blue cell viability assay.
Data shown was normalised to the untreated control and are shown as the % mean ±
S.E.M. Statistical analysis was carried out using One-Way ANOVA with Bonferroni
post test (*P<0.001).
------------------------------------------------------------2.3.9

UA and TMZ Combinational approach

If used in a clinical setting, UA therapy would most likely be used in combination with
existing chemotherapeutic regimens such as the current gold standard TMZ. We
hypothesised that a combinational approach with existing chemotherapeutic agents
could enhance the overall cytotoxicity of TMZ. TMZ is currently used in combination
with radiotherapy, which induces unfavourable off target side effects to the patient, with
no significant increase in survival. As UA is bioactive naturally available compound,
and is consumed regularly through plants and fruits, and therefore, has a high safety
profile.

As individual agents we have observed that UA demonstrated greater

cytotoxicity over shorter period of time then TMZ, more over at significantly lower
concentrations then that used for TMZ. To date there has been only one published
article that has combined ursolic acid with TMZ, and have demonstrated the
combination treatment of TMZ and UA synergistically enhanced cytotoxicity and
senescence in TMZ-resistant GBM cells and moreover they observed a reduction in
tumour volume by reducing MGMT in vivo, demonstrating that UA down regulates
MGMT status in GBM cells. (Zhu et al, 2016). As demonstrated below in figure 2.10
we observed no additive or synergistic effect between low doses of TMZ and UA. We
assume the reason for this is that U373MG are TMZ sensitive and therefore UA is not
having an effect on MGMT.

124

Figure 2.10 Combination of UA and low doses of TMZ
U373MG cells were treated with 0-20 µM UA after which 15µM TMZ was added to the
wells. Cells were then incubated for 6 days and analysed by Alamar blue. Cells were
also treated with a vehicle control of 0.2% DMSO. No deleterious effects were
observed. Data shown was normalised to the untreated control and are shown as the %
mean ± S.E.M. Statistical analysis was carried out using Two-Way ANOVA with
Bonferroni post test (*P<0.001).
-------------------------------------------------------
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2.3.10 UA inhibits GBM cell migration
One of the most important hall marks of GBM is an invasive behaviour and ability to
migrate into surrounding healthy brain tissue. Despite surgical resection, the majority of
the time the tumour recurs within 1cm of the surgical site (Demuth & Berens, 2004). An
important feature of a potential novel therapeutic for the treatment of GBM is its ability
to inhibit migration. A recent report has demonstrated that UA successfully inhibits
chemotaxis in polymorphonuclear leukocyte (PMN) using human whole blood (Mawa
et al, 2016). The scratch assay allows for the preliminary examination of the effects of
TMZ, Gefitinib, BCNU, and UA on the migration of U373MG cells. Cells were treated
with each compound, at a sub toxic concentration; so that it would not initiate a
cytotoxic response but potentially inhibit a migratory response. Figure 2.11 (A) shows
the transformation process when using ImageJ to calculate the size of the scratch. It can
be seen from the images in figure 2.11 (B) over the course of 7 hours, untreated cells
have migrated into the area of the scratch, therefore significantly reducing the size of
the scratch (P<0.05). TMZ demonstrates the greatest capacity to inhibit cell migration
of the chemotherapeutic compounds, reducing closure by 34% (P<0.05) compared to
untreated control. In comparison to this, there is a significant difference in the size of
the scratch in UA treated cells compared to the untreated control (P<0.05) as seen in
figure 2.11 (C). Using linear regression analysis, we have identified the slopes for all
compounds as being significantly different (P<0.0001). Thus, indicating that the rate of
migration has significantly slowed down as a result of exposure to sub toxic
concentrations of both the chemotherapeutic compounds and UA, therefore preventing
the scratch from closing. It would also appear that UA has a stronger capability to
inhibit migration over the current standard chemotherapeutics.
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Figure 2.11 UA inhibits GBM migration.
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Demonstrates the transformation process using image J software to analyse % size of
the scratch over time. (A) U373MG cell were either left untreated, or treated with TMZ
(100µM), Gefitinib (25µM), or BCNU (50µM), (DMSO 0.1%). Time dependent closure
of the scratch when was then analysed over a 7hour period. All experiments were
performed in triplicate. Image analysis was performed using image J Software
Statistical analysis was carried out using linear regression analysis and two-way
ANOVA with Bonferroni post-tests. (*P<0.001). (B) Time dependent closure of the
scratch, U373MG cells were left untreated, or treated with 12µM UA for 7 hours. All
experiments were performed in triplicate. Image analysis was performed using image J
software. Statistical analysis was carried out using linear regression analysis and twoway ANOVA with Bonferroni post-tests. (*P<0.001).

-----------------------------------------------------------
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2.3.11 JNK independent inhibition of migration by UA.
As stated previously, there has been much speculation as to the molecular mechanism
that induces cell death following UA treatment in vitro. Our results have previously
demonstrated that JNK plays a role in the cell death induced by ursolic acid, in addition
we have also demonstrated that UA is effective in inhibiting cellular migration in GBM
cells. To determine if JNK also played a role in the migration of GBM, cells were
treated with UA, SP600125, or both UA and SP600125 (12.5 µM), along with DMSO
control at a sub toxic concentration; so that it would not initiate a cytotoxic response
but potentially inhibit a migratory response. It is evident from our data (figure 2.12)
that treatment with UA has significantly slowed down the rate of migration when
compared to the untreated control (P < 0.05). No cytotoxicity or signficant difference
was obsereved between DMSO control and untreated cells. Interestingly, we observed a
partial inhibition in migration following the use of a JNK inhibitor alone, demonstrating
that JNK pathway play a role in GBM cell migration, which correlates this that
observed by (Zhou et al, 2012). However, when we combine UA with JNK inhibitor
SP600125, it does not enhance the inhibitory effects observed by UA alone. Our
results suggest that JNK does not play a role in the migration of U373MG cells in
response to UA treatment, but plays a role in alleviation of cell death.
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Figure 2.12 Ursolic acid induces JNK independent inhibition of cell migration in
GBM cells.
The effects of JNK inhibition using SP600125 on scratch closure when treated with UA.
Cells were treated with either, DMSO 0.1%, 12.5µM UA, SP600125 12.5µM, alone and
UA/SP combined. Images were taken at the time of the scratch and 7 hours later. There
is no significant difference observed between UA and UA combined with SP600125.
Image analysis was performed using ImageJ software. Statistical analysis was carried
out using One-Way ANOVA with Bonferroni post test. (*P<0.05).
-------------------------------------------------------------
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2.3.12 Ursolic acid triggers formation of acidic vesicle formation in GBM cells.
Having ruled out a role for caspases, we explored the hypothesis that UA resulted in
activation of the autophagic pathway Phosphatidylinositol 3-kinase PI3K/AKT/mTOR
signalling is involved in both the tumorigenesis and invasion of tumour cells. Cells were
exposed to autophagy inhibitor 3-methyladenine, and then treated with ursolic acid. As
observed below in figure 2.13 (A), 3-MA did not attenuate cytotoxic effects induced by
UA. In order to investigate the autophagy pathway was being activated by UA,
U373MG were also examined by flow cytometry using Acridine Orange following
treatment with UA, which is commonly employed for the detection of acidic vesicular
organelles (AVO’s). AVO’s are an important morphological characteristic in the
autophagic process. As seen in figure 2.13 (B) there is an increase in the formation of
acidic vesicular organelles (AVO’s) as demonstrated by an increase in the red
fluorescence signal following UA treatment with AO compared with the untreated cells
stained with AO. This data was quantified by the mean fluorescence value and a
significant difference was observed between treated and untreated cells (P<0.005, figure
2.13 (C)). Acridine orange fluorescence in cells validates the formation of AVO’S,
which is a significant characteristic of the autophagic process suggesting that the
autophagy pathway may be activated during UA induced cell death.
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Figure 2.13 UA results in the formation of Acidic vesicle organelles.
(A) U373MG cells were pre treated with 5mM 3-MA for 1 hr prior to addition of UA.
Cells were then incubated for 48 hrs and analysed by Alamar blue. Data shown was
normalised to the untreated control and are shown as the % mean ± S.E.M. Statistical
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analysis was carried out using One-Way ANOVA with Bonferroni post test (*P<0.001).
(B) U373MG cells were exposed to 25µM UA. After a 48hr incubation period cells were
loaded with 1µg/ml AO fluorescent probe and analysed by flow cytometry. Data shown
depicts the formation of acidic vesicular organelles measured by quantitative shifts in
the FL-2 channel (red fluorescence) intensity ratio following treatment with UA. Data
shown was normalised to the untreated control and represented as arbitrary unit’s ±
S.E.M. (C) Overlay of U373MG untreated cells with AO (black) with UA (25µM) with
AO (red). Quantification of mean fluorescence index and statistical analysis using non
parametric t-tests (P<0.05).
-------------------------------------------------------------
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2.4

Discussion

Current commonly used chemotherapies used for the treatment of GBM include a mixture of
alkylating agents, receptor tyrosine kinase inhibitors, antibiotics, alkaloid agents and
combinational therapies. The current standard of care for the treatment of GBM, as
previously described, requires a combination of therapies including surgery, radiation therapy
and chemotherapy with TMZ. Unfortunately, even with the multitude of therapies available,
survival rates have remain stagnant over the past 30 years and for those who receive maximal
treatment the 5 year survival rate is <10% (Ostrom et al, 2014). Poor survival statistics and
resistance to current treatment modalities, demonstrates a need for the devolvement of novel
approaches for the treatment of GBM. Our data has demonstrated that commonly used
chemotherapeutics induce a significant cytotoxic insult over a longer 6-day period, in contrast
to that of other medicinal compounds, cisplatin and clozapine (see appendix VI), where
cytotoxicity was identified after 48 hours. A key recurring issue with using compounds such
as cisplatin for the treatment of GBM is the high molecular weight of the compound.
Compounds that maintain a high molecular weight are unable to successfully cross the highly
selective blood brain barrier unlike that of Clozapine which has a low molecular weight and
therefore has no difficulty crossing the blood brain barrier. Although it has been postulated
that with a combined therapeutic approach, using radiotherapy which disrupts that BBB
therefore allowing passage of larger molecules to the site of the tumour (Agarwal et al,
2013). There have been numerous studies investigating novel delivery strategies to enhance
the permeability of the BBB in a non-invasive manner, to deliver therapeutics across the BBB
to reach the brain, which have been extensively reviewed by Zhang et al (Zhang et al, 2015),
demonstrating efficacy for novel combinational approaches for the treatment of GBM.

134

There has been considerable interest in the nutraceutical industry over the past 20 years, since
the development of the link between nutrition and pharmaceuticals to aid in the prevention or
curing of disease. There are numerous phytochemicals derived from food sources that have
been used for their potential health benefits, for example folic acid, found in dark green
vegetables which are said to prevent neural tube defects and catechins that are present in
green tea, are said to be cancer preventive (Oleszek, 2002). Recent studies suggest that
cranberries contain health enhancing bioactive ingredients can induce a cytotoxic response in
cancer cells (Shanmugam et al, 2013a; Weng et al, 2014) while remaining nontoxic to
normal cells, this has also been demonstrated in vivo (Wang et al, 2011). One of those
indigenous bioactive ingredients is ursolic acid (UA) demonstrating efficacy as a potential
therapy or as a chemo-preventative. To date there have been few reports on the effects UA in
GBM cells, It was reported that UA inhibits the endogenous reverse transcriptase (RT)
activity GBM cells which was previously shown to be involved in the control of proliferation
(Bonaccorsi et al, 2008). More recently a study has presented the anti-tumours activities of
UA in GBM cells demonstrating that apoptosis is induced by UA-triggered TGF-b1/miR21/PDCD4 pathway (Khan et al, 2012). Using validated methods for extraction, purification
and identification, our extract sample was confirmed to be the pentacyclic triterpene UA by
means of LC-MS. This is thought be due to the isomeric formations of the compounds.
Similarly, to others as mentioned previously, our data demonstrates that UA exhibits antitumour activity in the U373MG GBM cell line. We have shown that UA has increased
cytotoxic activity compared to that of the commonly used chemotherapeutics used for the
treatment of GBM. No synergy was observed between UA and TMZ combined. Currently
TMZ is administered orally on a daily basis at a dose of 75 mg/m2 throughout external beam
radiotherapy. Post radiotherapy, TMZ is then administered at a dose of 150-200 mg/m2 daily
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for 5 days every 28 days for maintenance (Hottinger et al, 2014). This level of treatment is
both invasive and prolonged. This further validates the efficacy of UA and its potential as a
therapeutic. It induces a greater cytotoxic response over a shorter period of time, making it an
ideal candidate from a therapeutic point of view. In addition, it has great potential as a chemo
preventive as it is readily bioavailable, making it inexpensive and easily accessible.
One of the most important hall marks of GBM is its invasive behaviour and ability to migrate
into surrounding healthy brain tissue. Despite surgical resection, tumour recurrence
commonly occurs within 1cm of the surgical site (Demuth & Berens, 2004). The distinct
characteristic of migration is therefore an important feature of any potential new
chemotherapeutic for treatment of GBM is the ability to inhibit migration of any remaining
cells post-surgery. In contrast to results observed by (Choi et al, 2014), our data demonstrated
significant reduction in cellular migration following treatment with TMZ, this could due to
differences in cell lines used and the sensitivity to TMZ. Moreover, we have observed a
significant reduction in migration after only 4 hours following treatment with a low dose UA
when compared to untreated cells. This finding is novel and echoes a recent report that UA
successfully inhibits chemotaxis in polymorphonuclear leukocyte (PMN) using human whole
blood (Mawa et al, 2016). We have also identified the role of JNK in promoting GBM cell
migration. We observed a significant partial inhibition in GBM migration following the
addition of a JNK inhibitor SP600125. Interestingly, when UA was co-treated with JNK
inhibitor SP600125 we observed no enhanced inhibition in migration. However, we
demonstrate a significant increased inhibition of cell migration following the combination of
UA with JNK inhibitor when compared to the JNK inhibitor alone. This demonstrates the
efficacy of UA as a potential anti-migratory therapeutic for the treatment of GBM and also
confirming the role of JNK in GBM migration.
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To date there has been many studies published with aim to developing an understanding of
the molecular mechanisms involved in the induction of cell death following treatment with
UA in vitro. With reports confirming that UA induces a cytotoxic effect on a variety of cancer
cells, there have been inconsistencies as to the mechanism in which cells are dying. Various
studies have suggested, apoptosis, autophagy and necrosis as the underlying mechanisms,
therefore it would appear to be cell line dependent. The more conventional mechanism of cell
death, apoptosis was demonstrated in a variety of cancer cells as a result UA treatment, for
example apoptosis in gallbladder cancer was observed both in vitro and in vivo and is thought
to be through the intrinsic mitochondrial-mediated apoptosis pathway (Weng et al, 2014).
UA-mediated caspase activation and apoptosis in human leukaemia cells both in vivo and in
vitro and has been demonstrated to be linked with PKB inactivation and JNK activation (Gao
et al, 2012). In colon cancer cells UA induced apoptosis by suppressing the EGFR/MAPK
pathway (Shan et al, 2009).
There are few reports of UA induced cell death in GBM models. One report has demonstrated
apoptosis in a different GBM model through increased caspase-3 expression and suppression
of the TGF-b1/ miR-21/PDCD4 Pathway (Wang et al, 2012b) miR-21 is a protein involved in
the regulation of apoptosis and has been shown to be up-regulated in GBM, it is thought to
exert anti-apoptotic effects through regulation of target-programmed cell death 4 (PDCD4)
(Chan et al, 2005; Wang et al, 2012b) whereas in contrast more recently necrosis has been
demonstrated in DBTRG-05MG GBM cells through rapid mitochondrial permeability
transition (MPT) and opening of the MTP pores (Lu et al, 2014). Recently a third mechanism
of cell death has also been demonstrated in U87MG GBM cells, UA induces autophagy
following Ca2+ release from the ER lumen and activation of the AMPK-mTOR kinase
signalling cascade (Shen et al, 2014).
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As observed from figure 2.9b, our data suggests that UA induces caspase independent, JNK
dependent cell death. Our data demonstrates a significant inhibition of cell death at a
concentration of 20µM but no inhibition was observed a 25 µM. As demonstrated previously
in section 2.3.3, the dose response curve for UA demonstrated a very steep hill slope,
identifying a narrow concentration range in which the IC50 (~21.5µM) and that anything
above this was very cytotoxic. It is postulated that the cytotoxicity induced at the higher
concentration of UA was too toxic for the inhibitor to overcome. It was initially hypothesised
that where significance was observed at 20 µM was due to an anomaly in the data or an
outlier, however this experiment was repeated in triplicate and the same outcome was
observed each time indicating that observations were true. This correlates with data observed
by (Zhang et al, 2010), who demonstrated that UA induces cell death via activation of JNK in
prostate cancer cells. Increasing evidence has shown that UA activates autophagy cancer cells
(Leng et al, 2013; Shen et al, 2014) which will be discussed further in chapter three.
Similarly, as shown by Xavier et al also demonstrated a caspase independent, JNK dependent
cell death by UA in colorectal cancer cells. Interestingly, they also note that apoptosis
corresponds to only a small percentage of the total cell death induced by UA (Xavier et al,
2013). As mentioned previously it is important to note the limitations of using a single
inhibitor assay to identify the role of JNK in UA induced cell death. SP600125 has been
previously shown to can bind to a broad range of protein kinases and inhibit some of them
with similar or greater potency than JNK, thus it is important to note that additional kinases
may be targets of SP600125, for example, SP600125 displays action against all three JNK
proteins (JNK1, JNK2 and JNK3), and at higher concentrations, can also inhibit the closely
related ERKs and p38 MAPKs (Bennett et al, 2001; Tanemura et al, 2010; Bubici & Papa,
2014b). To further confirm the role of JNK in UA induced cytotoxicity it would be important
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to demonstrate biochemical evidence of JNK activation. Similar to the experimental approach
carried out by Xavier et al, such as employing the use of Western blots, as this offers higher
specificity and sensitivity over the use of a single inhibitor. It was previously reported that
UA inhibits migration and invasion in vitro in human breast cancer cell line, and was
observed that the anti-invasive effects of UA were speculated to be through the inhibition of
Jun N-terminal kinase, AKT and a reduction of the level of NFκB transcriptional regulator
protein therefore leading to down-regulation of metalloproteinase-2 (MMP-2) and u-PA
expression (Yeh et al, 2010). It was also observed in C6 glioma cells that UA inhibits MMP9 resulting in the inhibition of tumour invasion (Huang et al, 2011). Our findings provide
evidence that UA is inhibiting/altering the migratory pathways of U373MG cells independent
of the JNK pathway. Further analysis is required to determine whether JNK is playing a role
in the regulation of MMP proteins in U373MG cells as a result of UA.
Following identification of a caspase independent mechanism, it was postulated that
autophagy maybe play a role in U373MG cell death following UA treatment. For the studies
using 3-MA we used CAP as a positive control. A studied carried out by GE et al in HeLa
cells that LC-3 protein could not be detected during starvation when cells were exposed to 3MA (Ge et al, 2014). Therefore, another control that could be added to this study is the use of
a serum or nutrient starvation as an alternative positive control for 3 MA, as autophagy is
naturally induced following nutrient starvation, this would be a good physiological
representation of the induction of autophagy.

Our data demonstrates that 3-MA did not

alleviate the cytotoxic effects of UA. However, this correlates with others who also
demonstrated that 3-MA did not inhibit cell death, although it has been demonstrated that
other autophagy inhibitors such as Wortmannin and LY294002 augmented the cytotoxic
insult induced by UA. Therefore, suggesting autophagy as a mechanism of cell death. It has
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been noted previously that 3-MA acts as both an inhibitor of Class I PI3K activity (inhibits
autophagy) and Class III PI3K activity (necessary for autophagy), and therefore the effect of
3-MA may not be observable in all cases (Wu et al, 2010). We speculate that this is the case
with our data as further studies employing the use of acridine orange by flow cytometry,
verified the formation AVOs following UA treatment, which are a morphological
characteristic of autophagy. Following UA treatment, we have identified the formation of
acidic vesicle organelles using flow cytometry which as described previously are a
morphological indicator of autophagic vesicles. It is important to note that this assay cannot
identify autophagic vesicles but is used as an indicator and further analysis is required to
categorically identify the autophagic pathway. Acridine orange crosses into acidic
compartments such as AVO’s and lysosomes and becomes protonated. Therefore, it cannot be
ruled out that the shift in fluorescence observed is from the uptake of acridine orange by
lysosomes and not acidic vesicle organelles that are associated with autophagy. However, it is
also noted that acridine orange stains late autophagic vacuoles, therefore, fluorescence
observed could indicate the presence of both lysosomes as well as autolysosomes. Two
methods that are commonly employed for the detection of autophagic processes are TEM and
the presence of autophagic processes is identification of microtubule-associated protein
1A/1B-light chain 3 LC3, both of which should be employed when trying to identify
autophagy. During autophagy, a cytosolic form of LC3 (LC3-I) is conjugated to
phosphatidylethanolamine to form LC3-phosphatidylethanolamine conjugate (LC3-II). LC3II degraded in the autolysosome. Thus, lysosomal turnover of the autophagosomal marker
LC3-II indicates starvation-induced autophagic activity (Tanida et al, 2004), and detecting
LC3 by immunoblotting or immunofluorescence has become a reliable method for
monitoring autophagy. Another commonly employed reliable approach is the use of TEM.
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TEM characterizes autophagy qualitatively, as early stage autophagosomes containing
morphologically intact cytosol or organelles or as late stage autolysosomes containing
partially degraded cytoplasmic as well as organelle material. However, it is important to note
that when classifying autophagy as a mechanism of cell death the NCCD have provided very
specific guidelines on how to do so. To identify cell death that is mediated by autophagy, is
that it can be suppressed by the inhibition of the autophagic pathway by chemicals (e.g.
VPS34) and/or genetic means (e.g., gene knockout/mutation) (Galluzzi et al, 2015). They
also express that cases of cell death that exhibit markers of autophagy such as the LC3/Atg8
or an increased degradation of autophagic substrates like sequestosome 1 (SQSTM1), but
cannot be blocked by autophagy inhibition should not be classified as autophagic cell death
(Galluzzi et al, 2015). Therefore, it is important to specify whether you are just identifying
the autophagic process which is most likely acting as a pro-survival mechanism or whether
you are identifying autophagy as a mechanism of cell death.
The data observed form this chapter has offered great insight into how GBM cells respond to
various compounds and provides significant basis for further experimental work with ursolic
acid. A limitation that has been noted in this chapter and perhaps throughout the thesis is not
having employed the use of normal non-malignant cell line to use as a comparator against the
U373MG GBM cells. When testing compounds and drugs that are potential therapeutic
compounds it is essential to identify the therapeutic window. The therapeutic window is a
range of doses that induce a therapeutic response without causing any significant adverse
effect in patients. Generally, the therapeutic window is a ratio between the minimum effective
concentrations (MEC) to the minimum toxic concentration (MTC). By employing the use of a
non-malignant cell line combined with the U373MG it would allow for the identification of
the maximum effective concentrations and minimum toxic concentration for ursolic acid.
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In conclusion we have identified a novel nutraceutical compound that has a greater cytotoxic
capacity against GBM cells than the currently used chemotherapeutics for the treatment of
brain cancer. We have identified a ROS-dependent, JNK-dependent and caspase dependent
mechanism of cell death in the current gold standard chemotherapeutic TMZ that is in line
with published data. Interestingly, in contrast to published data we demonstrated that low
doses of TMZ inhibits cell migrations in GBM cells. We show that Ursolic acid induces JNK
dependent cell death and JNK independent suppression of migration in human Glioblastoma
multiforme cells. It is widely accepted that TMZ induces an autophagic mechanism of cell
death in GBM cells (Kanzawa et al, 2004a; Natsumeda et al, 2011). Caspase independent cell
death is often linked with autophagy (Kroemer & Martin, 2005b; Rieckher & Tavernarakis,
2010). We demonstrated no inhibition of cell death using 3-MA, we have demonstrated
evidence of the formation of AVO’s which could indicate the presence of the autophagic
process. Further experiments are required in order to fully elucidate the mechanism of cell
death that is induced by UA, and whether autophagy is activated, which if it is the case could
be acting in a pro survival mechanism preceding cell death or cell death with autophagy.
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3

Cold Atmospheric Plasma induces ROS-independent cell

death in U373MG Glioma cells & demonstrates both synergistic
and inhibitory effects when combined with medicinal compounds.

Part of this chapter has been published (see Conway GE et al., Br J Cancer, 2016)
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3.1

Introduction

Over the past decade plasma science has emerged as a novel approach for applications in
areas such as food sterilization, medical devices, polymer science and biomedicine (von
Woedtke et al, 2013; Ziuzina et al, 2014). Physical plasmas are fully or partially ionized
gases which contain various concentrations of free electrical charges, atoms, ions and
electrons which are generated by an energy supply to a neutral gas (von Woedtke et al,
2013). Plasmas can be categorised as either thermal or non-thermal. Non-thermal plasma
(NTP) gains its reactivity from the high energy electrons while the ions and neutral species
remain at a low temperature (von Woedtke et al, 2013). NTP’s attained at low or
atmospheric pressure, have low power requirements and are also able to generate chemically
active species within gases such as reactive oxygen species (ROS) (O2•, O, and O3, OH•,
H2O2) and reactive nitrogen species (RNS) (NO3, N+2, NO). The operating principle of the
plasma discharge system used is Dielectric Barrier Discharge (DBD), as seen in figure 3.1
below.

Figure 3.1 Dielectric barrier discharge (DBD) system.

144

Schematic of the Cold Atmospheric Plasma Dielectric Barrier (CAP-DBD) system utilised in this
study. The sample is placed in between two electrodes, where both reactive oxygen and reactive
nitrogen species are generated.

The DBD generates high voltage pulsed cold plasma between two electrodes, one of which
is insulated. The insulator prevents the build-up of current between the electrodes and any
significant gas heating (Fridman et al, 2006). CAP can effectively control the concentrations
of intracellular ROS/RNS. CAP generated NO species results in the elevation of
intracellular NO concentration which therefore leads to increase of intracellular ROS
(Vandamme et al, 2012; Ishaq et al, 2014a).
ROS are naturally present in the body and at low concentrations mediate many biological
functions including cellular redox signalling and high concentrations of ROS are utilised as
a cytotoxic mechanism by innate immune cells (Ahn et al, 2011). In order to prevent cellular
damage and apoptosis due to the high reactivity of ROS, the cell contains antioxidant
enzymes such as glutathione peroxidise which act as scavengers to detoxify ROS (King &
Robins, 2006). Over the years it has become increasingly apparent that the generation of
ROS can be utilised therapeutically for the treatment of cancer (Curtin et al, 2002). A
recurring issue with the current chemotherapeutics used in the treatment for GBM is the
adverse side effects induced due to the high toxicity of the drugs, and developed resistance
to the therapeutic over time.
Recent studies have shown that high concentrations of ROS produced from CAP exposure
can generate a cytotoxic effect and induce apoptosis of cancer cells via disruption of the
mitochondrial membrane (Fridman et al, 2008; Ahn et al, 2011; Vandamme et al, 2012;
Köritzer et al, 2013). An important feature that has been demonstrated in previous studies, is
that CAP not only has the ability to induce cell death in GBM cells but also has a much

145

lower cytotoxic effect on normal astrocytes (Recek et al, 2015; Siu et al, 2015) .While there
is vast potential for the use of CAP as both a single agent and as a combinational therapy in
the treatment of cancers, experimental evidence supporting this application in GBM remains
to be carried out.
The aim of this chapter is to generate and optimise the CAP DBD for treatment with
mammalian cells. The anti-tumour effects of CAP using our DBD system in vitro on
U373MG GBM cells and the cervical cancer cell line HeLa will be evaluated. The
molecular mechanism involved that result in cell death following CAP treatment will be
investigated, and the combinational effect between CAP and a panel of medicinal and
nutraceutical compounds will be determined.

3.2

Materials & methods

3.2.1 Routine cell culture, maintenance and sub culture
The human glioblastoma cell line (U373MG-CD14) was kindly gifted from Dr Michael Carty
(Trinity College Dublin) and was the main cell line used in this study. Also employed for part
of this study was the human cervical cancer (HeLa, ATCC® CCL-2™) cell line which was
purchased from American Type Culture Collection (LGC Standards, Middlesex, UK) and
cultured as previously described in chapter two (section 2.1.1).
3.2.2 Non-thermal atmospheric plasma Dielectric barrier discharge (CAP-DBD) setup
The CAP-DBD device used is a novel prototype atmospheric low temperature plasma
generator (Ziuzina et al, 2013). The system consists of a variable high voltage transformer
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with an input voltage of 230 V at 50 Hz and a maximum high voltage output of 120 kV. The
two 15-cm-diameter aluminium disc electrodes were separated by a polypropylene sheet
which served both as a sample holder and as a dielectric barrier with a thickness of 1-2 mm.
The distance between the two electrodes was 14.2 mm - 26.6 mm depending on the size of
culture plate used. Voltage was monitored using an InfiniVision 2000 X-Series Oscillo-scope
(Agilent Technologies Inc., Santa Clara, CA, USA). The atmospheric air condition at the time
of treatment was 45% relative humidity (RH) and 22 °C. The samples were treated at 75 kV
for 0 – 300 seconds. Optical emission spectroscopy (OES) readings were taken between the
range of 200-850 nm using the Low Straylight Smart CCD Exemplar LS spectrophotometer
(BRC115U), with a 3,000 m/s integration time. Data was analysed using BWSpec4 and
OriginPro 8.
Optimisation of CAP-DBD experimentation with mammalian cells.
U373mg cells were seeded at a density of 1x104 and HeLa cells were seeded at 0.8x104 into
96well plates (Sigma-Aldrich, Arklow, Ireland) with 100µl media per well. Plates were left
overnight in the incubator at 37°C with 5% CO2 to allow the cells to adhere. Dose response
curves were established with both cells lines, with exposure time being the variable. Cell
were also exposed to CAP both in the presence and absence of cell culture media, to
investigate the most appropriate treatment conditions. Media was removed from the wells
prior to CAP treatment and fresh media was replaced immediately after treatment and
incubated at 37°C as indicated. No deleterious effects were observed in the vehicle control
samples. The 96 well plates were also placed both in and out of the CAP field. In field studies
required the 96 well plates being placed directly between the 2 electrodes. Out of field
(indirect) studies were carried out by placing the 96 well plates inside a plastic sample
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container which allowed for the samples to be placed out of the plasma field, these are
denoted as direct and indirect treatment of CAP.
3.2.3 Cytotoxicity assays
Alamar blue Assay
Alamar blue (Invitrogen) assay was used to investigate cell viability when performing the
cytotoxicity and proliferation studies in both cell lines as described previously in chapter 2
(section 2.3.3). The data (in fluorescence units from the microplate reader) for the test wells
were normalised to the assay control (DMEM or RPMI medium only) and cell growth was
calculated as a change of viability over time.
Trypan Blue assay
The Trypan Blue (Biosciences, Dun Laoghaire, Ireland) cell dye exclusion assay was also
performed 48 hrs post treatment in HeLa cells and 96 hrs post treatment in U373MG cells.
Both floating and trypsinised cells were collected and a 1x106 cells/ml cell suspension was
prepared. A 1:1 mixture of cell suspension and 0.4% trypan blue solution was loaded onto a
haemocytometer for counting.
3.2.4 JC-1 apoptosis Assay
After CAP treatment, cells were harvested and stained with 10 µg/ml JC-1 dye (Biosciences,
Dublin, Ireland) (Galluzzi et al, 2007), at room temperature for 10 minutes and analysed by
flow cytometry (BD Accuri C6). JC-1 was excited using the argon laser at a wavelength of
488 nm. Fluorescence was measured using the FL1 (530 nm) and FL2 (585 nm) channels
with emission spectral overlap compensation (7.5% FL1/FL2 and 15% FL2/ FL1).
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3.2.5 Spectrophotometric identification of reactive oxygen species (ROS).
ROS generation was determined using the cell permeable non-fluorescent probe H2DCFDA
(Biosciences, Dublin, Ireland) (Wu & Yotnda, 2011). A stock solution of 100µM H2DCFDA
was made up in DMSO, aliquot out and stored in -20°C freezer. Working solutions of 50µM
were made up fresh for each experiment in full media. Cells were plated in black flat
bottomed 96 well plates (Fischer Scientific, Ballycoolin, Ireland) overnight. Cells were then
preloaded with 10 µM H2DCFDA and placed in the incubator for 1 hr in the dark. Following
the incubation period cells were washed once with PBS. The wells of the 96 well plates were
emptied using a pipetting following PBS wash and exposed to CAP for 180 seconds at 75kV
or treated with H2O2 where indicated. After CAP treatment media was added to the wells and
fluorescence intensity was measured 1 hour later on a micro-plate reader (Victor 3V) at 492–
495/ 517–527 nm.
3.2.6

Confocal microscopy

Identification of ROS by confocal microscopy,
Both U373MG and HeLa cells were plated in 35 mm glass bottom dishes (MatTek
Corporation, USA) at a density of 5x104 and 8x104 cells per dish respectively. Cells were left
to adhere for 24 hrs in a 37°C incubator. Cells were then preloaded with 10µM H2DCFDA
and treated as stated above, cells were then analysed 1-hour post treatment using confocal
microscopy (ZEISS LSM 510 Meta). Images were captured using an excitation wavelength
488nm and emission wavelength of 515nm with a 40x objective.
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Mitochondrial ROS production by confocal microscopy
Stock solutions of MitoSOX (Biosciences, Dublin, Ireland) were made up as per
manufactures instruction. The contents of one vial (50µg) was dissolved in 13μL of DMSO to
make a 5mM stock solution which was aliquoted and stored at -20°C. A 2µM working
solution were made fresh for each experiment in full media. Both U373MG and HeLa cells
were plated in 35 mm glass bottom dishes (MatTek Corporation, USA) at a density of 5x104
and 8x104 cells per dish respectively. Cells were left to adhere for 24 hrs in a 37°C incubator.
Cells were loaded with 2µM MitoSOX 1-hour post treatment. Cells were incubated for 10
minutes at 37° C and analysed by confocal microscopy (ZEISS LSM 510 Meta). Images were
captured using an excitation wavelength 510nm and emission wavelength of 580nm with a
40x objective.
3.2.7 Identification of ROS by confocal microscopy.
ROS was also quantified by flow cytometry using H2DCFDA probe. Cells were stained with
0.1µM H2DCFDA for 30 minutes prior to CAP treatment. 1-hour post treatment cells were
harvested by means of trypsinisation, washed twice in PBS and analysed by flow cytometry.
Fluorescence was measured using the FL1 channel (530 nm).
3.2.8 Inhibitor studies
Commonly employed general caspase inhibitor zVAD-fmk was used in order to determine
whether caspases play a role in cell death as a result of CAP treatment. A working solution of
zVAD-fmk was prepared in full media from previously prepared stored stock solutions as
described in chapter 2 (sec 2.3.4.1). Cells were pre-treated for 1 hour with zVAD-fmk. Wells
were then emptied and exposed CAP. Cell viability was assessed 48 hours later using Alamar
Blue cell viability assay.
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N-acetyl-cysteine (NAC) a ROS inhibitor was used to identify whether ROS was involved in
cell death following CAP treatment. As described in chapter 2 (sec 2.3.4.2) 4mM NAC was
made up fresh for each experiment in full media. Cells were preloaded with NAC for 1 hour.
Wells were then emptied and exposed to CAP and NAC, fresh NAC was added immediately
after treatment. Cell viability was assessed 48 hours later using Alamar Blue cell viability
assay.
SP600125 is inhibitor of JNK which is commonly associated with apoptosis. Cells were pretreated with SP600125 (Sigma Aldrich, Arklow, Ireland) and also re-added immediately after
CAP treatment. Cell viability was assessed 48 hours later using Alamar Blue cell viability
assay.
3.2.9 Combinational Studies
Combinational studies employing short durations of CAP.
Cells were seeded into 96 well plates as previously described in chapter one, and left to
adhere overnight. Media was then removed from each well and exposed to between 10-60
secs CAP. Following CAP treatment cells were treated with a low medium and high dose of
either TMZ (0, 5, 10, 20µM), clozapine (6.25, 12.5, 50 µM), cisplatin (1.5, 3.1, 6.25, 25 µM),
or UA (6.25, 12.5, 25 µM). Cells treated with TMZ were analysed after 6 days, cells treated
with cisplatin, clozapine or UA were analysed by Alamar blue analysis after 48 hours. No
deleterious effects were observed from vehicle DMSO control of 0.1%.
Direct exposure of drug to CAP.
Cells were seeded into 96 well plates as previously described in chapter one, and left to
adhere overnight. Stock concentrations of TMZ (50mM, DMSO), clozapine (50mM, DMSO),
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UA (40mM, DMSO), Cisplatin (2mM, PBS), were directly exposed to CAP at 75kV for 15
minutes. Immediately after CAP treatment, working stocks of each compound were made up
in full media and added to untreated cells. As a negative control, cells were also treated with
the same concentrations of each compound that was not exposed to CAP. No deleterious
effects were observed from vehicle DMSO control of 0.25%
3.2.10 Statistical Analysis
All experiments were performed at least three independent times with a minimum of five
replicates per experiment. Data shown is pooled and presented as mean ± SEM (n= total
number of replicates) unless stated otherwise. Statistical analysis and curve fitting was
performed using Prism 5, GraphPad Software, Inc. (USA), as previously described in chapter
2. Unless otherwise indicated differences were considered significant with a p value < 0.05
Correlation graphics were attained using R statistical software (Lucent Technologies) (See
appendix (III-V).

3.3

Results

3.3.1 CAP induces cell death in cancer cells.
As demonstrated in figure 3.2 both (A) U373MG cells and (B) HeLa cells were exposed to
CAP in the presence of culture media and analysed after 48 and 72 hours, to determine the
cytotoxic effect over time. As observed U373MG cells demonstrated increased capacity to
withstand CAP treatment compared to that observed by HeLa cells. H2O2 was used as a
positive control for both cells lines which induced an effective 100% cell death. Interestingly
in the U373MG cells we observed a significant (P<0.05) difference in cell viability between
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48 and 72 hours, this could be due to variability in cell amongst plates, or the cells might be
undergoing the repair process and therefore a small increase in viability was observed. All
future experiments carried out were over a 24 or 48-hour period. Figure 3.2 (C and D) shows
a dose response curve of CAP treatment in both in the presence and absence of cell culture
media. Cells were either treated in the presence of media or media was removed prior to CAP
treatment. Media was also removed on the control plate for matched observations, no
deleterious effects were detected. There is a significant (p<0.05) reduction in cell viability in
response to CAP treatment in the U373MG (C) when the media is removed prior to treatment
compared to when media was present. It is evident that the Hela cells (D) are highly
susceptible to CAP treatment, showing 100% reduction in cell viability after 10 sec of
treatment when media was removed prior to treatment. No significance was observed
between media and no media, following statistical analysis by means of Two-way AONVA
with Bonferroni post-test.

153

Figure 3.2 U373MG cells demonstrated increased resistance to CAP over time.
(A) U373MG cells and (B) HeLa cells were exposed to CAP for 120 seconds in the presence
of cell culture media. Cell viability was then analysed using Alamar assay at different time
points. Experiments were completed a minimum of three time. Statistical analysis was carried
out using Two-Way ANOVA with Bonferroni comparison post-test. (*P <0.01). (C)U373MG
and (D) HeLa were exposed to CAP for up to 180 seconds at 75kV in 96 well plates in the
presence and absence of 100 µl cell culture media. 48 hours post treatment cell viability was
analysed by Alamar blue analyses. All experiments were repeated in triplicate with n=5 per
experiment. Statistical analysis was carried out using Two-Way ANOVA with Bonferroni
comparison post-test. (*P <0.05).
--------------------------------------------------------------
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3.3.2 Antioxidants only afford partial protection against cold atmospheric plasma
(CAP) cytotoxicity.
Upon investigation it was noted that the cell culture media used for the U373MG cells,
DMEM high glucose contained pyruvate, a well-known reactive oxygen species scavenger.
As seen in figure 3.3 (A), there is a correlation between increasing concentrations of pyruvate
with increases in cell viability. There is a significant difference (P<0.001) in cell viability
between CAP treatment and no CAP treatment at each concentration pyruvate. As
demonstrated (B), following CAP treatment, pyruvate is absent from the media. There is only
8% cell viability compared to when there is 100% pyruvate present, were we demonstrate a
significant (P<0.001) increase in cell viability by 35%. Therefore it is evident that pyruvate
appears to have some capacity to protect against the effects of CAP induced cell death.
Interestingly when the cells were also pre-treated with NAC ROS scavenger in media
containing 100% pyruvate (normal full media), there was no additional protection against cell
death. Therefore, indicating that CAP induced cytotoxicity in GBM cells is only partially
ROS dependent and that other signalling pathways may be playing an important role in cell
death.
It was concluded that for all further studies the experimental conditions for CAP treatment
would be as following unless otherwise stated; media would be removed prior to CAP
treatment and fresh media (with pyruvate) added immediately after treatment in order to
simulate similar conditions observed during surgery. All CAP treatments are carried out at
75kV with exposure time and post treatment time as the variables.
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Figure 3.3 CAP treatment in the presence and absence of pyruvate in cell culture media.
(A) U373MG cells were exposed to CAP for 180 seconds at 75kV both in the presence and
absence of cell culture media containing increasing concentrations of pyruvate. 48 hours
post treatment cell viability was analysed by Alamar blue analyses. All experiments were
repeated in triplicate with n=5 per experiment. Statistical analysis was carried out using
Two-Way ANOVA with Bonferroni comparison post-test comparing CAP treated and no CAP
treated samples (*P<0.001) (B) CAP treated U373MG cells with increasing concentrations
of pyruvate were compared to CAP treated U373MG cells in the presence of pyruvate and
4mM NAC. Statistical analysis was carried out on CAP treated samples with increasing
concentrations of pyruvate and NAC by means of One-way ANOVA with Bonferroni post-test
(*P<0.001).
--------------------------------------------------------------

3.3.3 GBM cells demonstrated increased resistance to CAP treatment
Previous studies have suggested that CAP has an antitumor effect in vitro in cell lines such as
cervical, colorectal, lung cancer and glioma (Ahn et al, 2011; Köritzer et al, 2013; Cheng et
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al, 2014; Ma et al, 2014; Siu et al, 2015). Despite the wide range of different CAP generating
devices being used worldwide, evidence is emerging that cell-type specific resistance can be
observed in tumour cells and GBM cells (and other brain-derived cells) appear to be
relatively resistant to CAP. We compared the sensitivity of U373MG GBM cells to a
commonly used human cervical carcinoma cell line (HeLa) (Ahn et al, 2011, 2014; Kim et al,
2014). Figure 3.4 depicts representative kinetic cytotoxicity results obtained when GBM cells
are exposed to CAP for 180 seconds at 75kV. Inhibition of normal metabolic processes in
GBM cells by CAP treatment was almost immediate, it was observed that only 4 hours post
CAP treatment there was a significant reduction in cell viability compared to untreated
controls, and after 24 hours almost 80% loss in cell viability was observed. Dose response
curves for both U373MG and HeLa were also established in a dose dependent manner by first
exposing cells to CAP for between 3 and 300 seconds at 75kV, as seen in (B). Cell viability
was quantified 48 hours post treatment. We confirmed findings by Ahn et al, 2014 that HeLa
cells are sensitive to CAP using our system, the IC50 value was determined to be 4.8 seconds
(95% confidence range of 4.2 - 5.6 seconds). As observed U373MG GBM cells, exhibited a
significant increase in resistance to CAP with an IC50 of 74.26 seconds (95% confidence
range of 47.24 - 116.8 seconds). A comparison of fit demonstrated a significant difference in
the IC50 values (P < 0.05) between both the U373MG and HeLa as a result of CAP treatment
and significant differences of the dataset were confirmed using a correlation analysis (see
appendix III). The cytotoxic response was confirmed using the trypan blue cell membrane
integrity assay and U373MG cells demonstrate a significantly (P<0.001) higher resistance to
the CAP treatment than that observed by the HeLa cells after 180sec treatment as
demonstrated in (C).
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We have previously demonstrated the increased resistance observed by U373MG GBM cells
following CAP treatment both the presence and absence of antioxidant pyruvate and also
with extended exposures to CAP (5 minutes). This correlates with the current literature on the
increase resistance observed in GBM tumour that they resist most treatment modalities and
have high reoccurrence rates. If used in a clinical setting, CAP or any variant of this
technological therapy would most likely be used multiple times and in combination with
existing chemotherapeutic regimens. We hypothesised that multiple treatments and/or
combinational therapy with existing chemotherapeutic agents, would be sufficient to
overcome the relative resistance of U373MG cells to CAP, for example TMZ combined with
low doses of CAP (which is demonstrated later in this chapter). As demonstrated in (D),
triplicate CAP exposures of 75kV for 180 seconds results in a significant reduction in
U373MG cell viability compared to a single treatment (5.669 - 43.16 %, P < 0.05).
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Figure 3.4 CAP induces a dose dependent cytotoxic effect in both U373MG cells and
HeLa cells
(A) U373MG cells were exposed to CAP at 75kV for 180seconds and analysed by Alamar
blue cell viability assay at 1, 4, 8, 21.5, 33.5, 45.5 hours post CAP treatment. All experiments
were repeated a minimum of three times. Each time point was normalised to an untreated
control that was left under the same conditions as the CAP treated plate. (B) Cells were
exposed to CAP at 75kV for up to 5 minutes. 48 hours later the cells were analysed using the
Alamar Blue cell viability assay. (C) Both U373MG cells and HeLa cells were exposed to
CAP at 75kV for up to 180 seconds. HeLa cells were trypsinised and counted using a
haemocytometer 48 hours post treatment. U373MG cells were analysed 96 hours post
treatment. (D) The effects of multiple CAP exposures were determined in both HeLa and
U373MG. Cells were exposed 3 times within a 10 hr. period with a minimum 4 hours between
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treatments. 48 hours later cells were then analysed using the Alamar blue assay. Results are
shown as the mean ± S.E.M. (n= minimum 24). Statistical analysis was carried out using
One-Way ANOVA with Tukey’s multiple comparison post-test, (*P <0.05 against untreated
control).

--------------------------------------------------------------

3.3.4 Loss in Mitochondrial membrane potential following CAP treatment.

Mitochondrial membrane potential (ΔΨm) is an important indicator of mitochondrial function
and can also be an indicator of early intrinsic apoptosis. A distinctive feature of the early
stages of programmed cell death is the disruption of active mitochondria. This mitochondrial
disruption includes changes in the membrane potential and alterations to the oxidationreduction potential of the mitochondria. Collapse of the ΔΨm results in the release of
cytochrome C into the cytosol and thus leading to cell death (Salido et al, 2007). In healthy
cells with high ΔΨm, JC-1 forms aggregates with intense red fluorescence. However, when
the ΔΨm has been disrupted the JC-1 remains in its monomeric form and fluoresces green.
Figure 3.5 (A) demonstrates the loss in Mitochondrial Membrane Potential (ΔΨm) due to
NTAP treatment. Both cell lines show a significant (P < 0.05) loss in mitochondrial function
indicating a reduction in cell viability after CAP treatment when compared to untreated
controls (B). This result correlates with both the Alamar blue and trypan blue results
indicating that NTAP induces differential cytotoxicity in HeLa and U373MG cells.
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Figure 3.5 CAP induces mitochondrial membrane depolarisation in HeLa and U373MG
cells.
Both cell lines were exposed to CAP at 75kV for 3mins. (A) After a 48hr incubation period
cells were loaded with 1µg/ml JC-1 dye and analysed by flow cytometry. (B) Data shown
depicts apoptosis measured by quantitative shifts in the ΔΨm (red to green) fluorescence
intensity ratio before and after H2O2 (1Mm – U373MG, 200µM- HeLa) and CAP expsoure
(60 sec). All experiments were repeated triplicate. Statistical analysis was carried out using
One-Way ANOVA with Tukey’s multiple comparison post-test. (*P <0.05).
--------------------------------------------------------------
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3.3.5 CAP induces mitchondrial ROS formation in cancer cells in situ
Recent literature using HeLa and GBM cell lines has stated that CAP generated ROS causes
DNA damage resulting in apoptosis (Vandamme et al, 2012; Cheng et al, 2014). It is also
well known that mitcohondrial depolarisation can be a result of oxidative stress produced by
ROS (Ahn et al, 2011). In order to determine that the cytotoxicity observed was from ROS
generated by CAP, both cell lines were preloaded with the cell permeable ROS-sensitive
fluorescence dye, H2DCFDA. ROS generation was first visualised using confocal microscopy
and we confirmed that CAP induced ROS-dependent H2DCFDA fluorescence in both cell
lines. The level of fluorescence in U373MG cells appeared to be lower than that oberseved in
HeLa cells (figure 3.6 (A)) and this was then confirmed using both spectrophotometry and
flow cytometry. As seen in figure 3.6 B, significantly higher levels of ROS fluorescence were
observed following CAP treatment in HeLa cells (P < 0.05), compared to untreated controls
and to CAP treated U373MG cells (p<0.05).
A similar result was also obsereved by flow cytometry as demonstrated in (C) CAP treatment
demonstrated a significant increase in ROS generation (P<0.001) compared to the untreated
control in HeLa cells. A slight dextral shift was observed in U373MG cells but the measured
mean fluorescence index was not signicantly altered. Following the identification of ROS
formation by H2DCFDA, cells were treated with mitochondrial superoxide indicator,
MitoSOX red. Mitochondrial ROS production as a result of CAP treatment has been
previuously demonstrated in HeLa cell by (Ahn et al, 2014). Figure 3.6 (D) demonstrates the
increase in intracellular fluorescence of mitochondrial ROS formation by confocal micrscopy
in both HeLa and U373MG cells compared to the untreated control. The level of fluorescence
was quantified using ImageJ (v1.49, NIH) software in both treated and untreated cells
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(McCloy et al, 2014). There is a significant increase in mitochondrial ROS after CAP
treamtent observed in both U373MG (P<0.05) and HeLa cells (P<0.001) compared to the
untreated controls.
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Figure 3.6 In situ verification of ROS production in both U373MG cells and HeLa cells
following CAP treatment.
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(A) In situ verification of ROS produciton in both U373MG cells and HeLa cells was
measured 1 hr after CAP exposure (75kV for 180sec) by confocal microscopy using 10µM
H2DCFDA. (B) ROS fluorescence intensity was quantified spectrophotometricaly, 1hr after
CAP expsoure (75kV for 180sec). All experiments were repeated in triplicate. Statistical
analysis was carried out using One-Way ANOVA with Tukeys multiple comparison post test
(*P<0.05). (C) ROS production in both U373MG and HeLa was also measured by flow
cytometry using 0.1µM H2DCFDA. Fluorescence was quantified using the mean H2DCFDA
fluroescence and compared to the untreated control (P<0.001). (D) In situ verification of
mitochondiral ROS production in both U373MG cells and HeLa cells was measured 1 hr
after CAP exposure (75kV for 180sec) by confocal microscopy using 2µM MitoSOX red. The
level of fluorescence was quantified using image J software and compared to the untreated
control. Statisical analysis was carried out using t-test with Mann Whitney test post test with
(P<0.05) U373MG and (P<0.001) HeLa cells.
--------------------------------------------------------------
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3.3.6 GBM cells demonstrate higher anti-oxidant activity against H2O2
The production of a variety of ROS by CAP, including H2O2 has been shown previously to
induce cytotoxicity (Ahn et al, 2014; Hirst et al, 2015; Xu et al, 2015). These free radicals,
particularly the CAP-generated NO species, are believed to result in an increase in
intracellular ROS, which in turn signals a cascade of events leading to apoptosis (Ishaq et al,
2014a). As observed from the optical emmision spectroscopy (OES) data, figure 3.7 (A), we
have identifed the presence of OH. in our OES mesurements, OH. is generated as a results of
O2- and H2O2 interactions in the plasma field, which as a result induces cell death (Xu et al,
2015). To investigate GBM cells response to specific extracellular reactive oxygen species,
we treated U373MG cells with increasing concentrations of H2O2. Interestingly simialrly to
that observed with CAP treatment, U373MG demonstrated increased resistance to H2O2
compared to HeLa cells. We hypothesised that the increased resistance displayed by
U373MG cells to CAP could be replicated using H2O2 as an oxidative stressor. (B)
Demonstrates that U373MG cells indeed have an increased tolerance for H2O2 compared to
that of HeLa cells. The IC50 value for H2O2 cytotoxicity is significantly higher (p<0.0001) for
U373MG cells (544.8 µM) compared to HeLa cells (27.91 µM) and significant differences of
the dataset were confirmed using a correlation analysis (see appendix IV). The generation of
H2O2 was significantly lower in U373MG cells (EC50 458.1µM) compared with HeLa cells
(EC50 55.36µM) (C) and significant differences of the dataset were confirmed using a
correlation analysis (see appendix IV). The presence of intracellular and mitochondrial ROS
was confirmed using MitoSOX red and H2DCFDA for both cell lines using confocal
microscopy as demosntrated below in figure 3.7 (D).
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Figure 3.7 GBM cells demonstrate a higher anti-oxidant activity against H2O2.
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(A) Using optical emission spectroscopy, chemical species produced by the CAP DBD system
were identified. OES measurements were taken between the range of 200-850nm (Exemplar
LS). This spectrum demonstrates distinct atomic lines at the wavelengths 280-400nm in the
ultraviolet region, these denote strong emissions from various nitrogen ions. Species within
the wavelength 300-390 nm are part of the N2 second positive system. Associated nitrogen
molecules from the nitrogen second positive system and ionised nitrogen molecules found
within the range 390-480 nm are part of the N2+ first negative system. (B) Both U373MG
cells and HeLa cells were treated with increasing concentrations of H2O2 (0-2mM). After 48
hours cell were analysed using the Alamar Blue assay. Statistical analysis was carried out
using non linear regression analyses. (C) Both U373MG cells and HeLa cells were preloaded
for 1hr with 10µM H2DCFDA. H2DCFDA was removed and a dose-response analysis was
performed using H2O2. The relative increase in fluroescence was determined one hour after
addition of H2O2. Statistical analyses was carried our using nonlinear regression analyses.
(D) Shows In-situ verification of ROS production in both U373MG cells and HeLa cells
which was measured 1 hr after the addition of H2O2 by confocal microscopy using both
10µM H2DCFDA and 2µM MitoSOX red. All experiments were repeated minimum in
triplicate.
------------------------------------------------------------
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3.3.7

CAP can induces ROS, JNK and Caspase independent cell death in
U373MG cells

Previously it has been reported that CAP induces ROS, JNK and caspase activation in
cancer cells (Vandamme et al, 2011; Hou et al, 2015; Siu et al, 2015). To confirm the
role of intracellular ROS in CAP and H2O2 induced apoptosis, HeLa (A) and U373MG
cells (B) were loaded with the well-known thiol antioxidant NAC for 48 hours after
CAP treatment (figure 3.8). As expected, the addition of NAC to H2O2 treated HeLa (A)
cells and U373MG cells (B) improved cell viability (p<0.05) indicating that NAC was
protecting against ROS induced cell death in both cell lines. While NAC improved cell
viability in HeLa cells following treatment of both cells and media with CAP (P < 0.05),
there was no protective effect noted for U373MG cells treated with CAP. Therefore, the
data strongly suggests that unlike HeLa cells, U373MG cells undergo ROS independent
cell death in response to CAP. To further elucidate the molecular mechanism underlying
U373MG cell death following CAP treatment, the protective effect of increasing
concentrations of the caspase inhibitor, zVAD-fmk and the JNK inhibitor, SP600125
were determined. No significant difference in cell viability was observed with
increasing concentrations of either zVAD-fmk (C) or SP600125 (D). Together, our
results indicate that CAP induces apoptosis by a ROS-, JNK- and caspase-independent
manner in GBM cells.
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Figure 3.8 CAP induces ROS, JNK and caspase independant cytotoxicity in GBM
cells.
Both HeLa (A) and U373MG (B) cells were preloaded for 1hr with 4mM NAC. Cells
were then treated with H2O2 or exposed to NTAP. After 48 hours, cells were analysed
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using the Alamar blue assay. Data shown was normalised to the untreated control and
are shown as the % mean ± S.E.M. (n= minimum 20). All experiments were repeated at
least three times. Statistical analysis was carried out using One-Way ANOVA with
Tukeys multiple comparison post test. (*P<0.05). (C) Following CAP treamtent cells
were loaded with increasing concentrations of SP600125 (0-50μM) inhibitior and
incubated for 48 hrs. Black bars represent increassing concentraitons of inhibitor alone
with no CAP treamtent. Dark and light grey bar represents the combination of inihibtor
and CAP treatment. The first three bars depict CAP treatment only with no 0µM
inhibitor. Cells were then analylsed using Alamar blue cell viability assay. (D)
U373MG cells were pretreated with increasing concetrations of zVAD-fmk for 1 hr
prior to CAP treatment. Cells were then incubated for 48 hrs and analysed by Alamar
blue. Black bars represent increassing concentraitons of inhibitor alone with no CAP
treamtent. Dark and light grey bar represents the combination of inihibtor and CAP
treatment. The first three bars depict CAP treatment only with no 0µM inhibitor. Data
shown was normalised to the untreated control and are shown as the % mean ± S.E.M.
(n= minimum 20). All experiments were repeated at least three times.
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3.3.8

A low dose of CAP demonstrates an additive capacity when combined with
therapeutic compounds overcoming the relative resistance of U373MG cells.

If used in a clinical setting, CAP or any variant of this technological therapy would
most likely be used multiple times and in combination with existing chemotherapeutic
regimens.

We

hypothesised

that

a

combinational

therapy

with

existing

chemotherapeutic agents or novel compounds, would be sufficient to overcome the
relative resistance to CAP. We also employed the use of an additional medicinal
compound, clozapine, in this study. Clozapine is an antipsychotic drug that has been
previously shown to cause increased oxidative stress in cells and tissues and also has
been associated with increased production of ROS and antioxidants (Polydoro et al,
2004; Pillai et al, 2007; Miljevic et al, 2010) Therefore our rationale for employing
clozapine was as a possible prodrug that could be activated by ROS generated from
CAP and enhance the overall cytotoxic effect with low doses of CAP (see appendix VI
for optimisation of clozapine). As seen in figure 3.9 (A), low doses (10 µM) of TMZ
greatly augmented the cytotoxicity observed due to CAP with toxicity levels
approaching 80-100%. Two-way ANOVA confirmed that there is variance in the data
due to the combination of TMZ and CAP which cannot be explained by TMZ and CAP
alone. This indicates the presence of an additive effect as observed on the graph (A) at
30sec CAP and 10μM TMZ with P<0.0001. As observed for clozapine (B), no
synergistic or additive effect was observed between low doses of the medicinal
compound and CAP. Interestingly the most dramatic effect was observed with cisplatin
(C) at 60 sec CAP, with an additive effect observed amongst all concentrations
examined, with an average 30% further reduction in cell viability following the
combination of these two methods (P<0.05). There was no additive or synergy observed
between UA and CAP (D).
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Figure 3.9 Additive effect observed between TMZ and CAP.
Following CAP treatment cells were treated with low concentrations of either (A) TMZ,
(B) clozapine, (C) cisplatin or (D) UA. Cells treated with TMZ were incubated for 6
days’ post and analysed by Alamar blue assay all other compounds were analysed after
48 hours. Data shown was normalised to the untreated control and are shown as the %
mean ± S.E.M. Statistical analysis was carried out using both One-Way ANOVA
(*P<0.05) and Two-Way ANOVA with Bonferroni post test. (*P<0.001). All experiments
were repeated at least three times.
-----------------------------------------------------------
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3.3.9

Chemotherapeutic compounds generally highly resistant to degradation by
CAP.

A risk when employing new technology as a potential combinational treatment with
other therapeutic compounds is that despite evidence of additive effects with some
compounds, that the chemical transformation of chemotherapeutic agents by CAP will
reduce its cytotoxicity. Therefore, using stock concentrations of TMZ (50mM, DMSO),
clozapine (50mM, DMSO), UA (40mM, DMSO), Cisplatin (2mM, PBS), the
compounds were exposed CAP at 75kV for 15 minutes, in advance of adding to GBM
cells. As demonstrated in figure 3.10 (A) below there is no significant difference
between TMZ that has been directly treated with CAP and untreated drug. Using nonlinear regression analyses there was also no significant difference demonstrated in the
IC50 value of the compound post treatment. This demonstrates the stability of the
compound if were to be used in a combinational therapeutic approach. However more
interestingly an inhibitory effect was observed with Clozapine. It is evident from figure
3.10 B, there is a difference between clozapine that has been exposed to CAP for an
extended period of time compared to that which was not exposed to CAP there was a
change in the IC50 value of clozapine from 62µM to 73µM following CAP exposure,
although this was calculated to not be significant using nonlinear regression. However,
Two-way ANOVA confirmed that there is variance (P<0.001) in the data due to the
combination of untreated clozapine and CAP treated clozapine. A significance
difference was observed at several concentrations of clozapine as demonstrated below
(B) (*P<0.005 - P<0.001). Our data suggests that there is a chemical interaction
between CAP and clozapine, as there is a reduction in the cytotoxicity of the drug when
directly exposed to the CAP. There was no difference observed in the IC50 values
between CAP treated cisplatin and cisplatin alone (C), although there was a significance
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observed at a concentration of 31.5µM (*P<0.05), which was above the calculated IC50
of cisplatin (12µM). Similarly, with UA (D) there was little difference observed
between the two treatment conditions. At 15.5µM, significance was observed following
direct treatment of the compound (*P<0.001). As there was no significant difference
between the IC50 values for UA and cisplatin following direct treatment, in combination
with only one significant value being observed using Two-way ANOVA it is postulated
that these values may be anomalies in the data, which could be explained by the
combination of triplicate experiment, intra experiment variation.
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Figure 3.10 Long term exposure to CAP does not reduce the cytotoxicity of
compounds.
Stock concentration of compounds (A) TMZ and (B) clozapine (C) cisplatin and (D) UA
were exposed directly to CAP at 75kV for 15 minutes. Compounds were then diluted
down in full media and added to the cells. Cells treated with TMZ were incubated for 6
days’ post and analysed by Alamar blue assay clozapine, cisplatin and UA were
analysed after 48 hours. Data shown was normalised to the untreated control and are
shown as the % mean ± S.E.M. Statistical analysis was carried out using both Two-Way
ANOVA, with Bonferroni post-test (*P<0.05- P<0.001) All experiments were repeated
at least three times.
-----------------------------------------------------------
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3.4

Discussion

GBM’s are very aggressive and are resistant to most chemotherapies and radiation
therapy (Curtin et al, 2005). Therefore, it is necessary to develop a novel therapy that
can induce cell death in GBM cancer cells. For this report, the effect of CAP was
investigated on two in vitro cells lines; HeLa cervical carcinoma cells, which are a well
characterised CAP model (Ahn et al, 2011; Panngom et al, 2013; Ma et al, 2014) and
the U373MG GBM cells which have yet to be characterised using CAP-DBD. The
evolving technology industry has led to the possibility of replacing or complementing
existing chemotherapies using technology based approaches. In this regard, there has
been great development in the area of plasma medicine over the past decade, with a
huge focus on the area of non-thermal atmospheric plasma as a potential therapy for the
treatment of cancer. Advances in wearable medical devices have led to the possibility of
replacing or complementing existing chemotherapies using a technology-based
approach. In accordance with previous studies, the anti-proliferative effect of CAP
treatment was confirmed in vitro (Ahn et al, 2011; Vandamme et al, 2012) in both cells
lines. Our data demonstrated a significant difference in the survival of U373MG when
treated in both the presence and absence of media. Following the removal of media
there is a small film of media that covers the cells; this prevents the cells from
completely drying out during the course of the treatment and having a harmful effect on
the cell viability. Upon further research, it was determined that the antioxidant pyruvate
was present in the U373MG cell culture media. Pyruvate is a well characterised ROS
scavenger, which we have shown to play a significant role in the survival of U373MG
cells following CAP treatment. Similar findings were also observed by others who
employed the use of similar media formulations i.e. media that included pyruvate.
(Adachi et al, 2015; Boehm et al, 2016). Even with the addition of pyruvate to the
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media, our data still showed a significant 50 percent reduction in cell viability following
CAP treatment over a 48-hour period, it was then noted that this cytotoxic insult could
be further enhanced following multiple treatments, resulting in an overall reduction in
cell viability of 68%, therefore overcoming the relative resistance of U373MG cells.
When looking from a clinical aspect, it would be envisaged that first application of CAP
could be applied following surgical resection and therefore to mimic these conditions
i.e. a moist environment where scavengers are plentiful, it was decided that treatment of
CAP for U373MG cells would be in the absence of media with media (with pyruvate)
added immediately after treatment.
The resistance to H2O2 induced apoptosis has been reported previously in GBM cells
(Datta et al, 2002a), but to the best of our knowledge, ROS-independent CAP
cytotoxicity has yet to be reported and characterised. We demonstrate here that
U373MG GBM cells display a significant resistance to cytotoxicity and ROS generation
(P<0.0001) when compared with a commonly studied CAP-sensitive cancer cell line
HeLa. It has been documented that reactive oxygen species generated by CAP treatment
can induce apoptosis in glioma cells as well as many other cancer cells (Vandamme et
al, 2012; Ahn et al, 2014; Siu et al, 2015). Our OES measurements confirmed notably
larger emissions for nitrogen species and very little emissions at the atomic oxygen
region of 777 nm and 845 nm, in agreement with those reported by others using
unmodified atmosphere, it is as a result of quenching with N2 and O2 (Walsh et al, 2010;
Misra et al, 2014). The presence of atomic oxygen is not required for the generation of
ROS. CAP generated NO results in intensification of intracellular NO concentration that
initiates a cascade of events, subsequently increases intracellular ROS (Vandamme et
al, 2012; Ishaq et al, 2014a).
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The current standard of care for the treatment of glioma involves repeated exposure to
chemotherapy/radiation over a period of weeks/months in order to ensure eradication of
the entire tumour. A similar effect was demonstrated with multiple exposures to CAP, a
triple exposure over a 10 hr period greatly enhanced cytotoxicity of the U373MG cells,
indicating that CAP can be both effective and cumulative against GBM. In the current
clinical setting, radiation therapy is used in combination with surgery and chemotherapy
to treat GBM. CAP is also based on the formation of intracellular chemically active
species. As the technology develops, the primary advantage of CAP over radiotherapy
is be the ability to generate these species in situ, at the site of the tumour and reduce the
resulting systemic side effects (Ishaq et al, 2014a). Moreover, the species generated by
CAP are short lived in comparison to the relatively long lived radioactive isotopes
introduced during radiation therapy (Stoffels et al, 2008). We were able to confirm the
generation of ROS by CAP treatment in HeLa cells as previously reported by (Ahn et
al, 2011). ROS generation was also observed in CAP treated U373MG cells (figure 2)
but, interestingly, at a significant lower level compared with CAP treated HeLa cells.
These results echoed H2O2 induced ROS levels, indicating that U373MG cells have a 5
to 10-fold greater capacity to neutralise ROS compared with HeLa cells.
ROS, JNK and caspase activation have all been reported in cancer cells following CAP
treatment (Vandamme et al, 2011; Hou et al, 2015; Siu et al, 2015). We hypothesised
that by activating multiple cell death pathways together, specific inhibition of these
pathways would not be preventative of cell death after longer treatments of CAP in
U373MG cells. To test this hypothesis, we titrated common inhibitors of ROS, JNK
and caspases. In line with previous findings (Köritzer et al, 2013), we found that
caspase inhibitors do not protect against the effects of CAP treatment. Furthermore, we
were unable to protect against cell death using ROS scavengers or JNK inhibitors in
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GBM cells. It has been hypothesised that CAP offers great potential as a possible
therapy for the treatment of GBM due to the wide variety of biological processes
affected and our own data is supporting this hypothesis. Our data suggests that several
pathways have been activated simultaneously by the CAP treatment for example
autophagy and blocking individual pathways is insufficient to inhibit cell death. To the
best of our knowledge, this is the first evidence of a cell line where CAP treatment can
induce cell death even in the presence of JNK, caspases and ROS inhibitors Our data
has suggested a caspase independent mechanism based on the use of general caspase
inhibitor Z-VAD. However, as stated previously, it has been recently noted by the
NCCD that ‘a growing body of evidence indicates that the pharmacologic or genetic
inhibition of the processes that are commonly considered as essential for cell death
execution often does not avoid the demise of mammalian cells, but rather alters its
kinetics and biochemical (and morphologic) manifestations.’ and therefore inhibitors
such as Z-VAD administered as therapeutic interventions fail to significantly limit
primary regulated cell death, in spite of the fact that they efficiently limit caspase
activation (Galluzzi et al, 2015). Therefore, based on our data alone without the use of
genetic knock down models or demonstration of caspase activation we cannot rule an
apoptotic mechanism of cell death. In contrast to the results observed for HeLa cells,
cytotoxicity in U373MG cells following CAP treatment is not alleviated by the presence
of NAC. NAC does protect against high concentrations (2mM) of H2O2 in U373MG
cells. Therefore, CAP is primarily inducing cell death through a H2O2 and ROSindependent mechanism in U373MG cells.
As observed our data demonstrates significant mitochondrial membrane depolarisation
as a result of cap treatment in both HeLa cells and U373MG cells, also in addition we
demonstrated an increase in mitochondrial ROS following CAP treatment, both of
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which are classic modifications observed during intrinsic apoptosis. During the early
stages of apoptosis, mitochondrial ROS production is stimulated, this results in the
release of cytochrome c from the mitochondria, this activates the executioner caspases 9
which activates caspase 3, resulting in the cells demise. As we have demonstrated
significant depolarisation of the mitochondria, another step to investigate apoptosis
would be to test for cytochrome c translocation from mitochondria into cytosol to
further identify apoptosis.
However, we demonstrate that NAC, a ROS inhibitor was unable to alleviate the
cytotoxicity induced by CAP, therefore one must also consider the process of
mitophagy. Mitophagy is a form of macroautophagy that selectively degrades damaged
mitochondria. Double-membraned autophagosomes enclose whole mitochondria, or
selectively target the damaged areas. Mitophagy is considered a homeostatic program
that maintains a healthy mitochondrial population and plays largely cytoprotective roles
in the context of disease pathogenesis (Ding & Yin, 2012), in contrast to this is has also
been postulated that mitophagy could act as an effector of cell death programs. For
example a recent study has demonstrated ceramide induced cell death required
mitophagy, involving LC3-ceramide interactions at the mitochondria (Sentelle et al,
2012). One way to determine if mitophagy is playing a role is to analysis mitochondrial
function via PTEN-induced putative kinase 1 (PINK1), which is involved with
mitochondrial quality control by identifying damaged mitochondria and targeting
specific mitochondria for degradation. PINK1 activity causes the parkin protein to bind
to depolarized mitochondria to induce mitophagy (Ding & Yin, 2012). As we observed
significant depolarisation of the mitochondria following CAP treatment, it could be that
the ROS damage that has been induced by CAP is so significant that inhibitors such as
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NAC would be unable to protect against cell death and therefore, mitophagy offers a
plausible mechanism of action.
We observed that U373MG cells were relatively resistant to CAP treatment, and so we
investigated methods to overcome this. We found that both multiple exposures to CAP,
and use of low concentrations of TMZ were sufficient to overcome the relative
resistance of U373MG cells to CAP. Both these approaches let to an improved
cytotoxicity of between 80% and 95%. Harsh side effects are associated with existing
standard of care for patients diagnosed with GBM and despite this; very limited gains in
long-term survival are evident. Therefore, lower doses of TMZ when used in
combination with CAP may lead to a more effective treatment whilst reducing the
harmful side effects. We have also demonstrated that longer direct treatment of different
therapeutic compounds with CAP (i.e. 15 minutes) can demonstrate only a marginal
inhibitory effect on the cytotoxicity of the compound. We believe that this is a very
important finding, especially since CAP is likely to be used in the clinic in combination
with existing chemotherapeutic agents. Further analysis of the interactions between
CAP and compounds will need to be carried out, using techniques such as LC-MS and
NMR, to determine the major chemical changes and rate of degradation of the
compound structure following direct exposure.
In conclusion, this chapter demonstrates that CAP induces a significant cytotoxic insult
that induces cell death in both U373MG GBM cells and HeLa cervical cancer cells.
U373MG cells demonstrate increased resistance to CAP when compared to HeLa cells,
which can be overcome when applied with cumulative exposures to CAP. We can
conclude that CAP induces a ROS, JNK and Caspase independent mechanism of cell
death in the U373MG GBM cells, where as we have shown HeLa cells die by ROS
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dependant mechanism. However, based on this data alone we cannot rule out any
specific pathway based on the use of inhibitors studies alone. We have demonstrated
that inhibition of caspase activity does not alleviate cell death, it could be that Z-VAD
does not have the capacity to inhibit all of the apoptotic caspases, also in contrast to this
its widely accepted that caspases are commonly dysregulated in cancer cells, resulting
in reduced caspase function (Devarajan et al, 2002; Fong et al, 2006; Shen et al, 2010),
However in order to rule out apoptosis as a mechanism of cell death further studies are
required, such as investigation of caspase cleavage and activation, cytochrome c release
as recommended by the NCCD. It is evident that the way in which cells respond to CAP
is cell specific and therefore the molecular mechanisms surrounding cell death
following CAP treatment need to be evaluated for each cell type being treated. This
study highlights the potential of in situ CAP generation as a future brain cancer therapy.
Further refinement of the technology will be necessary and the generation of microscale plasma fields promises to facilitate localised activation of cytotoxicity against
GBM cells when used in combination with new and existing chemotherapeutic
regimens.
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4

CAP results in activation of autophagy preceding cell

death in resistant glioblastoma cells

Part of this chapter has been submitted for publication and is currently under review.
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4.1

Abstract

Non thermal atmospheric plasma (CAP) has shown promising efficacy for the treatment
of cancer but the exact mechanisms of action remain unclear. Both apoptosis and
necrosis have been implicated as the mode of cell death in various cancer cells. We
have previously demonstrated a caspase-independent mechanism of cell death in p53mutated glioblastoma multiforme (GBM) cells. The purpose of this study was to
elucidate the molecular mechanisms involved in caspase-independent cell death induced
by CAP treatment. We confirmed that CAP induces rapid cell death in GBM cells,
independent of caspases. While depolarised mitochondria and permeable plasma
membranes were observed, We hypothesise the involvement of multiple signalling
pathways as a results of CAP treatment. We have identified a non-classical mechanism
of apoptotic cell death on the basis of morphological assessment and the use of
pharmacological inhibitors of apoptosis. We speculate that autophagy is being activated
as a pro survival strategy that precedes cell death, as we have demonstrated the rapid
formation of Acidic vesicle organelles (AVO’s) in response to CAP treatment.
Inhibition of Phosphoinositide 3-kinase (PI3K) class III protected against cell death in
CAP treated GBM cells, which further endorses out hypothesis that autophagy is
activated following CAP treatment. We determined that the resistance of U373MG
GBM cells to the mTOR inhibitor rapamycin could be overcome using low doses of
CAP in combination with rapamycin. In conclusion, we report here for the first time
that CAP induces autophagy in cancer cells prior to cell death and overcomes
rapamycin resistance in GBM cells.
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4.2

Introduction

Autophagy is a highly regulated process that all eukaryotic cells can carry out by
sequestering damaged or defective organelles within a double membrane bound vesicle
called an autophagosome, which then fuses with a lysosome to form an autolysosome
and in turn degrades or recycles the aggregated material and organelles(Kondo et al,
2005; Levine & Kroemer, 2008). Autophagy has been shown to exhibit a dual function
in the regulation of both cell survival and cell death. When under stressful conditions
such as nutrient deprivation a cell will promote autophagy by removing degraded
organelles and proteins before they have a negative impact on the cell and therefore
sustaining cellular integrity, and maintaining cellular homeostasis (Levine & Kroemer,
2008; Mizushima et al, 2008). Depending on the stimulus and surrounding
environment, autophagy has been shown to

promote cell death and it has been

identified in a small number of cases that defective autophagy contributes to cellular
pathology (Denton et al, 2012). Autophagy has been classified as class ІІ programmed
cell death (PCD) an alternative to the conventional type І programmed cell death
‘apoptosis’ (Bursch et al, 2000). However, as stated previously there is an increasing
body of evidence of a complex crosstalk between the apoptotic and autophagic
machinery, where autophagy is required for PCD to occur but is not necessarily
responsible for the cells demise. It could be that autophagy degrades cellular
components that then results in activation of the apoptosis machinery but this doesn’t
mean autophagy is directly responsible for cell death; the effect could be secondary
(Gump & Thorburn, 2011).
Apoptosis as described by Kerr et al is characterised morphologically by the following
attributes: condensation of both nucleus and cytoplasm, nuclear fragmentation, and
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separation of protrusions that form on the cell surface (Kerr et al, 1972). Molecular
mechanisms have since been extensively studied both in vivo and in vitro and it is now
accepted that caspases play a central role in both the intrinsic and extrinsic apoptotic
pathway, but it is also noted that caspase independent apoptosis (CICD) has also been
demonstrated, and can manifest with morphological signs of apoptosis, autophagy or
necrosis (Kroemer et al, 2005, 2009; Galluzzi et al, 2012). Intrinsic apoptosis is
characterised by permeabilisation of the mitochondria outer membrane and release of
cytochrome c into the cytoplasm which initiates activation of a caspase cascade though
caspase 9 and 3, whereas the extrinsic pathway involves, binding of ligands (FasL/
TNFα) to cell surface death receptors which leads to activation of caspase 8 and 3,
which through the activation of BID also involves mitochondrial outer membrane
permeabilisation (MOMP) (Galluzzi et al, 2015). There are significant morphological
and molecular differences between PCD І (apoptosis) and PCD ІІ (autophagy), with
autophagy having been associated with caspase independent cell death (Kroemer &
Martin, 2005b; Rieckher & Tavernarakis, 2010), along with other morphological
features for example the presence of double membrane autophagosomes, or ‘vesicular
redistribution of LC3 which have been reviewed previously (Kroemer et al, 2005,
2009). GBM a grade IV malignant astrocytomas, are commonly associated with PTEN
mutations, amplification of Receptor Tyrosine Kinases and hyper-activation of
Phosphoinositide 3-kinase PI3K (Hartmann et al; Akhavan et al, 2010), all of which are
involved in the regulation of the autophagic pathway.
Recent studies have suggested that treatment of GBM induces an autophagy prior to cell
death. More specifically it has been demonstrated that the current gold standard
chemotherapeutic for the treatment of GBM, TMZ, induces autophagy (Galluzzi et al,
2012), and not apoptosis as demonstrated by LC3 accumulation on the membranes of
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autophagosomes (Kanzawa et al, 2004b). Although activation of autophagy through
acute stimulus of TMZ can act in a cytoprotective manner, leading to transient
activation of autophagy and therefore contributing to TMZ resistant (Filippi-Chiela et
al, 2015). On the other hand it has also been demonstrated that inhibition of TMZ
induced autophagy by blocking end stage autophagosome and lysosome fusion,
enhances apoptotic cell death therefore enhancing a therapeutic outcome of TMZ
(Koukourakis et al, 2016a), similar findings has been observed and have been recently
reviewed by Yan et all (Yan et al, 2016). Through a number of genetic mutations that
inactivate pathways, GBM’s are considered resistant to apoptosis (Lefranc & Kiss,
2006). Inhibiting targets that keep autophagy downregulated or silenced such as mTOR,
could subsequently enhance TMZ induced autophagy. Similarly, it has been
demonstrated that radiotherapy also induces autophagy and not apoptosis in GBM (Ito
et al, 2005a; Lomonaco et al, 2009), mechanisms of which have been recently reviewed
by (Koukourakis et al, 2016a).
GBM’s are generally treated using a combination of physical, chemical and biological
treatments. Surgical interventions and radiation therapy in combination with either
pharmaceuticals or biopharmaceuticals have been the mainstay of cancer treatment for
decades (Fine, 2005; Stupp et al, 2005b; Begg et al, 2011). While successful in
improving patient prognosis in some cancers, many others such as GBM remain
refractory to treatment. In recent years, advances in materials and technologies have led
to the possibility of physical interventions for the treatment of cancer either alone (drug
free) or in combination with existing therapeutic modalities (Keidar et al, 2013; Thakor
& Gambhir, 2013).
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This emerging scientific field, plasma medicine, aims to use physical plasmas for
therapeutic applications and has been subject to intensive study over the last decade. Of
particular interest is the capability of cold atmospheric plasma (CAP) to induce cell
death preferentially in tumour cells, although the precise mechanisms by which cell
death is induced remain to be determined. CAP is also known as cold plasma and nonthermal atmospheric plasma. There have been a number of cell death mechanisms
reported such as cell cycle arrest (Köritzer et al, 2013; Siu et al, 2015), apoptosis
(Keidar et al, 2011; Ishaq et al, 2014b), necrosis (Hirst et al, 2015) in various cancer
models. An extensive review carried out on the therapeutic potential of autophagy in
brain cancer noted a number of studies investigating both novel and existing compounds
that activate autophagy in brain cancer models, for example, arsenic trioxide, EMC6
(endoplasmic reticulum membrane protein complex subunit 6), and cannabinoids
(Salazar et al, 2009; Kaza et al, 2012). Both novel and established approaches such as
those listed above promote an autophagic response in brain cancer and demonstrate the
potential to improve combinational therapeutic strategies.
Apoptosis has been the most studied mechanism of cell death, and is the more
conventional method of cancer cell death in response to treatment. Therefore, it is
logical that it be the first point of investigation when analysing a mechanism of cell
death. Following a thorough review of literature, previous studies using CAP in GBM
cells and studies carried out by others using different methods of treatment such a UA,
TMZ and radiation in resistant GBM cells it is apparent that autophagy appears to play a
significant role prior to cell death. This most likely relates to the genetic alterations that
are most commonly observed in GBM such as P53 mutations, PTEN deletions and
EGFR amplification. We have previously shown that CAP can induce cell death
independent of ROS, JNK and Caspases in P53 mutated GBM cells (Conway et al,
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2016). The aim of this study is to investigate whether CAP induces an autophagic
response in apoptosis resistant GBM cells. In addition to this investigate whether a
combination of CAP with mTOR inhibitors can provoke a synergistic effect in the
rapamycin resistant GBM cells.

4.3

Materials & Methods

4.3.1

Cell culture

Human glioblastoma (U373MG-CD14) cells were obtained from Dr Michael Carty
(Trinity College Dublin). U373MG cells, were cultured in DMEM high glucose (SigmaAldrich, Arklow, Ireland) supplemented with 10% FBS (Sigma-Aldrich, Arklow,
Ireland) which were maintained in a humidified incubator containing 5% CO2 at 37°C.
Media was changed every 2-3 days until 80% confluency was reached. Cells were
routinely sub-cultured using a final 1:1 ratio of 0.25% trypsin (Sigma-Aldrich, Arklow,
Ireland) and 0.1% EDTA (Sigma-Aldrich, Arklow, Ireland).
4.3.2

CAP device

The operating principle of the plasma discharge system used in this study is a Dielectric
Barrier Discharge (DBD) which generates high voltage pulsed non thermal plasma
between two electrodes, one of which is insulated, as previously described in chapter 3
and also by Ziuzina et al and Conway et al (Ziuzina et al, 2015; Conway et al, 2016).
The samples were treated at 75 kV for between 0-180 seconds depending on the
experiment.
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4.3.3

Alamar blue cell viability assay

U373MG cells were seeded at a density of 1x104 into 96 well plates (Sigma-Aldrich,
Arklow, Ireland) and allowed to adhere and grow overnight. Media was removed for the
duration of CAP treatment and fresh media was replaced immediately after treatment
and incubated at 37 °C as indicated. No deleterious effects were observed in the vehicle
control samples. In cytotoxicity studies using rapamycin (Sigma-Aldrich, Arklow,
Ireland), cells were seeded as described above, exposed to CAP (for combinational
studies) and were exposed to rapamycin (250 nM) and incubated for up to 48 hours.
Cell viability was analysed using Alamar blue. Cells were washed once with sterile
PBS, incubated for 2.5 hours at 37 °C with a 10% Alamar blue solution. Fluorescence
was measured using an excitation wavelength of 530 nm and emission wavelength of
595 nm on a Victor 3V 1420 (Perkin Elmer) multi-plate reader.
4.3.4

Haematoxylin & Eosin staining

Cells were plated in a T25 flask and incubated overnight as above, cells were treated
with CAP as described above or left untreated. Cell were harvested, the pellet was fixed
using 70% ethanol (Sigma Aldrich, Arklow, Ireland). A monolayer of both treated and
untreated of cells was generated using a cytospin. Cells were then stained with Harris
Haematoxylin for two minutes and 1% Eosin for 3 minutes. Cells were dehydrated in
alcohol and xylene and analysed by light microscopy (Olympus Bx41).
4.3.5

Confocal Microscopy

U373MG cells were plated in 35 mm glass bottom dishes at 1x104 cells per dish and
incubated for 24 hrs. Media was removed and cells were exposed to CAP for 60sec at
75kV after which fresh media was added. 4 hours after treatment cells were loaded with
propidium iodide (10µg/ml for 10minutes at 37ºC), AO (1µg/ml for 15 minutes 37ºC)
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or JC-1 mitochondrial membrane potential indicator (2.5µg/ml for 30 minutes 37ºC)
and the images were captured on a Zeiss 510 LZSM confocal inverted microscope.
Propidium iodide was excited with the aid of an external argon ion 488 nm laser and
detected by its emission above 585nm long pass filter. JC1 was detected by a multitrack dual excitation and emission scan, namely 488nm excitation and JC1 emission
between 505 - 530nm with a band pass filter and secondly 543nm excitation and JC1
emission above 560nm with a 560nm long pass filter. Finally, AO was also detected by
a multi-track dual excitation and emission scan, namely 477nm excitation and AO
emission above 585nm with the aid of a long pass 585nm filter and secondly by 488nm
excitation and the AO emission between 505 - 530nm with a band pass filter. All
images were recorded live through PBS. The total cell fluorescence was calculated
using ImageJ (v1.49, NIH) software. An outline was drawn around each individual cell,
as previously described by the total corrected fluorescence was then calculated as
follows; Total corrected cell fluorescence (TCCF) = Integrated density – (area of
selected cell x mean fluorescence of background readings) (McCloy et al, 2014).
4.3.6

Inhibitor studies

U373MG cells were pre-treated with 3-methyladenine (3-MA) (5mM) for 1 hour prior
(as described previously in chapter 2) to CAP treatment, and was added again
immediately after CAP treatment. Cells were treated for 180sec at 75kV. Cell viability
was assessed 48 hours later using Alamar blue.
4.3.7

Flow Cytometry

Cells were seeded in 6 well plates; cells were then treated with CAP as described above
for 60 secs, and or 3-MA (5mM) and further incubated for 48 hours. Cells were
harvested both 5 hours and 48 hours post treatment and stained with 1µg/ml AO
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incubated at 37°C for 20 minutes, washed twice with sterile PBS and analysed by flow
cytometry excited at 488 nm.
4.3.8

Statistical Analysis

All experiments were performed at least three independent times with a minimum of
five replicates per experiment. Data shown is pooled and presented as mean ± SEM (n=
total number of replicates) unless stated otherwise. Statistical analysis, and curve fitting
was performed using Prism 5, GraphPad Software, Inc. (USA). Using Shapiro-Wilk
normality test to calculate normality, our data was then normalised to the untreated
control. Unless otherwise indicated differences were considered significant with a *P
value < 0.05.

4.4

Results

4.4.1

CAP induces non apoptotic cell death in GBM cells.

We have previously demonstrated dose dependent cytotoxicity of CAP in U373MG
GBM cells (Conway et al, 2016) in chapter 3. Inhibition of normal metabolic processes
in GBM cells by CAP treatment was almost immediate, it was observed that only 4
hours post CAP treatment there was a significant reduction in cell viability compared to
untreated controls (figure 3.5 chapter 3). We have further demonstrated that gross
morphological changes were detected in cells 4 hours after CAP treatment, including
the apparent presence of internal vesicles (Figure 4.1 (A)). Morphological assessment of
cell death was carried out using H&E staining 24 hours after treatment (B). We did not
find evidence of any of the morphological hallmarks of apoptosis, specifically, there
was no evidence of any increase in membrane apoptotic blebbing, nuclear condensation
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/ fragmentation or apoptotic body formation in the CAP treated cells. Similarly, we did
not find any evidence of necrosis. However, based on morphological analysis alone we
cannot rule out necrosis. In order to determine is necrosis is occurring, use of necrosis
inhibitor necrostatin (Nec-1) could be employed. Multiple internal vesicles were
observed in the CAP treated cells that were not present in untreated controls. To further
mechanism of cell death, we employed nuclear dye propidium iodide (PI) and the ΔΨm
probe JC1, both of which are used in the analysis of cell death. PI was added to the cells
4 hours post CAP treatment. (C) Demonstrates localisation of PI, which has bound to
the nucleic acids within the nucleus of CAP-treated GBM cells. In contrast, no
fluorescent signal was observed in the untreated control cells, indicating the presence of
a healthy plasma membrane. The increase in fluorescence was quantified, as
demonstrated (C), and a significant increase in fluorescence following CAP treatment
was recorded. The mitochondria play a central role in both intrinsic apoptosis and
autophagy along with the removal of defective mitochondria therefore acting as a
control mechanism (Saito & Sadoshima, 2015). It is widely accepted that oxidative
stress, such as reactive oxygen species generated from CAP, target the mitochondria
which can result in mitochondrial dysfunction and therefore cell death, but similarly up
regulation of the autophagy process can result in mitochondrial dysfunction and cell
death (Karna et al, 2010; Lee et al, 2012). Previous studies have demonstrated that CAP
treatment results in loss of the mitochondrial membrane potential (ΔΨm) (Ahn et al,
2011; Conway et al, 2016). We examined the ΔΨm using the molecular fluorescent
probe JC-1 by confocal microscopy. As observed (D), in the untreated control JC-1
aggregates in healthy mitochondria exhibiting punctated red fluorescence, whereas in
comparison there is a significant reduction in JC-1 aggregates (red fluorescence) where
the membrane potential has decreased as a result of CAP treatment. The fluorescence
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intensity was quantified and we observed a significant decrease (p<0.05) in the red
fluorescent signal between the CAP treated cells and the untreated health controls.
ROS-dependent activation of caspases and apoptosis are believed to be the primary
routes for cell death in cancer cells exposed to CAP’s. U373MG cells loaded with the
well-known thiol antioxidant N-acetyl cysteine or caspase inhibitor zVAD-fmk
interestingly offer no protective effect when treated with CAP, which in agreement with
our previous data, (Conway et al, 2016) as observed in chapter three. Together, our
results confirm a ROS-dependent activation of apoptosis is not necessary for cell death
when U373MG GBM cells are exposed to CAP as demonstrated below (E).
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Figure 4.1 CAP induces ROS and caspase independent cells death in GBM cells.
(A) U373MG cells were treated with CAP for 60sec. Images were taken using confocal
microscopy 4 hours’ post treated of both treated and untreated samples to determine
morphological differences. (B) Cells were also subjected to CAP for 180 seconds, and
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fixed and stained with H&E 24 hours post treatment (bottom two panels). Cells were
examined under light microscopy and images were captured. All experiments were
repeated a minimum of three times. (C) In situ verification of nuclear membrane
degradation U373MG was measured 4 hr after CAP exposure (75kV for 60sec) by
confocal microscopy using prodiduim iodide 10µg/ml. The level of fluorescence was
quantified using image J software and compared to the untreated control. Statisical
analysis was carried out using a one sample t-test (*P<0.05). (D) In-situ verification of
ΔΨm was measured 4 hr after CAP exposure (75kV for 60sec) by confocal microscopy
using JC-1 2.5µg/ml. The level of fluorescence was quantified using image J software
and comapred to the untreated control. Statisical analysis was carried out using a
unpaired t-test (*P<0.05). (E) U373MG cells were preloaded for 1hr with 4mM NAC,
50µM zVAD-fmk, or a combination of both prior to CAP treatment. After 48 hours, cells
were analysed using the Alamar blue assay. Data shown was normalised to the
untreated control and are shown as the % mean ± S.E.M. (n= minimum 20). All
experiments were repeated at least three times. Statistical analysis was carried out
using One-Way ANOVA with Bonferroni’s post test. (*P<0.05).

-----------------------------------------------------------
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4.4.2

Identification of Acidic vesicle organelles (AVO’s) determined by confocal
microscopy

It was then postulated as to whether autophagy is being up-regulated following CAP
treatment and thus resulting in cell death. The observation of intracellular vesicles by
confocal microscopy in figure 4.2 below supported this hypothesis. As stated earlier in
chapter 2, it is important to note that this assay can only be employed as an indicator of
acidic vesicle organelles and further analysis is required to categorically identify the
autophagic pathway. Cells were loaded with AO, a cell-permeable, nucleic acidselective fluorescent cationic dye that aggregates and fluoresces in acidic vesicular
organelles, which are a known morphological characteristic in the autophagic process.
The presence of AVO’s was observed in CAP treated cells, but not in untreated cells,
this was quantified and a significant increase in formation of AVOS’s was determined
(A). We also confirmed and quantified AVO formation using flow cytometry 48 hours
post treatment with CAP (B). An increase in the formation of AVO’s was evident by the
increase in FL2 red fluorescence signal compared with the untreated cells and a
significant difference in the mean fluorescence index was observed between treated and
untreated cells (P<0.05). The presence of red fluorescence from acridine orange staining
validates the formation of AVO’S, which is a significant characteristic of the autophagic
process. There is a significant difference between the formation of AVO’s as determined
by flow cytometry which correlates with that observed from the confocal images above
(C).
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Figure 4.2 CAP induces the formation of acidic vesicles organelles (AVO’s) by
confocal microscopy.
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(A) In situ verification of AVO formation was measured 4 hr after CAP exposure (75kV
for 60sec) by confocal microscopy using Acridine orange 1µg/ml. The level of
fluorescence was quantified using image J software and compared to the untreated
control. Statistical analysis was carried out using unpaired t-test (*P<0.05). (B)
U373MG cells were exposed to CAP at 75kV for 60 seconds. After a 48hr incubation
period cells were loaded with 1µg/ml acridine orange dye and analysed by flow
cytometry. (C) The overlay shown between untreated and CAP treated GBM cells
depicts the formation of AVO’s by quantitative shifts the FL2 channel, red fluorescence
intensity ratio in both treated and untreated samples. Data was quantifed using the
mean fluroescence intensity and normalised to untreated control. All experiments were
repeated in triplicate. Statistical analysis was carried out using unpaired t-test (*P
<0.05).
-----------------------------------------------------------
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4.4.3

3-MA inhibits cell death in response to CAP but not the formation of
AVO’S

Having identified the formation of AVO’s by flow cytometry and confocal microscopy,
with the hypothesis that CAP results in activation of autophagy, the inhibitor 3methyladenenine (3-MA) was employed. The use of 3-MA significantly alleviated the
cytotoxic effect of CAP over a 48-hour period using spectrophotometric analysis
(Figure 4.3 (A)). Interestingly, there was no evidence of a reduction in the formation of
AVO’s 48 hours following CAP treatment when co-treated with 3-MA. This was
confirmed using flow cytometry (B), the data was then quantified using the mean
fluorescence values and statistically analysed using One-way AONVA. We observed
statistical significance, as expected between untreated samples and CAP treated samples
but no significance was observed between cells treated with and with 3-MA (C),
indicating that 3-MA dose not inhibit the formation of AVO’s after 48 hours CAP
treatment. We had previously observed the formation of AVO’s by confocal
microscopy as little as 4 hours post treatment, therefore, we postulated that 48 was two
late detect any changes, because 3-MA has been previously described to induce a
cytotoxic effect over long exposure periods (Wu et al, 2010). Therefore, the same
experiment was also carried out 4 hours post treatment (D) and as observed below there
was no alleviation on the formation of the AVO’s. The mean fluorescence value was
quantified and statistical analysis confirmed that 3-MA does not yield any significant
difference in the formation of AVO’s following incubation of GBM cells with CAP in
either 48hr post treatment or 4 hours post treatment.
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Figure 4.3 CAP induces PI3K independent AVO formation in GBM cells .
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(A) U373MG cells were preloaded for 1hr with 5mM 3-MA. Cells were exposed to CAP
for 180sec at 75kV. After 48 hours’ cell were analysed using the Alamar blue assay.
Data shown was normalised to the untreated control and are shown as the % mean ±
S.E.M. (n= minimum 20). All experiments were repeated at least three times. Statistical
analysis was carried out using one-way AONVA (*P<0.05). (B) U373MG cells were
pre-treated with or without 5mM 3-MA for 1 hour then exposed to CAP at 75kV for 60
seconds. After a 48hr incubation period cells were loaded with 1µg/ml Acridine orange
dye and analysed by flow cytometry. (1. 3-MA (red), 2. Untreated (black), 3. CAP
(green), 4. CAP & 3-MA (blue)). (C) Data shown (flow cytometry overlay) depicts the
formation of AVO’s by quantitative shifts the FL2 channel, red fluorescence intensity
ratio in both treated and untreated samples in the presence of absence of the 3-MA. (D)
U373MG cells were pre-treated with or without 5mM 3-MA for 1 hour then exposed to
ACP at 75kV for 60 seconds. After a 5hr incubation period cells were loaded with
1µg/ml Acridine orange dye and analysed by flow cytometry. (1.Untreated (black), 2. 3MA (blue), 3. CAP (red), 4. CAP & 3-MA(green)) Data was quantifed using the mean
fluroescence intensity and normalised to untreated control. All experiments were
repeated in triplicate. Statistical analysis was carried out using one-way ANOVA with
Bonferroni post-test (*p<0.05) (C-D).
-----------------------------------------------------------
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4.4.4

GBM cells demonstrate resistant to well-known autophagy inducers,
rapamycin and metformin.

It has been previously demonstrated that U373MG cells are resistant to autophagy
inducers (Takeuchi et al, 2005). Rapamycin is an inhibitor of the serine/threonine
protein kinase mTOR and acts as an inducer of autophagy in cells by negatively
regulating the P13K-Akt-mTOR pathway. Therefore, we postulated that by combining
CAP with Rapamycin we could enhance the cytotoxic effect of CAP, and overcome
rapamycin resistance. We investigate the combinational effect with another well-known
autophagy inducer metformin, which has previously been shown to activate adenosine
monophosphate-activated protein kinase (AMPK), an enzyme that coordinates control
of cell growth (Zhou et al, 2001). A variety of GBM cells have previously been shown
to be sensitive to the cytotoxic effect of 10mM metformin, in addition it has also been
demonstrated that metformin enhances the cytotoxicity of TMZ and radiation (Sesen et
al, 2015). We confirmed that U373MG are rapamycin resistant, the recommended
working concentrations for rapamycin, according to manufactures instructions for the
induction of autophagy is between 10-500nM. We noted that even when exposed to
high concentrations (>1.25 µM) there was no significant reduction in cell death
observed over a 48-hour period (figure 4.4 (A)). Interestingly we noted that U373MG
cells also demonstrate resistance to metformin (B). As there was no significant
reduction in cell death for rapamycin and metformin, the IC50 could not be calculated.
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Figure 4.4 GBM cells demonstrated increased resistance to autophagy inducers.
(A-B) U373MG cells were exposed to increasing concentrations of rapamycin (01250nM), and Metformin and analysed by Alamar blue cell viability assay after 48
hours. All experiments were repeated a minimum of three times. Cells were normalised
to an untreated control. No deleterious effects were observed from DMSO vehicle
control. Statistical analysis was carried out using non-linear regression analyses.
-----------------------------------------------------------

4.4.5

CAP demonstrates synergistic effect when combined with rapamycin in
GBM cells.

From the dose response curves established above we were able to identify a nontoxic
concentration for each compound for the combination with CAP. As demonstrated in
figure 4.5, there is a significant synergistic effect observed with all compounds when
combined with low doses of CAP (60 secs, 75kV) compared to cells treated with each
compound alone (P<0.001) (A). Rapamycin demonstrated a 58% difference in cell
viability following the combination of CAP with Rapamycin when compared to
rapamycin alone therefore overcoming rapamycin resistance. More interestingly there is
a significant synergy between CAP alone and CAP with rapamycin, demonstrating a
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further 30% reduction in cell viability than CAP alone (B). There was no significant
additional loss in cell viability following the combination of CAP with metformin.
Therefore, the combination of low doses of CAP (60sec) with non-toxic concentrations
of rapamycin induces a synergistic effect, significantly enhancing the cytotoxicity
induced by either treatment alone and overcoming GBM resistance.
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Figure 4.5 CAP induces an synergistic effect in rapamycin resistance GBM cells.
(A-B) Cells were pre-treated with 250nM rapamycin or 5mM metformin for 1 hour,
cells were then exposed to CAP (60sec at 75kV), and fresh rapamycin was added
immediately after. Cells were analysed 48 hours later by Alamar Blue analyses. All
experiments were repeated in triplicate. (A) Statistical analysis was carried out using
Two-way ANOVA with Bonferroni post-test (*P<0.001). (B) Statistical analysis of CAP
treated samples with inducers compared to CAP treated only cells were carried out
using One-way ANOVA with Bonferroni post-test (*P<0.05).
-----------------------------------------------------------
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4.5

Discussion

Recent advances in technology, engineering and materials science have led to a wide
range of biological applications for non-thermal atmospheric plasma. There has been
substantial development in the area of plasma medicine over the past decade, including
the use of CAP as a potential therapy for the treatment of cancer. The major advantage
of CAP over conventional therapies as an anti-tumor agent is the broad range of
biological responses that can be initiated, reducing the likelihood for resistance to
develop. The generation of short and long lived reactive species, generation of photons,
heat, pressure gradients, charged particles, and electrostatic and electromagnetic fields
have all been shown to induce biological effects (Stoffels et al, 2003; Kong et al, 2011;
Babington et al, 2015). CAP is a partially ionized gas that contains various
concentrations of free electrical charges, atoms, ions and electrons which are generated
by an energy supply to a neutral gas (von Woedtke et al, 2013), which generates a
unique physical and chemical environment when exposed to biological tissues including
activating short and long lived reactive oxygen species (ROS) (Stoffels et al, 2003;
Kong et al, 2011; Babington et al, 2015), many of which are known to induce biological
effects. Many studies have shown that CAP can induce a cytotoxic response in vitro in a
variety of cell lines, for example glioblastoma, cervical, breast, colorectal, and lung
(Kalghatgi et al, 2011; Ma et al, 2014; Hou et al, 2015; Conway et al, 2016), of which
the cell death mechanisms have been reported as apoptosis (Keidar et al, 2011; Ishaq et
al, 2014b), cell cycle arrest (Köritzer et al, 2013; Siu et al, 2015), and necrosis (Hirst et
al, 2015) depending on the tumour model studied and the CAP system used in these
studies. Many studies to date have demonstrated an important role for reactive oxygen
species generated by CAP treatment, including, H2O2, that induces apoptosis in glioma
cells as well as many other cancer cells (Vandamme et al, 2012; Ahn et al, 2014; Siu et
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al, 2015; Conway et al, 2016). We previously identified a ROS-independent mechanism
of cell death in GBM cells which are known to have a very high tolerance to ROS such
as H2O2 owing in part to expressing mutated P53 (Datta et al, 2002b) This mechanism
of cell death was dose dependent and was independent of both JNK, and caspase
activation. To date there has

been little to no studies identifying autophagy as a

mechanism of cell death in tumour cells following CAP treatment in GBM cells,
although it should be noted that Hirst and colleagues have observed both necrotic and
autophagic responses in primary prostate epithelial cells following CAP treatment, in
contrast with prostate cancer cell lines where apoptosis was the primary mechanism of
cell death (Hirst et al, 2015). We hypothesise that autophagy that is being activated, and
is acting in a cytoprotective manner prior to cells death when GBM cells are treated
with CAP in a caspase independent manner, similar to Koritzer et al who have also
demonstrated a caspase independent mechanism of cell death in CAP treated GBM cells
(Köritzer et al, 2013). Apoptosis was ruled out which was noted by lack of caspase
activation, however, they did identify cell senescence of the G2/M phase (Köritzer et al,
2013).
We determined here that the cytotoxic insult induced by 75kV CAP for 180 seconds
occurs rapidly, with 50% cell death observed after only 5 hours. Our findings that ROS
and caspase inhibitors did not affect cell death was confirmed by morphological
assessment of cells using H&E, where we observed no evidence of morphological
indicators of either apoptosis or necrosis (Elmore et al, 2016). These results correlate
with recently published data using CAP in U373MG cells, where the authors note a
significant increase in cytotoxicity after 24 hours using a different indicator of cell death
(MTT) (Siu et al, 2015). In the manuscript, the authors suggest that cell death of
U373MG in response to helium jet CAP is a result of apoptosis or necrosis depending
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on treatment time (Siu et al, 2015). However, the authors observed a loss in cell
viability within 24 hours, whereas a small increase in caspase 3 / 7 activity was only
observed at 48 hours and not at earlier time-points, indicating that caspases may not
play an important role. Recent recommendations on detection of apoptosis suggest a
combinational approach; the use of inhibitor studies, combined with biochemical
criteria and corroboration using morphological data (Vanden Berghe et al, 2013). We
have combined inhibitors with biochemical assays and morphological assessment to
determine that while mitochondrial dysfunction and loss of plasma membrane integrity
are features of cell death induced by CAP, caspase inhibition and hallmark
morphological features of apoptosis are not apparent. Therefore, it is likely that
apoptosis does not play an important role in our model.
Caspase independent cell death has often been associated with autophagy and
macroautophagosome formation (Tait & Green, 2008b). There is a very close
relationship between the autophagic process and apoptosis (Kroemer et al, 2009;
Galluzzi et al, 2012), with some studies suggesting that autophagy may coordinate with
apoptosis to induce cell death (Booth et al, 2014). Similarly it has previously been
suggested that the mitochondria maybe an organelle that integrates and regulates both
processes (Elmore et al, 2001). We previously confirmed depolarisation of the
mitochondrial membrane potential by flow cytometry 48 hours post CAP treatment
(Conway et al, 2016). Here, we confirm that CAP in fact results in a rapid
depolarisation of mitochondrial membrane potential, as quickly as 4 hours post CAP
treatment. The kinetics of mitochondrial depolarisation is indicative of a response that
does not require de novo gene expression. A distinct morphological feature of
autophagy is the formation of acidic vesicle organelles (AVO’s) (Paglin et al, 2001b).
We have identifed the formation of AVO’s by flow cytometry and confocal micrsocopy
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as early as 4 hours post CAP treatment. To confirm the autophagic process we
employed the use of well known autophagy inhibitor 3-MA (Petiot et al, 2000), which
succesfully protected against the cytotoxic effects of CAP. To the best of our
knowledge there has been no published data indicating autophagy mediating CAP
induced toxicity. 3-MA is a selective inhibitor of Class III PI3K activity which is
necessary for autophagy, however, long term exposure to 3-MA can induce autophagy
(Wu et al, 2010) by inhibiting class I PI3K activity (Ito et al, 2007; Leng et al, 2013).
Interestingly, when combined with flow cytometry, we did not observe any reduction in
the formation of AVO’s after 4 or 48 hours. It has been noted that in many cases,
autophagosomes accumulate despite a block in macroautophagy and despite a decrease
in flux through the entire autophagic process (Klionsky et al, 2016).

It has been

recently shown in LNCaP prostate cells treated with docetaxel that 3-MA was toxic by
itself and also increased autophagic vesicle formation and apoptosis. These paradoxical
effects of 3-methyladenine were largely independent of reactive oxygen species
production. Simialarly to our results, 3-MA treatment did not attenuate AV formation,
which is suggestive of increased autophagic activity. This phenomenon of increased
autophagy following 3-MA treatment is thought to be due to differing temporal effects
on class I and class III PI3K under nutrient rich conditions as described above by wu et
al. Our results suggest that while 3-MA protects GBM cells against CAP cytotoxicity,
accumulation and acidification of intracellular vesicles and formation of AVO’s
continues to take place in the presence of 3-MA. Therefore, it could be that 3-MA is
driving autophagy, Wu et al noted that in autophagy is induced due to prolonged
treatment with 3-MA in nutrient-rich condition is due to suppression of class I PI3K,
while sparing the class III PI3K (Wu et al, 2010). The effects of PI3K inhibitors may
vary depending on the activation of the two classes. The protective effect of 3-MA
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following CAP treatment could be that of autophagy acting in a cytoprotective role. 3Methyladenine also inhibits phosphorylation of Akt, JNK and p38 MAPK (Xue et al,
1999), thus demonstrating the possible off target effects of 3MA, and therefore as stated
by the NCCD, it is not sufficient to use inhibitors alone when identifying autophagy. It
is important to also consider as GBM cells are known to have mutated PI3k activity that
autophagy could be being induced independent of either PI3k class I or III. Recent
studies have provided evidence that loss of mitochondrial membrane induces autophagy
through a mechanism independent of the class III phosphatidylinositol 3 kinase
(PI3K/Vps34)-Beclin 1 pathway (Zhu et al, 2007). With still a lot to discover
surrounding the mechanisms of autophagy, and the debate as to whether autophagy, is
just feature of cell death, or is providing a cytoprotective role resulting in delayed cell
death by apoptosis, therefore in accordance with the Nomenclature Committee on Cell
Death (NCCD) (Galluzzi et al, 2012) based on our data, we suggest the CAP induces
autophagy prior to cell death occurring. In order to elucidate the precise role of
following CAP treatment further experimentation is required as advised by the NCCD
such as siRNA knock down of the autophagy genes.
Downstream of the PI3K/Akt/mTOR signalling pathway is the effector mammalian
target of rapamycin (mTOR), which has become a convincing therapeutic target. mTOR
is associated with growth factor signalling through PI3K, protein translation, autophagy,
and tumour cell metabolism. Induction of autophagic cell death as a therapeutic strategy
can be achieved by modulation of autophagy using regulators such as rapamycin
(mTOR) and metformin (protein kinase AMPK) (Kim & Guan, 2015). While rapamycin
is currently being used for the treatment of limgangeolimyomatosis (LAM) lung disease
and prevention of transplant rejection, recent studies have shown its effectiveness in the
treatment of various malignancies such as GBM. It has been demonstrated that
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inactivation of mTORC1 by rapamycin selectively induced autophagy and not apoptosis
in rapamycin sensitive GBM cells, it was also been noted that rapamycin has no
cytotoxic capacity on rapamycin resistant GBM cells, but interestingly they observed
that PI3K inhibitor, LY294002, and AKT inhibitor, UCN-01, synergistically sensitized
rapamycin resistant cells to rapamycin by stimulating the induction of autophagy
(Takeuchi et al, 2005). Interestingly we demonstrate that no effect of autophagy inducer
rapamycin. It has been previously shown that Ulk regulation by mTORC1 in response
to nutrients is commonly observed in eukaryotes. In addition, treatment of S. cerevisiae
with rapamycin has the capacity to induce autophagy in the presence of nutrients
(Kamada et al, 2000). Inhibition of mTORC1 by nutrient starvation or rapamycin
treatment activates autophagy, through the regulation of the ATG1/ULK kinase
complex by TORC1 and AMPK (Russell et al, 2014). In order to confirm whether
U373MG cells are rapamycin resistant, this experiment should be carried out in the
absence of nutrients, i.e. serum starvation to determine if autophagy could be induced.
A combination of mTOR inhibitor rapamycin with radiotherapy has also demonstrated a
greater therapeutic capacity by autophagy and cellular senescence in cancer cells (Nam
et al, 2013). It has also been previously demonstrated that rapamycin induces autophagy
in rapamycin sensitive GBM cell lines but many GBM cells are resistant to rapamycin
through the expression of the promyelocytic leukemia (PML) gene (Iwanami et al,
2013). We both pre- and co-treated rapamycin with 3-methyladenine but saw no
sensitisation to rapamycin (data not shown). Metformin, another autophagy inducer is
the most commonly used oral normoglycemic agent for type 2 diabetes but has also
been shown to exhibit anti-tumoral effects (Li, 2011; Sesen et al, 2015). Metformin has
been shown to inhibit mitochondrial activity through metformin induced AMPK
activation. Similarly to rapamycin, metformin inhibits mTOR signaling. Interestingly,
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P53 which in our GBM model is mutated, plays a central role in the extrinsic and
intrinsic apoptotic pathway but also functions to inhibit mTOR activity and regulate its
downstream targets ie. autophagy. We have demonstrated that U373MG GBM cells are
both rapapymcin and metformin resistant, this provides further evidence that the
resistance displayed by U373MG cells is as a result of its P53 status and therefore cells
are more likely to induce autophagy prior to cell death occuring.
Recently it has been demonstrated that rapamycin can enhance the cytotoxic capacity of
chemotherapeutics by apoptosis in rapamycin sensitive breast cancer cells, but the group
did not observe any additive or synergistic effect when combined with rapamycin
resistance breast cancer cell (Mondesire et al, 2004). We demonstrated a synergistic
effect when combining rapamycin with low doses of CAP in rapamycin resistant GBM
cells. Bcl-2 is a molecular marker associated with rapamycin resistance which is also
associated with P53, transcriptionally activates the BAX promoter or activates apoptosis
and could be a potential therapeutic target (Gomez-Manzano et al, 1997; Vignot et al,
2005b). More interestingly it was observed that inhibition of Akt expression resulted in
sensitisation of rapamycin to rapamycin resistant p53 mutated U373MG GBM cells
which therefore enhanced autophagic cell death (Takeuchi et al, 2005). We found no
synergy between metformin and CAP. Further studies are required to fully comprehend
the pathways involved in GBM induced autophagy, and to elucidate the interactions
taking place between CAP and rapamycin, also the mechanisms that promote the
additive effect, but demonstrates a promising potential therapeutic target for resistant
tumour cells. This study and that of others indicates that there is the potential to
overcome rapamycin resistance in GBM cells, and therefore potentially augment the
response observed between CAP and rapamycin.
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5

General Discussion
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Glioblastoma is considered to be the most biologically aggressive brain tumour due to
the localisation within the brain tissue, its highly invasive nature and has developed
increased resistance to most therapies for example TMZ chemotherapy and radiation. It
is evident that there is a need for the development and investigation of novel therapeutic
approaches for the treatment of brain cancer. It is essential that these targets have the
ability to overcome GBM resistance, be able to cross the blood brain barrier, however
not reduce the patient’s quality of life due to off target side effects. This thesis has
investigated two novel approaches to overcome these obstacles, whilst providing a
better understanding as to the molecular mechanism surrounding GBM cell death in
response to therapies.
A significant issue we observed was that U373MG cells do not follow the conventional
method of cell death; apoptosis but demonstrated possible activation of autophagy that
is preceding cell death. This is in contrast with the majority of papers that have been
published with regards to GBM, employing either CAP or UA, an apoptotic mechanism
of cell death was reported. An attention-grabbing article recently published, has marked
significant impact on GBM research for those who have employed in vitro studies using
the U87MG GBM model and possibly explains the findings reported in the literature.
The U87MG cells used in over 2000 published articles does not genetically resemble
the original tumour tissue used to seed the original U87MG cell line (Allen et al, 2016;
Dolgin, 2016). Gene expression analysis has identified that this cell line might possess
some resemblance to brain cancer but this needs to be further confirmed. This report
obviously puts into question the majority of the research undertaken over the past 50
years with regards to U87MG cells brain cancer research. Therefore, it is impossible to
compare and contrast data observed with other published work who claim to be using
GBM models, by means of the U87MG cells. A similar issue had arisen in the past
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between U373MG cells, where U251MG were formerly distributed as U373 MG,
However, this has since been rectified and a new deposit of U373MG known as U-373
MG (Uppsala) is now available, of which we use in this study.
It is widely accepted that autophagy has dual roles in cancer, acting as both a tumour
suppressor, preventing the accumulation of damaged proteins and organelles and also as
a mechanism of cell survival that can promote the growth of established tumors. It not
only acts as in a cytoprotective role but it is now evident that autophagy in a small;
number of cases has been established as a mechanism of cell death in response to
certain stimuli or cytotoxic agents. It is postulated that the prolonged stress incapacitates
the cytoprotective nature of autophagy and results in the induction of cell death (Yang et
al, 2011). The unique nature of GBM cells appear to make them resistant to apoptotic
stimuli, (Yao et al, 2003; Kanzawa et al, 2004b) and as a result an alternative caspase
independent mechanism of cell death is being implicated. It has been demonstrated that
certain cytotoxic agents used for the treatment of GBM induce autophagy associated
cell death for example, TMZ, radiation therapy and arsenic trioxide (Paglin et al, 2001a;
Kanzawa et al, 2003; Kondo et al, 2005; Natsumeda et al, 2011). Whether a cell
undergoes autophagic mediated cell death or autophagy in a cytoprotective manner prior
to cell death, most likely depends on the cellular framework. It has been demonstrated
that treatment with TMZ induced the inhibition of Akt-mTOR signalling pathway which
produced a temporary induction of autophagy, leading to cell resistance of the therapy
after which resulted in apoptotic cell death (Filippi-Chiela et al, 2015). Similarly,
another study demonstrated that autophagy, induced a cell survival mechanism was
activated following addition of therapeutic concentrations of TMZ in GBM cells over a
3-day period. They also demonstrate that inhibition of autophagy with inhibitor
bafilomycin A1 may enhance the antitumor effect of TMZ by inducing apoptosis
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(Kanzawa et al, 2004b). The same group observed autophagic cell death in GBM cells
treated with clinical concentrations of arsenic trioxide, therefore autophagy was
functioning in self-destructive manner (Kanzawa et al, 2003). In addition a study
monitoring patients both before and after TMZ treatment through immunohistochemical
analysis noted that induction of autophagy was increased in surgical samples after
treatment with TMZ (Natsumeda et al, 2011) These studies indicate that stressors such
as TMZ, that accelerate autophagy may result in autophagic cell death by disrupting the
balance between survival and cell death, Or in contrast this could demonstrate the cells
capacity to overcome the cytotoxic stress that is being induced as a results of treatment
or as noted by the NCCD in a small number of cases be mediating cell death. Similarly,
the literature has demonstrated that radiation therapy, induces autophagic cell death
which can be enhanced when combined with other therapies. There have been numerous
reports demonstrating that GBM cells exposed to radiation therapy that result in
apoptosis resistance (Koukourakis et al, 2016b), and as a result activates autophagy (Ito
et al, 2005b; Fujiwara et al, 2007; Benzina et al, 2008; Mehta et al, 2015). More
recently, it has been demonstrated that Akt inhibitors induce autophagic death, and not
apoptotic death in both radioresistant and radiosensitive U87 cell lines and enhance
overall sensitivity to radiation (Benzina et al, 2008; Mehta et al, 2015), moreover that
silencing the EGFR led to an improved autophagic response to irradiation and
suppressed migration in the T98G cell line (Palumbo et al, 2014a). A similar study
carried out by Plaumbo et al identified that the response to TMZ and radiation both
alone or combined induced an autophagic response, moreover U87MG (radiosensitive)
and U373MG (radioresistant) both induced autophagy but not apoptosis (Palumbo et al,
2014b). Interestingly, when both cell lines were pre-treated with mTOR inhibitor
rapamycin and an autophagy inducer, it sensitised the U373MG radioresistant cells to
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radiation (Palumbo et al, 2012b). These studies provide evidence that the autophagyassociated cell death pathway is the dominant mode of cell death rather than apoptosis
in irradiated GBM cells, and indicates a possible adjuvant therapeutic strategy to
enhance the conventional GBM treatment. It follows logically that the identification of
novel targeted autophagy-interfering agents either with radiation and TMZ alone or in
combination may represent a new strategy for the treatment of GBM. It is evident form
the literature that term the use of the term ‘autophagic cell death’ has been a matter of
much debate. As noted by the NCCD there are only a small number of cases in which
autophagic mediated cell death have been demonstrated (Grandér et al, 2009; Laane et
al, 2009; Liu et al, 2013). Grander et al showed that inhibition of autophagy through
siRNA-mediated repression of Beclin 1 expression inhibited apoptosis demonstrating a
significant role of autophagy in dexamethasone-induced cell death, using techniques
that are recommended by the NCCD it is satisfying that autophagy is playing a role in
cell death in this case. But in most cases that are being demonstrated as autophagic cell
death it is more likely that the autophagic process that is being identified is the cell
undergoing autophagy in a cytoprotective manner that is preceding cell death. The cell
tries to overcome the cytotoxic insult but in most cases the cell becomes overwhelmed
and therefore sends signals to activate a mechanism of cell death. Therefore, it is
hypothesised that this is where the confusion lies in the literature. As described earlier
there is a lot of cross talk between autophagy and apoptosis and that they can activate
each other when required. Therefore, it is necessary that the correcting terminology is
used when describing autophagy in relation to cell death. Similarly, data should not be
perceived as demonstrating autophagic cell death without following the guidelines of
the NCCD. It is important that in coming years that there is a standardised approach to
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identify autophagy and its involvement in cell death in conjunction with appropriate use
of terminology in publications to prevent misrepresentation of data.
To date and to the best of our knowledge we are the first to suggest activation of
autophagy in response to CAP treatment in cancer cells. While we have preliminary
evidence to support that apoptosis is not involved in our GBM model as described in
chapter three and chapter 4, further experimentation is required in order to fully rule out
an apoptotic mechanism of cell death. Our hypothesis is based on the lack of evidence
of any morphological or biochemical apoptotic indicators. While we did not directly
investigate necrosis as a potential mechanism, based on the H&E staining and confocal
imaging there was no morphological evidence of necrosis. However, experimentation
such as necrostatin stating to rule out necrosis and further demonstration of caspase
activation is required. We successfully identified the presence of acidic vesicle
organelles and using biochemical inhibitor 3-MA, we propose that autophagy is being
activated. We were able to overcome this resistance with a multiple dose treatment
demonstrating that CAP has the ability to overcome GBM resistance to therapies.
Equally, to that observed with CAP, there has been conflicting reports to date in GBM
as to the mechanism of cell death reported by UA. It has been demonstrated that UA
induces autophagy, in a ROS dependent manner (Shen et al, 2014), cell death by
apoptosis was also reported, demonstrating that UA induced inhibition of miR-21, an
anti-apoptotic oncogenic found in glioma therefore inducing apoptosis (Wang et al,
2012b). In addition, necrosis has also been identified as a possible mechanism through
demonstration of LDH leakage and HMGB-1 release following UA treatment.
Similarly, to results observed in our studies, this group also determined caspase
independent cell death using general caspase inhibitor zVAD-fmk, but interestingly in
the supplementary data provided they also investigated the possibility of autophagy.
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They did not observe any formation of acidic vesicle organelle by flow cytometry by
acridine orange staining. It should be noted that each of these studies were carried out
using different GBM cell lines, and therefore contain different genetic backgrounds. For
example, the DTGB-05MG cell line expresses wild type P53 (Kruse et al, 1992)
whereas our GBM model expresses a mutant form of P53. Interestingly, Wang et al
reported, the identification of apoptosis based on the use of acridine orange staining
along with TEM and Caspase 3 cleavage (Wang et al, 2012b). While caspase dependent
cell death is commonly associated with apoptosis, acridine orange and TEM are more
commonly employed in the identification of autophagy (Klionsky et al, 2016). To date
there has been no data published on the role of JNK following treatment with UA in
GBM. We have demonstrated that JNK plays a role in UA induced cell death in GBM
cells. This correlates with a study carried out by Xavier et al, who demonstrated that, in
apoptotic resistant colorectal cells, UA activates the autophagic pathway prior to cell
death through activation of the JNK pathway (Xavier et al, 2013). Moreover, initially
their study suggested an apoptotic mechanism of cell death, but their results which
indicated apoptosis, only accounted for 4% of the total number of dead cells, therefore
indicating activation of another cell death signalling pathway, which was then identified
to be autophagy. This study demonstrates the importance of critical analyses of the data.
Xavier and her colleagues had observed a significant positive result for apoptosis and
therefore could easily have been interrupted solely as an apoptotic mechanism of cell
death, and therefore misreporting the involvement of the autophagic signalling pathway.
We hypothesise that this misinterpretation of cell death is occurring in the case of CAP
induced cell death as described later in this discussion.
The degree of the stressor also plays a role on whether a cell will undergo autophagy as
a survival response, or mediate cell death. More notably in cancer cells there are a
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number of genetic mutations which make it more likely that a cell will undergo
autophagic cell death rather than apoptosis, for example P53, a mutation commonly
found in GBM cells. P53 is responsible for triggering apoptosis and activation of
caspases 3 and 8 (Haupt et al, 2003), therefore it stands to reason that cells that are
mutated in P53 are resistant to apoptotic cell death, this assumption correlates with data
observed in chapter two and three, where we have demonstrated a ROS and caspase
independent mechanism of cell death following CAP treatment. When we investigated
the effects of pyruvate (ROS scavenger) present in out DMEM media, we noted a
partial alleviation in the cytotoxicity induced by CAP by Pyruvate. Pyruvate is a
scavenger for H2O2, a species that is generated in abundance by CAP. More interestingly
when we examined the effects NAC with and without CAP there was no significant
difference observed, this is assumed to be due to the presence of pyruvate in the media
but more interestingly there was still only partial inhibition of cell death even in the
presence of both scavengers. Together, the data suggests a ROS-dependent and a ROSindependent mechanism of cell death induced by CAP. U373MG cells are known to
express mutated P53 and in all cytotoxic treatments examine including CAP,
chemotherapeutics and UA, bar TMZ, we have failed to demonstrate caspase activity
through the use of general caspase inhibitor. Previously it has been shown that TMZ,
the current gold standard for the treatment of GBM, induces an autophagy. Interestingly
they demonstrated low levels of caspase activation (0.3 fold increase) using caspase
inhibitor in P53 mutated U373MG cells with noted in caspase 3/7 activity (Lee et al,
2015). Similarly, to our results obtained in chapter one, we observed that cells treated
with TMZ, combined with caspase inhibitor, resulted in a small but significant (17%)
increase in cell viability. This data again relates with that observed by Xavier et al, it
would be easy to assume that a significant increase in cell viability following the

224

addition of a caspase inhibitor would indicate apoptotic mechanism of cell death, but in
this case it has been well established that TMZ induces autophagy, based on the
NCCD’s recommendations whether it is in a cytoprotective role or mediating cell death
remains to be elucidated We postulated that this represents a basal level of activity of
caspases, but is not strong enough to initiate an apoptotic response. Autophagy has also
been previously associated with caspase independent cell death (Rieckher &
Tavernarakis, 2010). In contrast to this, UA and CAP, demonstrate caspase independent
mechanism of cell death. There was no significant alleviation of cell death following the
addition of zVAD-fmk. As mentioned earlier we speculate that detection of small
amounts of caspase activity is being misrepresented for apoptosis. (Siu et al, 2015)
recently reported apoptotic effects in U373MG cells following CAP treatment. While
their cytotoxicity and viability studies (MTT assay) correlates with our data, they have
identified apoptosis as the mechanism of cell death, using only the Caspase-Glo® 3/7
assay, which measures caspase-3 and -7 activities in purified enzyme preparations. It is
evident from their data that the significance observed is mild, with less than 1-fold
increase in DVED cleavage, which is only noted at 48 hours after 120sec of treatment.
We postulate that although this was noted to be significant that it might be basal level
caspase activity and that cell death is being induced by alternative mechanisms, similar
to that observed by (Xavier et al, 2013) In the case of CAP and UA one might argue
that CICD is not the only mechanism cell death that could in playing a role here i.e.
necrosis, or programmed cell death 1 (apoptosis) (Kroemer & Martin, 2005b). Using
morphological techniques such as microscopic analysis of unstained and stained cells by
following both UA and CAP treatment, we have concluded there was no evidence of
cell swelling or rupturing, disintegrated cellular organelles, or loss of intracellular
contents, all of which are morphological characteristics of necrosis (Baskar et al, 2012).
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Similarly, we saw no evidence of apoptosis, chromatin condensation, plasma membrane
blebbing, nuclear fragmentation, However, it is evident that this data is limited and can
only be considered preliminary and further experimentation is required before these can
be ruled out. We provided evidence suggesting autophagy that is being activated
proceeding cell death by identifying the presence acidic vesicles organelles,
microscopic analysis and biochemical inhibitors. Autophagy has been defined
morphologically by Yu et al as a type of cell death that occurs in the absence of
chromatin condensation but is accompanied by autophagic vacuolization of the
cytoplasm (Yu et al, 2004a, 2004b) this is in accordance with the recently set guidelines
for the detection of autophagy (Klionsky et al, 2016) to which we have observed in our
data. However, in order to fully elucidate the role of autophagy following CAP and UA
treatment further experimentation is required that is in line with the NCCD
Treatment of cancers rarely employs a single standalone drug or one form of treatment.
Most therapies comprise of a regime that involves multiple different modalities, for
example as described previously for GBM tumours, generally speaking, following
surgical resection the patient is treated with a 6 week course of radiotherapy (typical
dose is around 60 Gy) with concomitant systemic therapy using alkylating agent (Stupp
et al, 2005a). The main issues arising with radiotherapy is radioresistance in GBM
tumours, and the invasive treatment regime of external beam radiation therapy, which
includes six weeks of localized radiation therapy five times per week (Carlsson et al,
2014). While radiotherapy remains a part of the gold standard regime, in many cases it
is only palliative because of radioresistance. GBM tumours that are radiosensitive,
similarly to that observed with TMZ, have been shown to undergo autophagy as a
mechanism of cell death (Ramirez et al, 2013). It has be demonstrated that knockdown
of proteins in the autophagic signalling pathway, Beclin-1 and Atg-5, reduce sensitivity
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to radiotherapy both alone or when combined with TMZ in radiosensitive GBM cells
(Palumbo et al, 2012a). The mechanisms surrounding radioresistance still remains to be
fully elucidated, and therefore demonstrates a need for the development of novel
technologies that overcome GBM resistance.
Developments in molecular and cell biology have led to better understanding of GBM
tumour development, leading to novel treatment strategies and novel approaches for
drug delivery. In an approach to overcome the issues associated with current therapeutic
strategies such as radiotherapy and chemotherapy, we have established methodology
and investigated a novel approach for treating our resistant GBM model using CAP.
Targeted drug delivery strategies to avoid the blood-brain barrier have shown efficiency
in clinical trials. The Gliadel wafer is a novel approach to treat GBM, which involves
after surgical resection, the wafer is placed in the tumour resected cavity and provides
controlled release delivery of carmustine (BCNU) from biodegradable polymer wafers.
However widespread use has been limited due to uncertainty in the toxicity of the wafer
along with adverse side effects observed in clinical trials. The most common adverse
side effects noted convulsions, confusion, brain oedema, infection, hemiparesis
(weakness of one side of the body), aphasia (inability to comprehend and formulate
language) visual field defects and surgical sites infections. A recent study analysing the
survival outcome and safety of the Gliadel wafer for those treated with high grade
glioma. They noted that there was an added 3-month increase in the median overall
survival compared to patients who were treated with other modalities, and a significant
increase in survival with combination of the Gliadel wafer with combined treatment
with TMZ (Chowdhary et al, 2015). Other forms of targeted therapies include small
molecule inhibitors which are organic compounds that are able to cross cell membranes
and target specific intracellular constituents, for example; tyrosine kinase inhibitors
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(TKIs). Monoclonal antibodies, on the other hand are used to target used the cell surface
proteins and other extracellular peptides, as they are big to cross the cell membrane.
Both of these methods have been explored as an immunotherapy with vaccination
delivery. A review carried out by Thomas et al noted that of 7 published clinical trials
using dendritic cell vaccines there was only an average overall survival of 24 months
(Thomas et al, 2012).
An attractive feature of CAP is its potential to act as a targeted therapy due to its high
selectivity for cancer cells while having little to no effect on normal cells, this
phenomenon has been observed in a variety of cell types including GBM (Wang et al,
2013; Guerrero-Preston et al, 2014; Kim & Chung, 2016), unlike that observed with
radiation and chemotherapy therapy. Similarly, another advantage of CAP is the
redundancy of the need to cross the blood brain barrier. While there are numerous
studies identifying the ability of CAP to induce a cytotoxic response in cancer cells, the
molecular mechanism involved still remains poorly understood. The majority of the
published work has suggested ROS mediated cell death, therefore indicating apoptosis,
there have also been studies reporting necrosis (Hirst et al, 2015). There is substantial
potential in the use of CAP as a combinational treatment, as observed we demonstrated
a synergy between CAP and low doses of TMZ, with a significant reduction in cell
viability than either treatment alone. A study was carried out by Köritzer et al which
demonstrated that CAP treatment was able to restore sensitivity in chemo resistant
GBM cells when combined with TMZ by inducing cell cycle arrest (Köritzer et al,
2013). The results outlined above demonstrate a potential mechanism for overcoming
chemo resistance in GBM cells by demonstrating a potential combinational targeted
therapeutic approach for the treatment of GBM, enhancing the overall cytotoxic
potential of either modality while reducing the concentrations of TMZ required while
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employing low doses of CAP. When developing a new therapy, more importantly a
combinational therapy, it is necessary to investigate the pharmokinetic behaviour
between the two components and also the inhibitory or enhanced cytotoxicity when
combined, for example it has been shown that cisplatin based chemotherapies act as
radiosenstitiers, therefore limiting the dose of radiation required (Boeckman et al, 2005;
Candelaria et al, 2006). Interestingly, as the dose of CAP was increased the synergistic
or additive effect between CAP and TMZ was lost. On the other hand, we detected a
marginal but significant inhibitory action on the cytotoxicity of certain drugs when
directly treated with CAP, indicating that there is an interaction occurring between the
species generated by CAP and the compound itself. Further studies including techniques
such as LS-MS or MNR and FTIR would be able to elucidate any alteration in the
compound after CAP treatment. Similarly, a recent study demonstrated the synergistic
effect between UA and radiation treatment, sub toxic concentrations of ursolic acid
sensitised adenocarcinoma gastric cancer cells to radiation therapy, through enhanced
G2/M arrest, increased ROS resulting in cell death by apoptosis (Yang et al, 2015).
Interestingly we demonstrated no synergy between UA and CAP as demonstrated in
chapter 2, and as described in chapter 4, on the other hand we have provided
preliminary evidence to suggest that autophagy is being active and is preceding cell
death. In addition, our studies have demonstrated that U373MG cells are resistant to
ROS generation following CAP treatment, and therefore might play a role in the lack of
synergy observed in GBM cells. From a clinical point of view this study gives evidence
of the safety CAP when used as a combinational approach. There is only negligible loss
in the bioactivity of the majority of the compounds when exposed to CAP for extended
periods of time. Therefore, demonstrating efficacy, it would be unlikely that CAP would
interfere with other treatment modalities that a patient might also be ongoing.
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One of the most important hallmarks of malignant gliomas is their invasive behaviour.
gliomas can be observed as comprising of two subpopulations of cells, the proliferative
cells at the tumour core, and cells invading the surrounding brain tissue. To date, the
majority of approved therapies are targeted towards inhibiting tumour cell growth by
targeting cell proliferation. EGFR targeted therapy employing TKIs (Gefitinib),
monoclonal antibodies (Cetuximab). TMZ and BCNU are both alkylating agents
targeting DNA and prevent proper DNA replication and thus inhibiting cell
proliferation. Studies have demonstrated that RTK are an appropriate target for
inhibiting cell migration and invasion as activation of RTK’s have been shown to
demonstrate anti-migratory activity in vitro and in vivo (Iwamoto et al, 2010; Zhu et al,
2011; Balaña et al, 2014; Chinchar et al, 2014; Zhao et al, 2015), however these
promising results have not translated during clinical trials (Iwamoto et al, 2010; Balaña
et al, 2014). Another target that has shown promising for inhibiting cell migration is the
26S proteasome. The 26S proteasome is an intracellular protease which degrades
proteins via the ubiquitin pathway (Areeb et al, 2016). Proteasome inhibitor Bortezomib
has been approved for the use in treating multiple myeloma, and once again
demonstrated promising results in vitro but this failed to translate in clinical trials (Odia
et al, 2015; Vlachostergios & Papandreou, 2015; Areeb et al, 2016). Interest has revived
recently in the investigation of medicinal plants to identify novel active phytochemicals
that might potentially lead to novel drug development. Anticancer drugs derived from
plants have been utilised in cancer therapy for years for example plant alkaloids such as
vincristine, the activities of flavonoids and the synergistic action shown by them with
other drugs make them ideal candidate for anticancer therapies. We have demonstrated
the ability of Ursolic acid, a naturally available bioactive compound has the ability to
suppress migration in GBM cells, which has also been successfully demonstrated by

230

other in a verity of other cancer cells. It has been previously demonstrated that
radiotherapy induces cell migration and invasion in glioma cells, the same group have
also has demonstrated that the MAPK pathway plays a significant role, with inhibition
of JNK reducing the rate of migration in glioma initiating and glioma stem cells
(Alapati et al, 2014). This also correlates with our data, were we observed a partial
inhibition in migration following the use of a JNK inhibitor. More interestingly we
demonstrate significantly increased inhibition of cell migration following the
combination of UA with JNK inhibitor then JNK alone, therefore demonstrating the
efficacy of UA as a potential anti-migratory therapeutic for the treatment of GBM but
also confirming the role of JNK in GBM migration.
In conclusion, Chapter two of this thesis has presented cytotoxicity profiles of a panel of
medicinal and phytochemical compounds, and also provides preliminary evidence of
autophagy following UA treatment. We have presented a strong rational for the
potential use of naturally available phytochemical ursolic acid as a potential therapeutic
target for the treatment of GBM. Not only does it exhibit a greater cytotoxic profile to
currently used chemotherapeutics over a shorter period of time, we have provided
sufficient evidence to support our hypothesis of an autophagic mechanism of cell death
and of a concomitant, JNK-independent inhibition of migration.
In chapter three we optimised and investigated the efficacy of CAP as a potential
therapeutic target to induce cytotoxicity and overcome GBM resistance. We have
successfully established a working model using GBM and HeLa cells using our CAPDBD system. Through repeated CAP exposures we have successfully overcome the
natural resistance of GBM to CAP. We demonstrated a synergistic effect between low
doses of TMZ and CAP. We have also demonstrated a mild inhibition of bioactivity
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following direct long term on some compounds. Part of this chapter was accepted and
published in the British Journal of Cancer in February 2016.
In chapter four we investigated autophagic process that precedes cell death following
CAP treatment. As per the guidelines for detecting both autophagy and apoptosis we
have provided preliminary evidence to rule out apoptosis as a mechanism of cell death
in our model and for the first time we demonstrate autophagy that is preceding a caspase
independent mechanism of cell death following CAP treatment in GBM cells. This
thesis provides evidence to suggest that GBM follows the non-conventional mechanism
of cell death in response to a variety of treatment modalities and therefore, we
hypothesise the mechanism of cell death in which in vitro cell lines follow is based on
the genetic mutations that are present in that cell line and further studies are required to
fully elucidate what pathways are involved.
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Appendix I
Cell counting using a Haemocytometer.
The haemocytometer was washed with 70% ethanol and a glass cover slip was placed
on top. 10µl of cell suspension to be counted was added to the haemocytometer.
Through capillary action the sample was drawn under the coverslip. The
haemocytometer was placed under a light microscope and focused using the x10
objective. Cells were counted in the four outer set of squares (each containing 16
smaller squares), as shown below (Maria Fuentes, 2013).
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Appendix II
Vehicle controls for (A) BCNU, (B) TMZ, (C) Gefitinib, (D) Cisplatin, (E) Clozapine
and (F) UA. Cells were treated with the highest concentration present in drug, either
0.2% DMSO or 0.6% H2O . No significant reduction in cell viability was observed in
the vehicle controls, calculated using student t-test.
A.

B.
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C.

D.
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E.

F.
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G.

295

Appendix III
Correlation analysis was carried out by a member of the DIT school of computing, Dr.
Yupeng Liu (Appendix III-V)
Comparison of dose response curves between U373MG and HeLa cells in response to
NTAP treatment (data plotted in chapter 3, figure 3.4). Using the statistical software R,
correlation analysis was carried out on both cell lines (U373MG and HeLa) in response
to NTAP treatment. The statistical procedure of calculating correlation is one of the
most frequently used procedures in biomedicine. Correlation is the agreement of values
from two data sets, and it expresses the degree of association between the investigated
phenomena. The following relationship base on correlation coefficient.

Exactly –1. A perfect downhill (negative) relationship (deep red colour)
–0.70. A strong downhill (negative) relationship
–0.50. A moderate downhill (negative) relationship
–0.30. A weak downhill (negative) relationship
0. No relationship (white colour)
+0.30. A weak uphill (positive) relationship
+0.50. A moderate uphill (positive) relationship
+0.70. A strong uphill (positive) relationship
Exactly +1. A perfect uphill (positive) relationship. (Blue colour)
It is evident that there is no correlation between the two cell lines, which coincides with
the results observed in the dose response experiment
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Appendix IV
Comparison of dose response curves between U373MG and HeLa cells following
treatment with H2O2 (data plotted in chapter 3, figure 3.14). Using the statistical
software R, correlation analysis was carried out on both cell lines in response to H2O2.
According to the colour scale the correlation coefficient appears to lie near zero,
indicating that U373MG and HeLa cells do not correlate. It is evident that there is no
correlation between the two cell lines, which coincides with the results observed in the
dose response experiment.
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Appendix V
Comparison of dose response curves between U373MG and HeLa cells following
treatment with H2O2 (data plotted in chapter 3, figure 3.15). According to the colour
scale the correlation coefficient appears to lie near zero, indicating that U373MG and
HeLa cells do not correlate.
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Appendix VI
Optimisation of clozapine.
Dose response curve was carried out as described in chapter for all other compounds.
Cells were analysed by Alamar blue after 48-hour period (A). Using statistical analysis
and nonlinear regression, the IC50 was calculated to 49.13µM interestingly neither of the
three inhibitors were able to attenuate any cytotoxicity induced. There was no
significant reduction in cell viability in the inhibitors alone, as observed in the control
data in figure (B). A significant reduction in cell viability was observed following
treatment with cisplatin (48%) and clozapine (41%) alone, therefore the compounds
were effective killing the cells. The vehicle control did not produce any deleterious
effects, therefore is not responsible for the significant additive effect seen between
clozapine and SP600125, resulting in a further 10% reduction in cell viability. Our data
suggests that cisplatin and clozapine induces cell death via a ROS, caspase and JNK
independent mechanism.
A
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B.

(A) U373MG cells were treated with increasing concentrations (0 ≤ 500) of clozapine.
Cells were also treated with a vehicle control of 0.2% DMSO (see appendix II). After 48
hours were analysed using Alamar blue cell viability assay. All experiments were
repeated minimum in triplicate. Data shown was normalised to the untreated control
and are shown as the % mean ± S.E.M. Non-linear regression statistical analysis was
carried out using Prism5 statistical software. (B) Each inhibitor was made up in full
media. U373MG cells were pre-treated for 1 hour with increasing concentrations of
either NAC (ROS), SP600125 (JNK), zVAD-fmk (caspase), after which 50µM clozapine
(IC50) was added to each well. Following incubation of 48 hours’ cell viability was
analysed by Alamar blue analyses. Experiments were repeated in triplicate. All
experiments were normalised to untreated control and expressed as a % of the SEM.
Statistical analysis was carried out using One-Way ANOVA with Bonferroni post-test
(p<0.05).
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Appendix VII
Haematoxylin &Eosin staining protocol
Cells are trypsinised and pelleted by centrifugation at 1200 RPM for 5 minutes. The
pellet in the resuspended in ThinPrep PreservcCyte which is a methanol based buffered
preservative solution. 1.5ml of cell suspension is then added to the cytospin cassette
(containing a glass slide) and spun at 800rpm for 5 minutes to form a monolayer of cells
on the glass slide. Cells are the fixed in industrial methylated spirits.
H+E staining
1) Bring cells back to water.
 Dip slides into 70% alcohol for 3 minutes
 Dip slides into 50% alcohol for 3 minutes
 Dip slides into distilled water for 3 minutes
2) Stain with Harris haematoxylin (Sigma Aldrich, Arklow) for 2 minutes
3) Rinse well with tap water
4) Stain with 1% eosin (Sigma Aldrich, Arklow) for 3 minutes
5) Rinse well with tap water
6) Dehydrate cells
 Dip slides into 50% alcohol for 3 minutes
 Dip slides into 70% alcohol for 3 minutes
 Dip slides into 100% alcohol for 3 minutes
 Dip slides into xylene for 3 minutes, mount in DPX mounting medium
(Sigma Aldrich, Arklow) and coverslip and view under microscope.
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